Bispecific antibodies against CD3 and CD20
By designing a novel CD3xCD20 bispecific antibody that binds to the CD3 and CD20 antigen-binding regions, highly efficient killing of CD20-expressing cells was achieved, solving the problems of low efficiency and large side effects in existing technologies, and making it suitable for the treatment of CD20-positive tumors.
Patent Information
- Application Number
- CN202210117824.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2015-07-16
- Filing Date
- 2016-01-08
- Publication Date
- 2026-11-17
- Estimated Expiration
- 2036-01-08
AI Technical Summary
Existing CD3xCD20 bispecific antibodies are inefficient and have side effects when killing CD20-expressing cells, making it difficult to effectively target and kill CD20-expressing cells, especially those with low CD20 copy numbers.
Develop a novel CD3xCD20 bispecific antibody containing a first antigen-binding region derived from a CD3 antibody and a second antigen-binding region derived from a CD20 antibody. This antibody can induce cytotoxicity through CD4+ T cells and CD8+ T cells, thereby improving the killing efficiency against CD20-expressing cells.
This antibody has demonstrated a highly effective ability to kill CD20-expressing cells, especially tumor cells, in both in vitro and in vivo experiments. It induces rapid and intense cell killing at low doses, making it suitable for the treatment of CD20-positive tumors and related diseases.
Smart Images

Figure CN114478792B_ABST
Abstract
Description
[0001] This application is a divisional application of Chinese patent application 201680014755.4, "Bispecific antibody against CD3 and CD20", filed on January 8, 2016. Technical Field
[0002] This invention relates to bispecific antibodies against CD3 and CD20 and the use of such bispecific antibodies, particularly their use in treating diseases in which specific targeting and T-cell-mediated killing of cells expressing CD20 is desired. Background Technology
[0003] CD3 has been known for many years, and therefore has become a target in many areas. In particular, antibodies against CD3 or the T-cell receptor complex (of which CD3 is a component) are known. The in vitro characterization of five humanized OKT3 effector functional variant antibodies has been described (Xu et al.). . , 2000, Cell Immunol. 200(1):16-26).
[0004] In the absence of sustained immunosuppressive therapy after the onset of type 1 diabetes, treatment with the anti-CD3 monoclonal antibody hOKT3gamma1 (Ala-Ala) resulted in improvements in C-peptide response and clinical parameters for at least 2 years (Herold et al.). . ,2005, Diabetes, 54(6):1763-9).
[0005] CD3 antibodies that cross-react with CD3 in cynomolgus monkeys and / or rhesus monkeys have been described (WO2012162067, WO2008119567).
[0006] A promising approach to improving targeted antibody therapy involves delivering cytotoxic cells specific to cancer cells expressing antigens. This concept of using T cells to effectively kill tumor cells has been described in Staerz. et. al(Muler and Kontermann, 2010, BioDrugs 24: 89-98). However, the initial clinical studies were quite disappointing, mainly due to low efficacy, severe side effects (cytokine storm), and the immunogenicity of bispecific antibodies (Muller and Kontermann, 2010, BioDrugs 24: 89-98). Advances in the design and application of bispecific antibodies have partially overcome the initial cytokine storm barrier and improved clinical efficacy without dose-limiting toxicities (Garber, 2014, Nat. Rev. Drug Discov. 13: 799-801; Lum and Thakur, 2011, BioDrugs 25: 365-379). As described for catumaxomab (Berek et al. 2014, Int. J. Gynecol. Cancer 24(9): 1583-1589; Mau-Sørensen et al. 2015, Cancer Chemother. Pharmacol. 75:1065-1073), the key to overcoming the initial cytokine storm barrier lies in the absence or silencing of the Fc domain.
[0007] CD20 (also known as human B-lymphocyte-restrictive differentiation antigen or Bp35) is a hydrophobic transmembrane protein located on pre-B and mature B lymphocytes, with a molecular weight of approximately 35 kDa (Valentine et al.). . (1989) J. Biol. Chem. 264(19):11282-11287; and Einfield et al ., (1988) EMBO J. 7(3):711-717). CD20 is found on the surface of more than 90% of B cells from peripheral blood or lymphoid organs, and is expressed during early pre-B cell development and remains present until plasma cell differentiation. CD20 is present on both normal B cells and malignant B cells. In particular, CD20 is expressed on more than 90% of B-cell non-Hodgkin's lymphomas (NHL) (Anderson et al.). . (1984) Blood 63(6):1424-1433), but not found in hematopoietic stem cells, pre-B cells, normal plasma cells or other normal tissues (Tedder et al.). . (1985) J. Immunol. 135(2):973-979).
[0008] Therapies targeting CD20 to treat cancer, as well as autoimmune and immune diseases, are known in the art. For example, the chimeric CD20 antibody rituximab has been used or proposed for the treatment of cancers such as non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), and small lymphocytic lymphoma (SLL). The human monoclonal CD20 antibody ofatumumab has been used or proposed, particularly, for the treatment of various indications of CLL, follicular lymphoma (FL), neuromyelitis optica (NMO), and diffuse and relapsing-remitting multiple sclerosis (RRMS). The human monoclonal CD20 antibody obinutuzumab has been used or proposed for the treatment of CLL. Furthermore, the humanized CD20 antibody ocrelizumab is being developed for RRMS.
[0009] Gall et al. (2005 Experimental Hematology 33: 452) disclosed the CD3xCD20 bispecific antibody CD20bi, which is generated by the chemical heteroconjugation of the CD20-specific chimeric antibody rituximab (Rituxan) and anti-CD3 (Orthoclone OKT-3).
[0010] Stanglmaier et al. (2008 Int. J. Cancer: 123, 1181) described a trifunctional bispecific anti-CD3x anti-CD20 antibody, Bi20 / FBTA05, which combines CD20-specific mouse IgG2a and CD3-specific rat IgG2b.
[0011] Wu et al. (2007 Nat Biotechnol. 25: 1290-1297) and WO2011014659 described bispecific (CD3 and CD20), tetravalent immunoglobulin G (bi-variable domain immunoglobulin, DVD-Ig).
[0012] WO2011090762 describes the generation of CD3xCD20 polypeptide heterodimers.
[0013] WO2011028952 specifically describes the generation of CD3xCD20 bispecific molecules using Xencor's XmAb bispecific Fc domain technology.
[0014] WO2014047231 describes REGN1979 and other CD3xCD20 bispecific antibodies produced using FcΔAdp technology from Regeneron Pharmaceuticals.
[0015] Sun et al. (2015, Science Translational Medicine 7, 287ra70) described a B cell-targeting anti-CD20 / CD3 T cell-dependent bispecific antibody constructed using a "knobs-into-holes" technique.
[0016] Bispecific antibodies combining CD3 and CD20 can be used in therapeutic contexts where specific targeting of CD20-expressing cells and T-cell-mediated killing are needed, and there is still a need for other effective CD3xCD20 bispecific antibodies. Summary of the Invention
[0017] The purpose of this invention is to provide a novel, effective bispecific antibody comprising a first antigen-binding region derived from a CD3 antibody and a second antigen-binding region derived from a CD20 antibody.
[0018] The novel CD3xCD20 bispecific antibody can be used in therapeutic contexts where specific targeting of CD20-expressing cells and T-cell-mediated killing are desired. This novel CD3xCD20 bispecific antibody is highly effective in killing CD20-expressing cells, including those with low CD20 copy numbers, and has been shown to be highly effective in eradicating tumor cells in animal models. The novel CD3xCD20 bispecific antibody is advantageous because it induces rapid and potent cell killing at low doses. Furthermore, the novel CD3xCD20 bispecific antibody is capable of targeting CD4+ cells. + T cells and CD8 + Both CD3xCD20 and CD3xCD20 induce cytotoxicity, making them suitable for conjugating T cells to kill CD20-positive tumors and other diseases involving CD20-positive cells. Furthermore, CD3xCD20 bispecific antibodies effectively deplete B cells from lymphoid structures. Therefore, the object of this invention is to provide a bispecific CD3xCD20 antibody that can cross CD4+. + T cells and CD8 + Both T cells induce cytotoxicity. Another object of the present invention is to provide a bispecific CD3xCD20 antibody that is highly effective in killing CD20-expressing cells, such as CD20-expressing tumor cells. Another object of the present invention is to provide a bispecific CD3xCD20 antibody that is highly effective in killing CD20-expressing cancer cells.
[0019] These and other aspects of the invention are described in more detail below. Attached Figure Description
[0020] Figure 1: The binding of bispecific CD3xCD20 antibody to Daudi (AF) and Jurkat (GI) cells. (A) Binding of bsIgG1-huCD3-H1L1-FEALxCD20-7D8-FEAR and IgG1-7D8, (B) Binding of bsIgG1-huCD3-H1L1-FEALxCD20-2F2-FEAR and IgG1-2F2, (C) Binding of bsIgG1-huCD3-H1L1-FEALxCD20-RTX-FEAR and IgG1-RTX, (D) Binding of bsIgG1-huCD3-H1L1-FEALxCD20-11B8-FEAR and IgG1-11B8, (E) Binding of bsIgG1-huCD3-H1L1-FEALxCD20-GA101-FEAR and IgG1-GA101, (F) Binding of bsIgG1-huCD3-H1L1-FEALxCD20-2C6-FEAR (and IgG1-7D8). The data shown are the geometric mean (AE) and median fluorescence intensity (F) of the fluorescence intensity bound to Daudi cells for two representative experiments (AE from one experiment and F from another experiment), as determined by flow cytometry.(G) The binding of bsIgG1-huCLB-T3 / 4-FEALxCD20-7D8-FEAR (huCLB-T3 / 4x7D8), bsIgG1-huCLB-T3 / 4-FEALxCD20-2F2-FEAR (huCLB-T3 / 4x2F2), bsIgG1-huCLB-T3 / 4-FEALxCD20-GA101-FEAR (huCLB-T3 / 4xGA101), bsIgG1-huCLB-T3 / 4-FEALxCD20-11B8-FEAR (huCLB-T3 / 4x11B8) and monospecific bivalent IgG1-7D8-FEAR to Daudi cells, (H) The binding of bsIgG1-huCD3-H1L1-FEALxCD20-7D8-FEAR, bsIgG1-huCD3-H1L1-FEALxCD20-2F2-FEAR, bsIgG1-huCD3-H1L1-FEALxCD20-GA101-FEAR, bsIgG1-huCD3-H1L1-FEALxCD20-RTX-FEAR, bsIgG1-huCD3-H1L1-FEALxCD20-11B8-FEAR, bsIgG1-huCD3-H1L1-FEALxCD20-2C6-FEAR, bsIgG1-huCD3-H1L1-FEALxb12-FEAR, and monospecific bivalent IgG1-huCD3-H1L1-FEAL to JurkaT cells, (I) The binding of bsIgG1-huCLB-T3 / 4-FEALxCD20-7D8-FEAR, bsIgG1-huCLB-T3 / 4-FEALxCD20-2F2-FEAR, bsIgG1-huCLB-T3 / 4-FEALxCD20-GA101-FEAR, bsIgG1-huCLB-T3 / 4-FEALxCD20-RTX-FEAR, bsIgG1-huCLB-T3 / 4-FEALxCD20-11B8-FEAR, bsIgG1-huCLB-T3 / 4-FEALxCD20-2C6-FEAR, bsIgG1-huCLB-T3 / 4-FEALxb12-FEAR, and monospecific bivalent IgG1-huCLB-T3 / 4-FEAL to JurkaT cells. The data shown represent the median fluorescence intensity of a representative experiment, as determined by flow cytometry.
[0021] Figure 2The bispecific antibody bsIgG1-huCD3-H1L1-FEALxCD20-7D8-FEAR (CD3xCD20) binds simultaneously to T cells and B cells in a concentration-dependent manner. The simultaneous binding of the bispecific antibody bsIgG1-huCD3-H1L1-FEALxCD20-7D8-FEAR (CD3xCD20) to B and T cells in blood was analyzed by flow cytometry. Data shown are from a representative experiment. The data shown are the number of double-positive (CD19 and CD4 [A] or CD19 and CD8 [B]) events, as determined by the number of events in the upper right quarter of the CD4 / CD19 or CD8 / CD19 flow cytometry dot plot. Solid and hollow symbols indicate data from different healthy donors. IgG1-2F2 (2F2, CD20-specific) and bsIgG1-huCD3-H1L1-FEALxb12-FEAR (CD3xb12, CD3-specific) were included as negative control antibodies.
[0022] Figure 3In vitro cytotoxicity was induced in human B-cell lymphoma and B-cell leukemia cell lines using a CD3xCD20 bispecific antibody. (A) Daudi cells were incubated with the monospecific CD20 antibodies IgG1-huCD3-H1L1-FEALxCD20-7D8-FEAR (CD3x7D8), IgG1-huCD3-H1L1-FEALxCD20-11B8-FEAR (CD3x11B8), IgG1-7D8 (7D8), IgG1-7D8-FEAR (7D8-FEAR; containing an inactivated Fc region), IgG1-11B8-F405L or IgG1-11B8-FEAR (11B8-FEAR; containing an inactivated Fc region), and the bispecific control antibody IgG1-huCD3-H1L1-FEALxb12-FEAR (CD3xb12), with PBMCs used as effector cells. (B) Daudi cells were incubated with BsIgG1-huCD3-H1L1-FEALxCD20-7D8-FEAR (CD3x7D8), monospecific CD20 antibody IgG1-7D8-FEAR (7D8-FEAR; containing an inactivated Fc region), and bsIgG1-huCD3-H1L1-FEALxb12-FEAR (CD3xb12), and purified T cells were used as effector cells. (CF) Daudi cells were incubated with two different CD3 arms (huCD3-H1L1-FEAL and huCLB-T3 / 4-FEAL Fab arms, indicated by hollow and solid symbols, respectively) and four different CD20 arms: 7D8 (BsIgG1-huCD3-H1L1-FEALxCD20-7D8-FEAR and BsIgG1-huCLB-T3 / 4-FEALxCD20-7D8-FEAR; [C]), 11B8 (BsIgG1-huCD3-H1L1-FEALxCD20-11B8-FEAR and BsIgG1-huCLB-T3 / 4-FEALxCD20-11B8-FEAR; [D]), GA101 (BsIgG1-huCD3-H1L1-FEALxCD20-GA101-FEAR and BsIgG1-huCLB-T3 / 4-FEALxCD20-GA101-FEAR; [E]), and 2F2 (BsIgG1-huCD3-H1L1-FEALxCD20-2F2-FEAR and BsIgG1-huCLB-T3 / 4-FEALxCD20-2F2-FEAR; [F]) were incubated with CD3xCD20 bispecific antibodies. (GM) Different B-cell lines were used as target cells and incubated with the antibodies shown.The CD3xCD20 bispecific antibody comprises the huCD3-H1L1-FEAL Fab arm shown and different CD20 Fab arms (7D8, 11B8, 2F2, GA101, or RTX). The CD3 antibody alone is IgG1-huCD3-H1L1. Purified T cells were used as effector cells. (N) Daudi cells were incubated with bsIgG1-huCD3-H1L1-FEALxCD20-7D8-FEAR (CD3x7D8), bsIgG1-huCD3-H1L1-FEALxCD20-2C6-FEAR (CD3x2C6), and bsIgG1-huCD3-H1L1-FEALxb12-FEAR (CD3xb12), and purified T cells were used as effector cells. The data shown are the mean percentage ± SD of specific lysis in triplicate wells, and the data for each figure were obtained from a representative experiment.
[0023] Figure 4 : Using purified total T cells (CD3) via bsIgG1-huCD3-H1L1-FEALxCD20-7D8-FEAR + CD4 + T cells (CD3) + CD8 - ) and CD8 + T cells (CD3) + CD8 + As effector cells, Daudi cells were dose-dependently induced for cytotoxicity in vitro. Daudi cells were incubated with different subsets of T cells shown and serial dilutions of bsIgG1-huCD3-H1L1-FEALxCD20-7D8-FEAR or control antibodies IgG1-huCD3-H1L1-FEALxb12-FEAR and IgG1-7D8-FEAR (data not shown). Data shown are mean percentage of tumor cell lysis in triplicate wells ± SEM (A, B).
[0024] Figure 5Kinetics of bsIgG1-huCLB-T3 / 4-FEALxCD20-7D8-FEAR-dependent cytotoxicity in Daudi cells. Daudi cells were incubated with bsIgG1-huCLB-T3 / 4-FEALxCD20-7D8-FEAR in the presence of purified T cells isolated from two different donors (A and B). Cytotoxicity was evaluated after 4, 12, 24, 48, and 72 hours of incubation (A) or after 3, 16, and 24 hours of incubation (B). Data shown are percentage of cell killing ± SD in triplicate wells of cells incubated with bsIgG1-huCLB-T3 / 4-FEALxCD20-7D8-FEAR for different incubation times. Data shown in A and B are from two independent experiments using purified T cells isolated from two different donors.
[0025] Figure 6 The in vitro cytotoxicity induction efficacy of CD3xCD20 bispecific antibodies was studied using different effector:target ratios. Cytotoxicity assays were performed using different CD3xCD20 bispecific antibodies and different E / T ratios. The CD3xCD20 bispecific antibodies included bsIgG1-huCD3-H1L1-FEALxCD20-7D8-FEAR (A), bsIgG1-huCD3-H1L1-FEALxCD20-11B8-FEAR (B), bsIgG1-huCD3-H1L1-FEALxCD20-GA101-FEAR (C), bsIgG1-huCD3-H1L1-FEALxCD20-RTX-FEAR (D), and bsIgG1-huCD3-H1L1-FEALxCD20-2F2-FEAR (E). bsIG1-huCLB-T3 / 4-FEALxb12-FEAR was included as a negative control with an E / T ratio of 10:1. The data shown are the mean percentage of lysate ± SD for a representative experiment, in triplicate, as determined in the cytotoxicity assay. Each line represents a different E / T ratio (as shown).
[0026] Figure 7Cytotoxic activity of CD3xCD20 bispecific antibody in the Raji-luc co-transplantation model of NOD-SCID mice. (A) Mean tumor size of mice treated with the specified dose of solvent (PBS) or bsIgG1-huCD3-H1L1-FEALxCD20-7D8-FEAR. Error bars represent SEM. (B) Tumor size of each mouse after treatment with PBS or bsIgG1-huCD3-H1L1-FEALxCD20-7D8-FEAR on day 21 post-tumor inoculation. Statistical analysis of the day 21 data was performed using Kruskal-Wallis (Dunn multiple comparisons as post-hoc test), **p<0.01. (C) Kaplan-Meier plot, tumor size cutoff set at 600 mm. 3 Statistical significance of the survival difference between the bsIgG1-huCD3-H1L1-FEALxCD20-7D8-FEAR-treated group and the PBS-treated control group was evaluated by Mantel Cox analysis. *p<0.05, **p<0.01, ns not significant. (D) Mean tumor size of mice treated with the specified dose of solvent (PBS) or bsIgG1-huCLB-T3 / 4-FEALxCD20-7D8-FEAR. Error bars represent SEM. (E) Tumor size of mice in different treatment groups on day 25 post-tumor inoculation. Statistical analysis was performed using the Kruskal-Wallis test (Dunn multiple comparisons were performed post-hoc). (F) Kaplan-Meier plot, with tumor size cutoff set at 500 mm. 3 Statistical significance of the differences between the treatment group and the solvent control group was analyzed by Mantel Cox analysis. *p<0.05, **p<0.01, ns not significant. (G) Mean tumor size of mice treated with the specified dose of solvent (PBS), bsIgG1-huCD3-H1L1-FEALxCD20-7D8-FEAR, or bsIgG1-huCD3-H1L1-FEALxCD20-11B8-FEAR. Error bars represent SEM. (H) Tumor size of each mouse on day 20 after tumor inoculation with PBS or bsIgG1-huCD3-H1L1-FEALxCD20-7D8-FEAR or bsIgG1-huCD3-H1L1-FEALxCD20-11B8-FEAR. Statistical analysis of the data on day 20 was performed using one-way ANOVA (Tukey multiple comparisons as post-hoc tests). *p<0.05, **p<0.01. (I) Kaplan-Meier plot, tumor size cutoff set at 500 mm3 The statistical significance of the survival difference between the bsIgG1-huCD3-H1L1-FEALxCD20-7D8-FEAR treatment group and the PBS-treated control group was evaluated by Mantel Cox analysis. *p<0.05, **p<0.01, ns not significant.
[0027] Figure 8 Antitumor activity of bsIgG1-huCD3-H1L1-FEALxCD20-7D8-FEAR in the Daudi-luc xenograft model in HIS mice. (A) Mean tumor size in the Daudi-luc xenograft model of BRGS-HIS mice after treatment with specified dose levels of PBS (solvent control), bsIgG1-huCD3-H1L1-FEALxCD20-7D8-FEAR (mAb2), or the control bispecific antibody bsIgG1-huCD3-H1L1-FEALxb12-FEAR (mAb1). Tumor burden was assessed by bioluminescence imaging. Error bars represent SEM. (B) Statistical analysis was performed on day 21 (Kruskal-Wallis test followed by Dunn post-hoc multiple comparison test). ** p < 0.01. (C) Characterization of peripheral blood leukocyte populations in BRGS-HIS mice carrying Daudi-luc xenografts on day 9 after treatment with either bsIgG1-huCD3-H1L1-FEALxCD20-7D8-FEAR or the control bispecific antibody bsIgG1-huCD3-H1L1-FEALxb12-FEAR, as determined by flow cytometry. %hCD45 + The cell count represents the total percentage of human leukocytes in mouse peripheral blood. %hCD19 + %hCD3 + and %hCD3 + FSC hi These represent the percentages of B cells, T cells, and activated T cells in a human leukocyte population, respectively.
[0028] Figure 9 A study of the effects of a single dose of bsIgG1-huCD3-H1L1-FEALxCD20-7D8-FEAR in cynomolgus monkeys. The study investigated the effects of different doses of bsIgG1-huCD3-H1L1-FEALxCD20-7D8-FEAR on the B-cell count (CD19) over time in the peripheral blood of cynomolgus monkeys treated with different doses (0.01, 0.1, 1, or 10 mg / kg). + CD21 + (A) and T-cell count (CD4) +Add CD8 + (B) Days -18 and -11 represent pre-drug administration B- and T-cell counts. B cells (C) and T cells (D) as percentages of the total lymphocyte population over time in lymph node samples from cynomolgus monkeys treated with different doses of bsIgG1-huCD3-H1L1-FEALxCD20-7D8-FEAR (0.01, 0.1, 1, or 10 mg / kg). Plasma levels of IL-2, IL-6, IL-8, IL-10, IFN-γ, and TNF-α in cynomolgus monkeys treated with different doses of bsIgG1-huCD3-H1L1-FEALxCD20-7D8-FEAR (0.01, 0.1, 1, or 10 mg / kg). (E). Pharmacokinetic profile of bsIgG1-huCD3-H1L1-FEALxCD20-7D8-FEAR in blood samples at various time points before and after administration up to 70 days. (F). Dashed lines represent predicted IgG1 pharmacokinetic profiles using a two-compartment model, k 10 The clearance constant is 0.006 h. -1 Vitamin C (plasma volume) 40 mL·kg -1 and a weight of 3.5 kg.
[0029] Figure 10The bispecific CD3xCD20 antibody binds to wild-type CD20 and CD20-AxP expressed in HEK293F cells. CD3xCD20 bispecific antibodies (bsIgG1-huCD3-H1L1-FEALxCD20-7D8-FEAR [huCD3x7D8], bsIgG1-huCLB-T3 / 4-FEALxCD20-7D8-FEAR [huCLB-T3 / 4x7D8], bsIgG1-huCD3-H1L1-FEALxCD20-2F2-FEAR [huCD3x2F2], bsIgG1-huCLB-T3 / 4-FEALxCD20-2F2-FEAR [huCLB-T3 / 4x2F2], bsIgG1-huCD3-H1L1-FEALxCD20-11B8-FEAR [huCD3x11B8], bsIgG1-huCLB-T3 / 4-FEALxCD20-11B8-FEAR The binding of [huCLB-T3 / 4x11B8], bsIgG1-huCD3-H1L1-FEALxCD20-GA101-FEAR [huCD3xGA101], bsIgG1-huCD3-H1L1-FEALxCD20-RTX-FEAR [huCD3xRTX], and bsIgG1-huCD3-H1L1-FEALxCD20-2C6-FEAR [huCD3x2C6] to wild-type CD20 (A) and CD20 mutant (CD20-AxP) (B) expressed in HEK293F cells was measured by flow cytometry. The data shown are mean fluorescence intensities from a representative experiment.
[0030] Figure 11 T cell activation after incubation of PBMCs with bsIgG1-huCD3-H1L1-FEALxCD20-7D8-FEAR Healthy donor PBMCs were incubated with bsIgG1-huCD3-H1L1-FEALxCD20-7D8-FEAR or positive and negative control antibodies, and T cell activation was measured by measuring the T cell population (CD28). + Evaluation of CD69 expression in cells. Experiments were performed using PBMCs isolated from five healthy donors. Results from two representative donors are shown.
[0031] Table 1 . Invention Details definition As used herein, the term "human CD3" or "CD3" refers to human differentiation cluster 3 protein, which is part of the T-cell co-receptor protein complex and is composed of four different chains. CD3 is also found in other species, therefore the term "CD3" may be used herein and is not limited to human CD3 unless the context contradicts it. In mammals, this complex comprises a CD3γ (gamma) chain (human CD3γ chain UniProtKB / Swiss-Prot No P09693 or cynomolgus monkey CD3γ UniProtKB / Swiss-Prot No Q95LI7), a CD3δ (delta) chain (human CD3δ UniProtKB / Swiss-Prot No P04234 or cynomolgus monkey CD3δ UniProtKB / Swiss-Prot No Q95LI8), two CD3ε (epsilon) chains (human CD3ε UniProtKB / Swiss-Prot No P07766; cynomolgus monkey CD3ε UniProtKB / Swiss-Prot No Q95LI5; or rhesus monkey CD3ε UniProtKB / Swiss-Prot No G7NCB9) and a CD3ζ (zeta) chain (human CD3ζ UniProtKB / Swiss-Prot No. P20963; Cynomolgus monkey CD3ζ UniProtKB / Swiss-Prot No Q09TK0). These chains associate with molecules called T-cell receptors (TCRs) and generate activation signals in T lymphocytes. TCRs and CD3 molecules together form the TCR complex.
[0033] The term "human CD20" or "CD20" refers to human CD20 (UniProtKB / Swiss-Prot No P11836) and any variants, isotypes, and species homologs of CD20, including those naturally expressed in cells (including tumor cells) or expressed in cells transfected with the CD20 gene or cDNA. Species homologs include rhesus macaque CD20 (macaca mulatta; UniProtKB / Swiss-Prot No H9YXP1).
[0034] As used herein, the term "chimeric antibody" refers to an antibody in which the variable region is derived from a non-human species (e.g., from rodents) and the constant region is derived from a different species (e.g., humans). Chimeric antibodies can be produced through antibody engineering. "Antibody engineering" is a general term used for different types of antibody modification, and it is a method well-known to those skilled in the art. In particular, chimeric antibodies can be produced using standard DNA techniques, as described in Sambrook et al. . , 1989, Molecular Cloning: A Laboratory Manual, New York: Cold Spring Harbor Laboratory Press, Ch. 15. Therefore, chimeric antibodies can be genetically engineered or enzyme-engineered recombinant antibodies. The production of chimeric antibodies is within the knowledge of those skilled in the art; therefore, the chimeric antibodies of this invention can be produced by methods other than those described herein. Chimeric monoclonal antibodies are developed for therapeutic applications to reduce antibody immunogenicity. They typically contain a non-human (e.g., mouse) variable region specific to the target antigen, and human constant antibody heavy and light chain domains. In the context of chimeric antibodies, the term "variable region" or "variable domain" refers to the region containing both the CDR and framework regions of the immunoglobulin's heavy and light chains.
[0035] As used herein, “humanized antibody” refers to a genetically engineered non-human antibody containing a human antibody constant domain and a non-human variable domain, modified to contain a high level of sequence homology with the human variable domain. This can be achieved by transplanting six non-human antibody complementarity-determining regions (CDRs) (which together form the antigen-binding site) onto a homologous human receptor frame region (FR) (see WO92 / 22653 and EP0629240). To fully reconstruct the binding affinity and specificity of the parent antibody, it may be necessary to replace the frame residues from the parent antibody (i.e., the non-human antibody) with human frame regions (reversion mutations). Structural homology modeling can help identify amino acid residues in the frame regions that are important for antibody binding properties. Therefore, humanized antibodies may contain a non-human CDR sequence, primarily a human frame region (optionally containing one or more amino acid reversion mutations to non-human amino acid sequences), and a fully human constant region. Optionally, additional amino acid modifications, not necessarily reversion mutations, may be applied to obtain humanized antibodies with preferred characteristics, such as affinity and biochemical properties.
[0036] As used herein, the term "human antibody" refers to an antibody having variable and constant regions derived from human germline immunoglobulin sequences. Human antibodies may include amino acid residues not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutations in vivo). However, as used herein, the term "human antibody" is not intended to include antibodies in which a CDR sequence derived from another mammalian species (e.g., mouse) has been grafted onto a human frame sequence. The human monoclonal antibodies of the present invention can be produced by various techniques, including conventional monoclonal antibody methods, such as those employed by Kohler and Milstein. Nature The standard somatic cell hybridization technique is described in 256:495 (1975). Although somatic cell hybridization is preferred, other techniques for producing monoclonal antibodies may, in principle, be used, such as viral or oncogene conversion of B-lymphocytes, or phage display using a human antibody gene library.
[0037] A suitable animal system for preparing hybridomas that secrete human monoclonal antibodies is the mouse system. Hybridoma generation in mice is a well-established procedure. Immunoassay protocols and techniques for isolating immune spleen cells for fusion are known in the art. Fusion couples (e.g., mouse myeloma cells) and fusion procedures are also known.
[0038] Human monoclonal antibodies can be produced using transgenic or transchromosomal mice that carry a portion of the human immune system rather than the mouse system.
[0039] The term "immunoglobulin" refers to a class of structurally related glycoproteins composed of two pairs of polypeptide chains: a pair of low-molecular-weight light (L) chains and a pair of heavy (H) chains, all four chains linked together by disulfide bonds. The structure of immunoglobulins has been well characterized. See, for example, Fundamental Immunology Ch. 7 (Paul, W., ed., 2nd ed. RavenPress, NY (1989)). In short, each heavy chain typically contains a heavy chain variable region (referred to herein as V). H or VH) and heavy chain constant region (hereinafter referred to as C) H Or CH). Heavy chain constant regions typically contain three domains C. H 1. C H 2 and C H 3. Each light chain typically contains a light chain variable region (referred to as V in this article). L or VL) and light chain constant region (hereinafter referred to as C) L Or CL). The constant region of a light chain typically contains a domain C. L V H and V LThe region can be further subdivided into highly variable regions (or hypervariable regions, which can be highly varied in terms of the sequence and / or form of the structurally defined rings), also known as complementary determinant regions (CDRs), which alternate with more conservative regions called framing regions (FRs). Each V H and V L It typically contains three CDRs and four FRs, arranged in the following order from the amino terminus to the carboxyl terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4 (see also Chothia and Lesk J.Mol. Biol). 196 , 901-917 (1987)). Unless otherwise stated or contradicted in the context, the CDR sequences in this paper are determined according to the IMGT rules (Brochet X., Nucl Acids Res. 2008;36:W503-508 and Lefranc MP., Nuclear Acids Research 1999;27:209-212; see also the Internet http: / / www.imgt.org / ).
[0040] Unless otherwise stated or contradicted in the context, references to amino acid positions in constant regions in this invention are made according to EU numbering (Edelman et al., Proc Natl Acad Sci US A. 1969 May;63(1):78-85; Kabat et al., Sequences of Proteins of Immunological Interest, Fifth Edition.1991 NIH Publication No. 91-3242).
[0041] In the context of this invention, the term "antibody" (Ab) refers to an immunoglobulin molecule, a fragment of an immunoglobulin molecule, or any derivative thereof, which has the ability to specifically bind antigens under typical physiological conditions and has a significant half-life, such as at least about 30 minutes, at least about 45 minutes, at least about 1 hour, at least about 2 hours, at least about 4 hours, at least about 8 hours, at least about 12 hours, about 24 hours or more, about 48 hours or more, about 3, 4, 5, 6, 7 or more days, etc., or any other relevant functionally defined period (e.g., sufficient time to induce, promote, enhance, and / or regulate physiological responses related to antibody binding to antigens, and / or sufficient time for antibody to recruit effector activity). The variable regions of the heavy and light chains of the immunoglobulin molecule contain binding domains that interact with antigens. The constant regions of the antibody (Ab) mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and components of the complement system such as C1q, which is a first component of the classical pathway of complement activation. As shown above, the term "antibody" in this document, unless otherwise stated or clearly contradicted by the context, includes fragments of an antibody that are antigen-binding fragments, i.e., those that retain the ability to specifically bind antigens. It has been shown that the antigen-binding function of an antibody can be achieved by fragments of a full-length antibody. Examples of antigen-binding fragments included in the term "antibody" include (i) Fab' or Fab fragments, a type of antibody composed of V... L V H C L and C H (i) a monovalent fragment consisting of a 1-domain structure, or the monovalent antibody (Genmab) described in WO2007059782; (ii) an F(ab')2 fragment, which is a bivalent fragment containing two Fab fragments connected by a disulfide bridge in the hinge region; (iii) an Fd fragment, which is essentially composed of V H and C H 1. Composed of structural domains; (iv) Fv fragment, which is essentially composed of the V of the antibody single arm. L and V H Domain composition; (v) dAb fragment (Ward et al) . Nature 341 , 544-546 (1989)), which is basically composed of V H Domain composition and also known as domain antibody (Holt et al.; Trends Biotechnol. 2003 Nov; 21 (11):484-90); (vi) Camel or nanobody (Revets et al.; Expert Opin Biol Ther. 2005 Jan; 5(1):111-24) and (vii) separate complementarity-determining regions (CDRs). Furthermore, despite the two structural domains of the Fv segment, V L and V H These proteins are encoded by individual genes, but they can be produced as a single protein chain using recombination methods, linked together by synthetic linkers. L and V H Regions pair to form monovalent molecules (called single-chain antibodies or single-chain Fvs (scFvs), see, for example, Bird et al.) . Science 242 , 423-426 (1988) and Huston et al . PNAS USA 85 , 5879-5883 (1988)). Such single-chain antibodies are included within the scope of the term antibody unless otherwise specified or clearly indicated by the context. Although such fragments are generally included within the meaning of antibody, they are collectively and individually distinctive features of the present invention, exhibiting different biological properties and functions. In the case of the present invention, these and other useful antibody fragments, as well as bispecific forms of such fragments, are further discussed herein. It should also be understood that the term antibody, unless otherwise stated, also includes polyclonal antibodies, monoclonal antibodies (mAbs), antibody-like polypeptides such as chimeric antibodies and humanized antibodies, and antibody fragments (antigen-binding fragments) that retain the ability to specifically bind antigens, provided by any known technique, such as enzyme cleavage, peptide synthesis, and recombinant techniques. The resulting antibodies may have any isotype.
[0042] In the context of this invention, the term "bispecific antibody" refers to an antibody having two different antigen-binding regions defined by different antibody sequences.
[0043] When used herein, unless the context contradicts, the term “Fab-arm” or “arm” refers to a heavy-light chain pair and is used interchangeably with “half-molecule” in this document.
[0044] When used in this article, unless the context contradicts, the term "Fc region" refers to an antibody region containing at least a hinge region, a CH2 domain, and a CH3 domain.
[0045] As used herein, the term "isotype" refers to a class of immunoglobulins (e.g., IgG1, IgG2, IgG3, IgG4, IgD, IgA, IgE, or IgM) encoded by genes in the heavy chain constant region.
[0046] In the context of this invention, the term "monovalent antibody" refers to an antibody molecule that can bind to a single molecule of an antigen and therefore cannot undergo antigen cross-linking.
[0047] "CD20 antibody" or "anti-CD20 antibody" is the antibody mentioned above, which specifically binds to the antigen CD20.
[0048] "CD3 antibody" or "anti-CD3 antibody" is the antibody mentioned above that specifically binds to the antigen CD3, especially human CD3ε (epsilon).
[0049] "CD3xCD20 antibody" or "anti-CD3xCD20 antibody" is a bispecific antibody that contains two different antigen-binding regions, one of which specifically binds to the antigen CD20 and the other specifically binds to CD3.
[0050] In a preferred embodiment, the bispecific antibody of the present invention is isolated. As used herein, "isolated bispecific antibody" means a bispecific antibody that is substantially free of other antibodies with different antigen specificities (e.g., an isolated bispecific antibody that specifically binds to CD20 and CD3 is substantially free of monospecific antibodies that specifically bind to CD20 or CD3).
[0051] The term "epitaph" refers to a protein determinant that specifically binds to an antibody. Epitopes are typically composed of surface clusters of molecules, such as amino acids or sugar side chains, and usually possess specific three-dimensional structural features as well as specific charge characteristics. Conformational and non-conformational epitopes differ in that binding to the former, but not the latter, is lost in the presence of denaturing solvents. Epitopes can contain amino acid residues that directly participate in binding and other amino acid residues that do not directly participate in binding, such as amino acid residues that are effectively blocked or covered by the specific antigen-binding peptide (in other words, the amino acid residues are within the footprint of the specific antigen-binding peptide).
[0052] As used herein, the term "monoclonal antibody" refers to a preparation of an antibody molecule having a single molecular composition. Monoclonal antibody compositions exhibit single binding specificity and affinity for a specific epitope. Therefore, the term "human monoclonal antibody" refers to an antibody exhibiting single binding specificity having variable and constant regions derived from human germline immunoglobulin sequences. Human monoclonal antibodies can be produced via hybridomas comprising B cells derived from transgenic or transchromosomally transgenic non-human animals, such as transgenic mice, having a genome containing human heavy chain and light chain transgenes, fused into immortalized cells.
[0053] As used herein, the term "binding" in the context of antibody binding to a predetermined antigen or epitope is generally used when, on a BIAcore 3000 instrument, the antigen is measured as a ligand and the antibody as an analyte by, for example, surface plasmon resonance (SPR) technology, having a corresponding K D Approximately 10 -7 M or smaller, for example, about 10-8 M or smaller, for example, about 10 -9 M or smaller, approximately 10 -10 M or smaller or about 10 -11 The binding affinity of M or even lower, and compared to its affinity for non-specific antigens (e.g., BSA, casein) that are not the intended antigen or closely related antigens, corresponding to a K affinity at least 10 times lower, for example at least 100 times lower, for example at least 1,000 times lower, for example at least 10,000 times lower, for example at least 100,000 times lower, for example at least 100,000 times lower, for example at least 100,000 times lower. D The antibody binds to the predetermined antigen with affinity. The amount of affinity reduction depends on the antibody's K... D This makes the K of the antibody... D When the level is very low (i.e., the antibody is highly specific), the amount by which the affinity for the antigen is lower than that for the non-specific antigen can be at least 10,000 times.
[0054] As the term "k" is used in this article d ” (sec -1 This refers to the dissociation rate constant of a specific antibody-antigen interaction. This value is also known as k. off value.
[0055] As the term "K" is used in this article D "(M) refers to the dissociation equilibrium constant of a specific antibody-antigen interaction.
[0056] When used herein, the term "heterodimeric interaction between the first and second CH3 regions" refers to the heterodimeric interaction between the first CH3 region and the second CH3 region in a first-CH3 / second-CH3 heterodimeric protein.
[0057] When used herein, the term “homodimeric interaction between first and second CH3 regions” refers to the interaction between a first CH3 region and another first CH3 region in a first-CH3 / first-CH3 homodimeric protein, and the interaction between a second CH3 region and another second CH3 region in a second-CH3 / second-CH3 homodimeric protein.
[0058] The term "reduction conditions" or "reduction environment" refers to the conditions or environment in which the substrate, in this case, the cysteine residue in the hinge region of the antibody, is more likely to be reduced rather than oxidized.
[0059] The present invention also provides V containing the bispecific antibody of the embodiments. L District, V H Bispecific antibodies against regions or functional variants of one or more CDRs. V is used in cases of bispecific antibodies. L VH Functional variants of the CDR still allow each arm of the bispecific antibody to retain at least a significant proportion (at least about 50%, 60%, 70%, 80%, 90%, 95% or more) of the affinity and / or specificity / selectivity of the parent bispecific antibody, and in some cases, such bispecific antibodies can associate with greater affinity, selectivity and / or specificity than the parent bispecific antibody.
[0060] Such functional variants typically retain significant sequence identity with the parental bispecific antibody. The percentage of identity between two sequences is a function of the number of common positions shared by the sequences (i.e., %homology = number of common positions / total number of positions x 100), taking into account the number of vacancies and the length of each vacancy, which needs to be incorporated into the optimal alignment of the two sequences. The percentage of identity between two nucleotide or amino acid sequences can, for example, be determined using the algorithm of E. Meyers and W. Miller, Comput. Appl. Biosci 4, 11-17 (1988), which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weighted residue table, a vacancy length penalty of 12, and a vacancy penalty of 4. Alternatively, the percentage of identity between two amino acid sequences can be determined using the algorithm of Needleman and Wunsch, J. Mol. Biol. 48, 444-453 (1970).
[0061] Instance variants include those that differ from the parental bispecific antibody sequence primarily through conserved substitutions of the VH and / or VL and / or CDR regions; for example, 10, such as 9, 8, 7, 6, 5, 4, 3, 2, or 1 substitution in the variant is a conserved amino acid residue substitution.
[0062] In the case of this invention, conservative substitutions can be defined by substitutions within the amino acid types reflected in the table below: Types of amino acid residues with conserved substitutions In the context of this invention, unless otherwise stated, the following notes are used to describe mutations: i) an amino acid substitution at a given position is written, for example, K409R, meaning that lysine at position 409 is replaced with arginine; and ii) for specific variants, a specific three- or one-letter code is used, including the codes Xaa and X, to indicate any amino acid residue. Thus, a lysine substitution at position 409 for arginine is called K409R, and a lysine substitution at position 409 for any amino acid residue is called K409X. In the case of a lysine deletion at position 409, it is represented as K409*.
[0063] As used herein, the term "recombinant host cell" (or simply "host cell") refers to a cell in which an expression vector has been introduced, such as an expression vector encoding the antibody of the present invention. Recombinant host cells include, for example, transfected tumor cells, such as CHO, CHO-S, HEK, HEK293, HEK-293F, Expi293F, PER.C6, or NSO cells, and lymphocytes.
[0064] The term "treatment" refers to the administration of an effective amount of the therapeutically active bispecific antibody of the present invention for the purpose of alleviating, improving, stopping or eradicating (curing) symptoms or disease states.
[0065] The term "effective dose" or "therapeutic effective dose" refers to the amount of medication required to effectively achieve the desired therapeutic outcome, including the dosage and time needed to achieve that outcome. The therapeutically effective dose of a bispecific antibody can vary depending on factors such as disease condition, individual age, sex, weight, and the bispecific antibody's ability to elicit the desired response in the individual. A therapeutically effective dose is still a dose in which any toxic or harmful effects of the antibody or its components outweigh the beneficial therapeutic effects.
[0066] The term "anti-individual genotype antibody" refers to an antibody that recognizes a unique determinant cluster that normally associates with the antigen-binding site of the antibody.
[0067] Other aspects and embodiments of the invention As described above, the present invention relates to a bispecific antibody comprising two different antigen-binding regions, one having binding specificity for CD3 and the other having binding specificity for CD20.
[0068] Therefore, the present invention relates to a bispecific antibody comprising (i) a first binding arm comprising a first antigen-binding region comprising a first antigen-binding region binding to human CD3ε (epsilon), wherein the first antigen-binding region comprises a) Heavy chain variable (VH) regions CDR1, CDR2 and CDR3 having the sequences shown in SEQ ID NO:1, 2 and 3 respectively, and light chain variable (VL) regions CDR1, CDR2 and CDR3 having the sequence shown in SEQ ID NO:4, sequence GTN and the sequence shown in SEQ ID NO:5 respectively; b) Heavy chain variable (VH) regions CDR1, CDR2 and CDR3 having the sequences shown in SEQ ID NO:1, 2 and 3 respectively, and light chain variable (VL) regions CDR1, CDR2 and CDR3 having the sequence shown in SEQ ID NO:4, sequence GTN and the sequence shown in SEQ ID NO:5 respectively; c) Heavy chain variable (VH) regions CDR1, CDR2 and CDR3 having the sequences shown in SEQ ID NO:73, 2 and 3 respectively, and light chain variable (VL) regions CDR1, CDR2 and CDR3 having the sequence shown in SEQ ID NO:4, sequence GTN and the sequence shown in SEQ ID NO:5 respectively, wherein X2 of SEQ ID NO:73 is selected from M and P; d) Heavy chain variable (VH) regions CDR1, CDR2 and CDR3 having the sequences shown in SEQ ID NO:74, 2 and 3 respectively, and light chain variable (VL) regions CDR1, CDR2 and CDR3 having the sequence shown in SEQ ID NO:4, sequence GTN and the sequence shown in SEQ ID NO:5 respectively, wherein X3 of SEQ ID NO:74 is A; e) Heavy chain variable (VH) regions CDR1, CDR2 and CDR3 having the sequences shown in SEQ ID NO:1, 75 and 3 respectively, and light chain variable (VL) regions CDR1, CDR2 and CDR3 having the sequence shown in SEQ ID NO:4, sequence GTN and the sequence shown in SEQ ID NO:5 respectively, wherein X4 of SEQ ID NO:75 is E; f) Heavy chain variable (VH) regions CDR1, CDR2 and CDR3 having the sequences shown in SEQ ID NO:1, 2 and 77 respectively, and light chain variable (VL) regions CDR1, CDR2 and CDR3 having the sequence shown in SEQ ID NO:4, sequence GTN and the sequence shown in SEQ ID NO:5 respectively, wherein X6 of SEQ ID NO:77 is selected from F, G, I, K, L and N; g) Heavy chain variable (VH) regions CDR1, CDR2 and CDR3 having the sequences shown in SEQ ID NO:1, 2 and 78 respectively, and light chain variable (VL) regions CDR1, CDR2 and CDR3 having the sequence shown in SEQ ID NO:4, sequence GTN and the sequence shown in SEQ ID NO:5 respectively, wherein X7 of SEQ ID NO:78 is P; h) Heavy chain variable (VH) regions CDR1, CDR2 and CDR3 having the sequences shown in SEQ ID NO:1, 2 and 79 respectively, and light chain variable (VL) regions CDR1, CDR2 and CDR3 having the sequence shown in SEQ ID NO:4, sequence GTN and the sequence shown in SEQ ID NO:5 respectively, wherein X8 of SEQ ID NO:79 is selected from A and G; i) Heavy chain variable (VH) regions CDR1, CDR2, and CDR3 having the sequences shown in SEQ ID NO:1, 2, and 80, respectively, and light chain variable (VL) regions CDR1, CDR2, and CDR3 having the sequence shown in SEQ ID NO:4, sequence GTN, and the sequence shown in SEQ ID NO:5, respectively, wherein X8 of SEQ ID NO:80 is selected from M, R, and V; or j) Heavy chain variable (VH) regions CDR1, CDR2, and CDR3 having the sequences shown in SEQ ID NO:55, 56, and 57, respectively, and light chain variable (VL) regions CDR1, CDR2, and CDR3 having the sequence shown in SEQ ID NO:58, sequence DTS, and the sequence shown in SEQ ID NO:59, respectively; and (ii) A second binding arm containing a second antigen-binding region that binds to human CD20.
[0069] This provides bispecific antibodies with different binding affinities to CD3ε. In one embodiment, the binding affinity to CD3 is preferably lower than that to the parental anti-CD3 binding arm. Experimental data have shown that the bispecific CD3xCD20 antibody with an anti-CD3 binding arm as described above in c)-i) (which has a substitution that reduces the binding affinity to CD3ε) maintains the tumor-killing efficacy of the parental bispecific anti-CD3xCD20 antibody.
[0070] In one embodiment, the present invention relates to a bispecific antibody comprising (i) a first binding arm comprising a first antigen-binding region comprising a first antigen-binding region comprising (a) heavy chain variable (VH) regions CDR1, CDR2, and CDR3 having sequences shown in SEQ ID NO:1, 2, and 3, respectively, and light chain variable (VL) regions CDR1, CDR2, and CDR3 having sequences shown in SEQ ID NO:4, sequence GTN, and sequences shown in SEQ ID NO:5 or SEQ ID NO:54, respectively; or (b) heavy chain variable (VH) regions CDR1, CDR2, and CDR3 having sequences shown in SEQ ID NO:55, 56, and 57, respectively, and light chain variable (VL) regions CDR1, CDR2, and CDR3 having sequences shown in SEQ ID NO:58, sequence DTS, and sequences shown in SEQ ID NO:59, respectively; and (ii) a second binding arm comprising a second antigen-binding region ...
[0071] In one embodiment, the present invention relates to a bispecific antibody comprising a first binding arm including a first antigen-binding region for binding human CD3ε (epsilon), wherein the first antigen-binding region comprises heavy chain variable (VH) regions CDR1, CDR2, and CDR3 having sequences shown in SEQ ID NO:1, 2, and 3, respectively, and light chain variable (VL) regions CDR1, CDR2, and CDR3 having sequences shown in SEQ ID NO:4, sequence GTN, and sequence shown in SEQ ID NO:5, respectively.
[0072] The term "binding arm containing an antigen-binding region" refers to an antibody molecule or fragment that contains an antigen-binding region. Therefore, a binding arm can be, for example, six VH and VL CDR regions, VH and VL sequences, a Fab fragment, or a half-molecule antibody (i.e., containing one heavy chain and one light chain).
[0073] In one embodiment, the first antigen-binding region comprises a first heavy chain variable sequence (VH) and a first light chain variable sequence (VL), and the second antigen-binding region comprises a second heavy chain variable sequence (VH) and a second light chain variable sequence (VL).
[0074] In one embodiment, the first binding arm comprises a first heavy chain containing a first heavy chain variable sequence (VH) and a first heavy chain constant sequence (CH) and a first light chain containing a first light chain variable sequence (VL) and a first light chain constant sequence (CL), and (ii) the second binding arm comprises a second heavy chain containing a second heavy chain variable sequence (VH) and a second heavy chain constant sequence (CH) and the second light chain contains a second light chain variable sequence (VL) and a second light chain constant sequence (CL).
[0075] In one embodiment, the bispecific antibody is a full-length antibody, such as a full-length IgG1 antibody, for example, a full-length IgG1,λ (lambda),κ (kappa) antibody or an IgG1,κ (kappa),κ (kappa) antibody.
[0076] First connecting arm The first binding arm includes a first antigen-binding region that binds to human CD3ε (epsilon), wherein the first antigen-binding region includes a) Heavy chain variable (VH) regions CDR1, CDR2 and CDR3 having the sequences shown in SEQ ID NO:1, 2 and 3 respectively, and light chain variable (VL) regions CDR1, CDR2 and CDR3 having the sequence shown in SEQ ID NO:4, sequence GTN and the sequence shown in SEQ ID NO:5 respectively; b) Heavy chain variable (VH) regions CDR1, CDR2 and CDR3 having the sequences shown in SEQ ID NO:1, 2 and 3 respectively, and light chain variable (VL) regions CDR1, CDR2 and CDR3 having the sequence shown in SEQ ID NO:4, sequence GTN and the sequence shown in SEQ ID NO:5 respectively; c) Heavy chain variable (VH) regions CDR1, CDR2 and CDR3 having the sequences shown in SEQ ID NO:73, 2 and 3 respectively, and light chain variable (VL) regions CDR1, CDR2 and CDR3 having the sequence shown in SEQ ID NO:4, sequence GTN and the sequence shown in SEQ ID NO:5 respectively, wherein X2 of SEQ ID NO:73 is selected from M and P; d) Heavy chain variable (VH) regions CDR1, CDR2 and CDR3 having the sequences shown in SEQ ID NO:74, 2 and 3 respectively, and light chain variable (VL) regions CDR1, CDR2 and CDR3 having the sequence shown in SEQ ID NO:4, sequence GTN and the sequence shown in SEQ ID NO:5 respectively, wherein X3 of SEQ ID NO:74 is A; e) Heavy chain variable (VH) regions CDR1, CDR2 and CDR3 having the sequences shown in SEQ ID NO:1, 75 and 3 respectively, and light chain variable (VL) regions CDR1, CDR2 and CDR3 having the sequence shown in SEQ ID NO:4, sequence GTN and the sequence shown in SEQ ID NO:5, wherein X4 of SEQ ID NO:75 is E; f) Heavy chain variable (VH) regions CDR1, CDR2 and CDR3 having the sequences shown in SEQ ID NO:1, 2 and 77 respectively, and light chain variable (VL) regions CDR1, CDR2 and CDR3 having the sequence shown in SEQ ID NO:4, sequence GTN and the sequence shown in SEQ ID NO:5 respectively, wherein X6 of SEQ ID NO:77 is selected from F, G, I, K, L and N; g) Heavy chain variable (VH) regions CDR1, CDR2 and CDR3 having the sequences shown in SEQ ID NO:1, 2 and 78 respectively, and light chain variable (VL) regions CDR1, CDR2 and CDR3 having the sequence shown in SEQ ID NO:4, sequence GTN and the sequence shown in SEQ ID NO:5 respectively, wherein X7 of SEQ ID NO:78 is P; h) Heavy chain variable (VH) regions CDR1, CDR2 and CDR3 having the sequences shown in SEQ ID NO:1, 2 and 79 respectively, and light chain variable (VL) regions CDR1, CDR2 and CDR3 having the sequence shown in SEQ ID NO:4, sequence GTN and the sequence shown in SEQ ID NO:5 respectively, wherein X8 of SEQ ID NO:79 is selected from A and G; i) Heavy chain variable (VH) regions CDR1, CDR2, and CDR3 having the sequences shown in SEQ ID NO:1, 2, and 80, respectively, and light chain variable (VL) regions CDR1, CDR2, and CDR3 having the sequence shown in SEQ ID NO:4, sequence GTN, and the sequence shown in SEQ ID NO:5, respectively, wherein X8 of SEQ ID NO:80 is selected from M, R, and V; or j) Heavy chain variable (VH) regions CDR1, CDR2 and CDR3 having the sequences shown in SEQ ID NO:55, 56 and 57 respectively, and light chain variable (VL) regions CDR1, CDR2 and CDR3 having the sequence shown in SEQ ID NO:58, sequence DTS and the sequence shown in SEQ ID NO:59 respectively.
[0077] In one embodiment, the first binding arm includes a first antigen-binding region for binding human CD3ε (epsilon), wherein the first antigen-binding region includes (a) heavy chain variable (VH) regions CDR1, CDR2, and CDR3 having sequences shown in SEQ ID NO:1, 2, and 3, respectively, and light chain variable (VL) regions CDR1, CDR2, and CDR3 having sequences shown in SEQ ID NO:4, sequence GTN, and sequences shown in SEQ ID NO:5 or SEQ ID NO:54, respectively; or (b) heavy chain variable (VH) regions CDR1, CDR2, and CDR3 having sequences shown in SEQ ID NO:55, 56, and 57, respectively, and light chain variable (VL) regions CDR1, CDR2, and CDR3 having sequences shown in SEQ ID NO:58, sequence DTS, and sequences shown in SEQ ID NO:59, respectively.
[0078] In one embodiment, the first binding arm includes a first antigen-binding region that binds to human CD3ε (epsilon), wherein the first antigen-binding region includes heavy chain variable (VH) regions CDR1, CDR2, and CDR3 having sequences shown in SEQ ID NO:1, 2, and 3, respectively, and light chain variable (VL) regions CDR1, CDR2, and CDR3 having sequences shown in SEQ ID NO:4, sequence GTN, and sequence shown in SEQ ID NO:5, respectively.
[0079] The six CDR sequences defined in (a) above are derived from a mouse antibody called SP34. A humanized form of this antibody has been produced, and the humanized antibody is referred to herein as huCD3 and further disclosed in WO2015001085 (Genmab).
[0080] The six CDR sequences defined in (b) above are derived from huCLB-T3 / 4. huCLB-T3 / 4 is the humanized form of the mouse CD3 antibody CLB-T3 / 4 (Parren et al., Res Immunol. 1991, 142(9):749-63, incorporated herein by reference in its entirety, including the sequence disclosure). Briefly, the mouse VH and VL sequences of CLB-T3 / 4 published in Parren et al. (1991) were compared with human VH and VL libraries using IMGT's V-QUEST. The closest human lineages found were IGHV3-21*01 (for the VH gene) and IGKV3-11*01(+IGKJ4*02) (for the VL gene). All different amino acid residues in the mouse VH and VL sequences were replaced with human equivalents, except those within the CDR regions of CLB-T3 / 4. Because no associated J-region was found for the VH sequence, the common WGQGTLVTVSS sequence was used for the FR4 region of the heavy chain. Both sequences were cloned into the associated expression vector and expressed via co-transfection of HEK293F cells. huCLB-T3 / 4 has a VH region (VH huCLB-T3 / 4) containing the sequence shown in SEQ ID NO:17 and a VL region (VL huCLB-T3 / 4) containing the sequence shown in SEQ ID NO:18. huCLB-T3 / 4 has the VH CDR1, CDR2, and CDR3 sequences shown in SEQ ID NO:55, 56, and 57, respectively, and the VL CDR1, CDR2, and CDR3 sequences shown in SEQ ID NO:58, sequence DTS, and SEQ ID NO:59, respectively.
[0081] Various humanized huCD3 antibodies and huCLB-T3 / 4 binding human CD3ε (epsilon).
[0082] In one embodiment, the bispecific antibody defined in any of the embodiments disclosed herein comprises a first heavy chain variable sequence (VH), wherein said VH sequence has at least 90%, at least 95%, at least 97%, or at least 99% amino acid sequence identity with an amino acid sequence selected from the following VH sequences: a) The VH sequence shown in SEQ ID NO:6; b) The VH sequence shown in SEQ ID NO:7; c) The VH sequence shown in SEQ ID NO:8; d) The VH sequence shown in SEQ ID NO:9; and e) The VH sequence shown in SEQ ID NO:17.
[0083] In one implementation, the VH sequence of the first antigen-binding region is selected from: a) The VH sequence shown in SEQ ID NO:6; b) The VH sequence shown in SEQ ID NO:7; c) The VH sequence shown in SEQ ID NO:8; d) The VH sequence shown in SEQ ID NO:9; e) The VH sequence shown in SEQ ID NO:17.
[0084] In one embodiment, the bispecific antibody as defined in any of the embodiments disclosed herein comprises a first VL sequence of a first antigen-binding region, wherein said VL sequence has at least 90%, at least 95%, at least 97%, or at least 99% amino acid sequence identity with an amino acid sequence selected from the following VL sequences: a) The VL sequence shown in SEQ ID NO:10; b) The VL sequence shown in SEQ ID NO:11; c) The VL sequence shown in SEQ ID NO:12; and d) The VL sequence shown in SEQ ID NO:18.
[0085] In one implementation, the VL sequence of the first antigen-binding region is selected from: The VL sequence shown in SEQ ID NO:10; a) The VL sequence shown in SEQ ID NO:11; b) The VL sequence shown in SEQ ID NO:12; and c) The VL sequence shown in SEQ ID NO:18.
[0086] In one embodiment, the bispecific antibody as defined in any of the embodiments disclosed herein comprises first VH and VL sequences, wherein the VH and VL sequences of the first antigen-binding region are selected from: a) The VH sequence shown in SEQ ID NO:6 and the VL sequence shown in SEQ ID NO:10; b) The VH sequence shown in SEQ ID NO:8 and the VL sequence shown in SEQ ID NO:10; c) The VH sequence shown in SEQ ID NO:9 and the VL sequence shown in SEQ ID NO:10; d) The VH sequence shown in SEQ ID NO:6 and the VL sequence shown in SEQ ID NO:11; e) The VH sequence shown in SEQ ID NO:6 and the VL sequence shown in SEQ ID NO:12; f) The VH sequence shown in SEQ ID NO:7 and the VL sequence shown in SEQ ID NO:10; g) The VH sequence shown in SEQ ID NO:7 and the VL sequence shown in SEQ ID NO:11; h) The VH sequence shown in SEQ ID NO:7 and the VL sequence shown in SEQ ID NO:12; i) The VH sequence shown in SEQ ID NO:8 and the VL sequence shown in SEQ ID NO:11; j) The VH sequence shown in SEQ ID NO:8 and the VL sequence shown in SEQ ID NO:12; k) The VH sequence shown in SEQ ID NO:9 and the VL sequence shown in SEQ ID NO:11; l) The VH sequence shown in SEQ ID NO:9 and the VL sequence shown in SEQ ID NO:12; and m) The VH sequence shown in SEQ ID NO:17 and the VL sequence shown in SEQ ID NO:18.
[0087] In one embodiment, the bispecific antibody as defined in any of the embodiments disclosed herein comprises first VH and VL sequences, wherein the VH and VL sequences of the first antigen-binding region are selected from: a) The VH sequence shown in SEQ ID NO:6 and the VL sequence shown in SEQ ID NO:10; b) The VH sequence shown in SEQ ID NO:17 and the VL sequence shown in SEQ ID NO:18.
[0088] In one embodiment, the bispecific antibody defined in any of the embodiments disclosed herein comprises the first VH and VL sequences shown in SEQ ID NO: 17 and 18.
[0089] In one embodiment, any bispecific antibody as defined in the disclosed embodiments comprises a first antigen-binding region having at least 90% sequence identity with the VH sequence shown in SEQ ID NO:6 and at least 90% sequence identity with the VL sequence shown in SEQ ID NO:10. In one embodiment, the sequence deviation is located in the frame sequence rather than the CDR sequence. Therefore, in one embodiment, the present invention relates to a bispecific antibody comprising a first antigen-binding region having at least 90% sequence identity with the VH sequence shown in SEQ ID NO:6 and at least 90% sequence identity with the VL sequence shown in SEQ ID NO:10, wherein the CDR sequence for the heavy chain is shown in SEQ ID NO:1, 2 and 3, and the CDR sequence for the light chain is shown in the sequences shown in SEQ ID NO:4, sequence GTN and SEQ ID NO:5, such that the CDR sequence is not mutated.
[0090] In one embodiment, any bispecific antibody as defined in the disclosed embodiments comprises a first antigen-binding region having at least 95% sequence identity with the VH sequence shown in SEQ ID NO:6 and at least 95% sequence identity with the VL sequence shown in SEQ ID NO:10. In one embodiment, the present invention relates to a bispecific antibody comprising a first antigen-binding region having at least 95% sequence identity with the VH sequence shown in SEQ ID NO:6 and at least 95% sequence identity with the VL sequence shown in SEQ ID NO:10, wherein the CDR sequence for the heavy chain is shown in SEQ ID NO:1, 2, and 3, and the CDR sequence for the light chain is shown in SEQ ID NO:4, the GTN sequence, and the sequence shown in SEQ ID NO:5, such that the CDR sequence is not mutated.
[0091] In one embodiment, any bispecific antibody as defined in the disclosed embodiments comprises a first antigen-binding region having at least 97% sequence identity with the VH sequence shown in SEQ ID NO:6 and at least 97% sequence identity with the VL sequence shown in SEQ ID NO:10. In one embodiment, the present invention relates to a bispecific antibody comprising a first antigen-binding region having at least 97% sequence identity with the VH sequence shown in SEQ ID NO:6 and at least 97% sequence identity with the VL sequence shown in SEQ ID NO:10, wherein the CDR sequence for the heavy chain is shown in SEQ ID NO:1, 2, and 3, and the CDR sequence for the light chain is shown in SEQ ID NO:4, sequence GTN, and the sequence shown in SEQ ID NO:5, such that the CDR sequence is not mutated.
[0092] In one embodiment, any bispecific antibody as defined in the disclosed embodiments comprises a first antigen-binding region having at least 98% sequence identity with the VH sequence shown in SEQ ID NO:6 and at least 98% sequence identity with the VL sequence shown in SEQ ID NO:10. In one embodiment, the present invention relates to a bispecific antibody comprising a first antigen-binding region having at least 98% sequence identity with the VH sequence shown in SEQ ID NO:6 and at least 98% sequence identity with the VL sequence shown in SEQ ID NO:10, wherein the CDR sequence for the heavy chain is shown in SEQ ID NO:1, 2, and 3, and the CDR sequence for the light chain is shown in SEQ ID NO:4, sequence GTN, and the sequence shown in SEQ ID NO:5, such that the CDR sequence is not mutated.
[0093] In one embodiment, any bispecific antibody as defined in the disclosed embodiments comprises a first antigen-binding region having at least 99% sequence identity with the VH sequence shown in SEQ ID NO:6 and at least 99% sequence identity with the VL sequence shown in SEQ ID NO:10. In one embodiment, the present invention relates to a bispecific antibody comprising a first antigen-binding region having at least 99% sequence identity with the VH sequence shown in SEQ ID NO:6 and at least 99% sequence identity with the VL sequence shown in SEQ ID NO:10, wherein the CDR sequence for the heavy chain is shown in SEQ ID NO:1, 2, and 3, and the CDR sequence for the light chain is shown in SEQ ID NO:4, sequence GTN, and the sequence shown in SEQ ID NO:5, such that the CDR sequence is not mutated.
[0094] This provides the bispecific antibody of the present invention, wherein the VH and VL sequences can be modified within at least 90% sequence identity with the parental sequence. Preferably, the variant has the same properties as the parental antibody. In some embodiments, the sequences are modified only in the frame sequence, such that the CDR sequence is identical to the parental CDR sequence.
[0095] In one embodiment of the bispecific antibody defined in any of the embodiments disclosed herein, the first antigen-binding region comprises the VH sequence shown in SEQ ID NO:6 and the VL sequence shown in SEQ ID NO:10.
[0096] In one embodiment, the first binding arm of the bispecific antibody as defined in any of the embodiments disclosed herein is derived from a mouse antibody.
[0097] In one embodiment, the first binding arm of the bispecific antibody as defined in any of the embodiments disclosed herein is derived from a humanized antibody.
[0098] In one embodiment, the first binding arm of a bispecific antibody as defined in any of the embodiments disclosed herein is derived from a full-length antibody.
[0099] In one embodiment, the first binding arm of the bispecific antibody as defined in any of the embodiments disclosed herein is derived from a full-length IgG1,λ (lambda) or IgG1,κ (kappa) antibody.
[0100] Second connecting arm Suitable CD20 antibodies used as the second binding arm of the bispecific antibody of the present invention are CD20 antibodies that bind to the epitope on human CD20, which do not contain or require the amino acid residue alanine at position 170 or proline at position 172, but contain or require the amino acid residue asparagine at position 163 and asparagine at position 166. Examples of such antibodies are antibodies called 2F2 and 7D8, as disclosed in WO2004035607 (Genmab), and antibodies called 2C6, as disclosed in WO2005103081 (Genmab). The CDR sequences of 2F2, 7D8, and 2C6 are disclosed in Table 1.
[0101] Other suitable CD20 antibodies for use as the second binding arm of the bispecific antibody of the present invention are CD20 antibodies that bind to an epitope on human CD20 that does not contain or requires the amino acid residue alanine at position 170 or proline at position 172. An example of such an antibody is 11B8, as disclosed in WO2004035607 (Genmab). The CDR sequence of 11B8 is disclosed in Table 1.
[0102] Other suitable CD20 antibodies that can be used as the second antigen-binding region of the bispecific antibody of the present invention are CD20 antibodies with a low functional dissociation rate, meaning that the antibody slowly dissociates from CD20 after binding.
[0103] k d Dissociation constant or k off The rate can be obtained from the title of Example 5 in WO2004035607. Anti-CD20 F(ab) 2 "Dissociation rate of the fragment" The method described below is used for determination. Therefore, in one embodiment, the CD20 antibody has a concentration of 1.0 x 10⁻⁶. -4 sec -1 Or below, for example 8.0 x 10 -5 sec -1 Or below, for example 8.0 x 10 -5 sec -1 Up to 4.0 x 10 -5 sec-1 k within the range d The dissociation constant, as determined by the method described above.
[0104] Other suitable CD20 antibodies for use as the second binding arm of the bispecific antibody of the present invention are CD20 antibodies having a six-CDR sequence known as 11B8, as disclosed in WO2004035607. The CDR sequence of 11B8 is disclosed in Table 1.
[0105] In one embodiment, the bispecific antibody as defined in any of the embodiments disclosed herein comprises a second antigen-binding region that binds to human CD20, the second antigen-binding region comprising heavy chain variable (VH) regions CDR1, CDR2, and CDR3 having sequences selected from: (i) VH CDR1 region of SEQ ID NO:32, VH CDR2 region of SEQ ID NO:33, VH CDR3 region of SEQ ID NO:34, (ii) VH CDR1 region of SEQ ID NO:38, VH CDR2 region of SEQ ID NO:39, and VH CDR3 region of SEQ ID NO:34. (iii) VH CDR1 region of SEQ ID NO:42, VH CDR2 region of SEQ ID NO:43, VH CDR3 region of SEQ ID NO:44, or (iv) VH CDR1 region of SEQ ID NO:49, VH CDR2 region of SEQ ID NO:50, and VH CDR3 region of SEQ ID NO:51.
[0106] In a preferred embodiment, the bispecific antibody defined in any of the embodiments disclosed herein comprises a second antigen-binding region comprising the VH CDR1 region of SEQ ID NO:32, the VH CDR2 region of SEQ ID NO:33, and the VH CDR3 region of SEQ ID NO:34.
[0107] In one embodiment, the bispecific antibody as defined in any of the embodiments disclosed herein comprises a second antigen-binding region that binds to human CD20, the second antigen-binding region comprising heavy chain variable (VH) regions CDR1, CDR2, and CDR3 and light chain variable (LH) regions CDR1, CDR2, and CDR3 sequences selected from: (i) VH CDR1 region of SEQ ID NO:32, VH CDR2 region of SEQ ID NO:33, VH CDR3 region of SEQ ID NO:34, VL CDR1 region of SEQ ID NO:35, VL CDR2 region of DAS, and VL CDR3 region of SEQ ID NO:36. (ii) VH CDR1 region of SEQ ID NO:38, VH CDR2 region of SEQ ID NO:39, VH CDR3 region of SEQ ID NO:34, VL CDR1 region of SEQ ID NO:35, VL CDR2 region of DAS, and VL CDR3 region of SEQ ID NO:36. (iii) VH CDR1 region of SEQ ID NO:42, VH CDR2 region of SEQ ID NO:43, VH CDR3 region of SEQ ID NO:44, VL CDR1 region of SEQ ID NO:45, VL CDR2 region of DAS, and VL CDR3 region of SEQ ID NO:46. (iv) VH CDR1 region of SEQ ID NO:49, VH CDR2 region of SEQ ID NO:50, VH CDR3 region of SEQ ID NO:51, VL CDR1 region of SEQ ID NO:52, VL CDR2 region of DAS, and VL CDR3 region of SEQ ID NO:53. (v) VH CDR1 region of SEQ ID NO:32, VH CDR2 region of SEQ ID NO:33, VHCDR3 region of SEQ ID NO:34, VL CDR1 region of SEQ ID NO:45, VL CDR2 region of DAS, and VL CDR3 region of SEQ ID NO:46. (vi) VH CDR1 region of SEQ ID NO:32, VH CDR2 region of SEQ ID NO:33, VH CDR3 region of SEQ ID NO:34, VL CDR1 region of SEQ ID NO:52, VL CDR2 region of DAS and VL CDR3 region of SEQ ID NO:53, (vii) VH CDR1 region of SEQ ID NO:38, VH CDR2 region of SEQ ID NO:39, VH CDR3 region of SEQ ID NO:34, VL CDR1 region of SEQ ID NO:45, VL CDR2 region of DAS, and VL CDR3 region of SEQ ID NO:46. (viii) VH CDR1 region of SEQ ID NO:38, VH CDR2 region of SEQ ID NO:39, VH CDR3 region of SEQ ID NO:34, VL CDR1 region of SEQ ID NO:52, VL CDR2 region of DAS, and VL CDR3 region of SEQ ID NO:53. (ix) VH CDR1 region of SEQ ID NO:42, VH CDR2 region of SEQ ID NO:43, VH CDR3 region of SEQ ID NO:44, VL CDR1 region of SEQ ID NO:35, VL CDR2 region of DAS, and VL CDR3 region of SEQ ID NO:36. (x) VH CDR1 region of SEQ ID NO:42, VH CDR2 region of SEQ ID NO:43, VHCDR3 region of SEQ ID NO:44, VL CDR1 region of SEQ ID NO:52, VL CDR2 region of DAS, and VL CDR3 region of SEQ ID NO:53. (xi) VH CDR1 region of SEQ ID NO:49, VH CDR2 region of SEQ ID NO:50, VH CDR3 region of SEQ ID NO:51, VL CDR1 region of SEQ ID NO:35, VL CDR2 region of DAS and VL CDR3 region of SEQ ID NO:36, or (xii) VH CDR1 region of SEQ ID NO:49, VH CDR2 region of SEQ ID NO:50, VH CDR3 region of SEQ ID NO:51, VL CDR1 region of SEQ ID NO:45, VL CDR2 region of DAS and VL CDR3 region of SEQ ID NO:46.
[0108] In a preferred embodiment, the bispecific antibody defined in any of the embodiments disclosed herein comprises a second antigen-binding region comprising the VH CDR1 region of SEQ ID NO:32, the VH CDR2 region of SEQ ID NO:33, the VH CDR3 region of SEQ ID NO:34, the VL CDR1 region of SEQ ID NO:35, the VL CDR2 region of DAS, and the VL CDR3 region of SEQ ID NO:36.
[0109] In one embodiment, the bispecific antibody as defined in any of the embodiments disclosed herein comprises a VH sequence having at least 90%, at least 95%, at least 97%, or at least 99% amino acid sequence identity with the amino acid sequence shown in SEQ ID NO:27, and a VL sequence having at least 90%, at least 95%, at least 97%, or at least 99% amino acid sequence identity with the amino acid sequence shown in SEQ ID NO:28.
[0110] In one embodiment, the bispecific antibody as defined in any of the embodiments disclosed herein comprises a VH sequence having at least 90%, at least 95%, at least 97%, or at least 99% amino acid sequence identity with the amino acid sequence shown in SEQ ID NO:37 and a VL sequence having at least 90%, at least 95%, at least 97%, or at least 99% amino acid sequence identity with the amino acid sequence shown in SEQ ID NO:28.
[0111] In one embodiment, the bispecific antibody defined in any of the embodiments disclosed herein comprises a VH sequence having at least 90%, at least 95%, at least 97%, or at least 99% amino acid sequence identity with the amino acid sequence shown in SEQ ID NO:40 and a VL sequence having at least 90%, at least 95%, at least 97%, or at least 99% amino acid sequence identity with the amino acid sequence shown in SEQ ID NO:41.
[0112] In one embodiment, the bispecific antibody as defined in any of the embodiments disclosed herein comprises a VH sequence having at least 90%, at least 95%, at least 97%, or at least 99% amino acid sequence identity with the amino acid sequence shown in SEQ ID NO:47, and a VL sequence having at least 90%, at least 95%, at least 97%, or at least 99% amino acid sequence identity with the amino acid sequence shown in SEQ ID NO:48.
[0113] In one embodiment, the bispecific antibody as defined in any of the embodiments disclosed herein comprises a VH sequence having at least 90%, at least 95%, at least 97%, or at least 99% amino acid sequence identity with the amino acid sequence shown in SEQ ID NO:27, and a VL sequence having at least 90%, at least 95%, at least 97%, or at least 99% amino acid sequence identity with the amino acid sequence shown in SEQ ID NO:41.
[0114] In one embodiment, the bispecific antibody as defined in any of the embodiments disclosed herein comprises a VH sequence having at least 90%, at least 95%, at least 97%, or at least 99% amino acid sequence identity with the amino acid sequence shown in SEQ ID NO:27, and a VL sequence having at least 90%, at least 95%, at least 97%, or at least 99% amino acid sequence identity with the amino acid sequence shown in SEQ ID NO:48.
[0115] In one embodiment, the bispecific antibody as defined in any of the embodiments disclosed herein comprises a VH sequence having at least 90%, at least 95%, at least 97%, or at least 99% amino acid sequence identity with the amino acid sequence shown in SEQ ID NO:37, and a VL sequence having at least 90%, at least 95%, at least 97%, or at least 99% amino acid sequence identity with the amino acid sequence shown in SEQ ID NO:41.
[0116] In one embodiment, the bispecific antibody as defined in any of the embodiments disclosed herein comprises a VH sequence having at least 90%, at least 95%, at least 97%, or at least 99% amino acid sequence identity with the amino acid sequence shown in SEQ ID NO:37, and a VL sequence having at least 90%, at least 95%, at least 97%, or at least 99% amino acid sequence identity with the amino acid sequence shown in SEQ ID NO:48.
[0117] In one embodiment, the bispecific antibody as defined in any of the embodiments disclosed herein comprises a VH sequence having at least 90%, at least 95%, at least 97%, or at least 99% amino acid sequence identity with the amino acid sequence shown in SEQ ID NO:40, and a VL sequence having at least 90%, at least 95%, at least 97%, or at least 99% amino acid sequence identity with the amino acid sequence shown in SEQ ID NO:28.
[0118] In one embodiment, the bispecific antibody as defined in any of the embodiments disclosed herein comprises a VH sequence having at least 90%, at least 95%, at least 97%, or at least 99% amino acid sequence identity with the amino acid sequence shown in SEQ ID NO:40, and a VL sequence having at least 90%, at least 95%, at least 97%, or at least 99% amino acid sequence identity with the amino acid sequence shown in SEQ ID NO:48.
[0119] In one embodiment, the bispecific antibody as defined in any of the embodiments disclosed herein comprises a VH sequence having at least 90%, at least 95%, at least 97%, or at least 99% amino acid sequence identity with the amino acid sequence shown in SEQ ID NO:47, and a VL sequence having at least 90%, at least 95%, at least 97%, or at least 99% amino acid sequence identity with the amino acid sequence shown in SEQ ID NO:28.
[0120] In one embodiment, the bispecific antibody as defined in any of the embodiments disclosed herein comprises a VH sequence having at least 90%, at least 95%, at least 97%, or at least 99% amino acid sequence identity with the amino acid sequence shown in SEQ ID NO:47, and a VL sequence having at least 90%, at least 95%, at least 97%, or at least 99% amino acid sequence identity with the amino acid sequence shown in SEQ ID NO:41.
[0121] In one embodiment, the bispecific antibody as defined in any of the embodiments disclosed herein comprises a second VH and VL sequence, wherein the VH and VL sequence of the second antigen-binding region is selected from: (i) The VH sequence of SEQ ID NO:27 and the VL sequence of SEQ ID NO:28, (ii) The VH sequence of SEQ ID NO:37 and the VL sequence of SEQ ID NO:28, (iii) The VH sequence of SEQ ID NO:40 and the VL sequence of SEQ ID NO:41, (iv) The VH sequence of SEQ ID NO:47 and the VL sequence of SEQ ID NO:48, (v) The VH sequence of SEQ ID NO:27 and the VL sequence of SEQ ID NO:41, (vi) The VH sequence of SEQ ID NO:27 and the VL sequence of SEQ ID NO:48, (vii) The VH sequence of SEQ ID NO:37 and the VL sequence of SEQ ID NO:41, (viii) The VH sequence of SEQ ID NO:37 and the VL sequence of SEQ ID NO:48, (ix) The VH sequence of SEQ ID NO:40 and the VL sequence of SEQ ID NO:28, (x) The VH sequence of SEQ ID NO:40 and the VL sequence of SEQ ID NO:48, (xi) The VH sequence of SEQ ID NO:47 and the VL sequence of SEQ ID NO:28, or (xii) The VH sequence of SEQ ID NO:47 and the VL sequence of SEQ ID NO:41.
[0122] In one embodiment of the bispecific antibody as defined in any of the embodiments disclosed herein, the second antigen-binding region comprises the VH sequence of SEQ ID NO:27 and the VL sequence of SEQ ID NO:28.
[0123] In one embodiment, the second binding arm of the bispecific antibody as defined in any of the embodiments disclosed herein is derived from a human antibody.
[0124] In one embodiment, the second binding arm of a bispecific antibody as defined in any of the embodiments disclosed herein is derived from a full-length antibody.
[0125] In one embodiment, the second binding arm of the bispecific antibody as defined in any of the embodiments disclosed herein is derived from an IgG1,κ (kappa) antibody.
[0126] Bispecific antibody form This invention provides a bispecific CD3xCD20 antibody that effectively promotes T-cell-mediated killing of CD20-expressing tumor cells. Specific antigen-binding regions can be selected from the set of antibodies or antigen-binding regions provided by this invention, depending on the functional properties required for a particular application. Many different forms and uses of bispecific antibodies are known in the art and are reviewed in Kontermann; Drug Discov Today, 2015 Jul;20(7):838-47; and MAbs, 2012 Mar-Apr;4(2):182-97.
[0127] The bispecific antibody of the present invention is not limited to any particular bispecific form or method of producing it.
[0128] Examples of bispecific antibody molecules that can be used in this invention include (i) a single antibody having two arms containing different antigen-binding regions; (ii) a single-chain antibody having specificity for two different epitopes, for example, two scFvs tandemly linked by an additional peptide linker; (iii) a dual-variable domain antibody (DVD-Ig) wherein each light and heavy chain contains two variable domains tandemly linked by short peptide bonds (Wu et al., Generation and Characterization of a Dual Variable Domain Immunoglobulin (DVD-Ig™) Molecule, In: Antibody Engineering, Springer Berlin Heidelberg (2010)); (iv) chemically linked bispecific (Fab')2 fragments; (v) Tandab, which is a fusion of two single-chain biantibodies to produce a tetravalent bispecific antibody having two binding sites for each target antigen; (vi) flexibody, which is a combination of scFv and biantibodies to produce a multivalent molecule; (vii) so-called "dock and lock" (viii) The so-called Scorpion molecule, which, according to the "dimerization and docking domain" in protein kinase A, when applied to Fab, yields a trivalent bispecific binding protein consisting of two identical Fab fragments linked to different Fab fragments; and (ix) the biantibody.
[0129] In one embodiment, the bispecific antibody of the present invention is a bispecific antibody, a cross antibody, or a bispecific antibody obtained through controlled Fab-arm exchange (e.g., described in WO2011131746 (Genmab)).
[0130] Examples of different types of bispecific antibodies include, but are not limited to: (i) IgG-like molecules having complementary CH3 domains to facilitate heterodimerization; (ii) recombinant IgG-like dual-targeting molecules wherein each side of the molecule contains a Fab fragment or a portion of a Fab fragment of at least two different antibodies; (iii) IgG fusion molecules wherein a full-length IgG antibody is fused to an additional Fab fragment or a portion of a Fab fragment; (iv) Fc fusion molecules wherein a single-chain Fv molecule or a stable biantibody is fused to a heavy chain constant-domain, Fc region, or a portion thereof; (v) Fab fusion molecules wherein different Fab fragments are fused together to a heavy chain constant-domain, Fc region, or a portion thereof; and (vi) ScFv- and biantibody- and heavy chain antibody (e.g., domain antibody, nanobody) wherein different single-chain Fv molecules or different biantibodies or different heavy chain antibodies (e.g., domain antibody, nanobody) are fused to each other or to another protein or carrier molecule fused to a heavy chain constant-domain, Fc region, or a portion thereof.
[0131] Examples of IgG-like molecules with complementary CH3 domains include, but are not limited to, the Triomab / Quadroma molecule (Trion Pharma / Fresenius Biotech; Roche, WO2011069104), the so-called nodule-to-pore molecule (Genentech, WO9850431), CrossMAbs (Roche, WO2011117329), and electrostatically matched molecules (Amgen, EP1870459 and WO2009089004; Chugai, US201000155133; Oncomed, WO2010129304), and the LUZ-Y molecule (Genentech, Wranik et al. J. Biol. Chem. 2012, 287(52): 43331-9, doi:10.1074 / jbc.M112.397869. Epub 2012 Nov). 1) DIG-body and PIG-body molecules (Pharmabcine, WO2010134666, WO2014081202), chain exchange engineered domain antibody (SEEDbody) molecules (EMDSerono, WO2007110205), Biclonics molecules (Merus, WO2013157953), FcΔAdp molecules (Regeneron, WO201015792), bispecific IgG1 and IgG2 molecules (Pfizer / Rinat, WO11143545), Azymetric scaffold molecules (Zymeworks / Merck, WO2012058768), mAb-Fv molecules (Xencor, WO2011028952), bivalent bispecific antibody (WO2009080254), and DuoBody® molecules (Genmab A / S, WO2011131746).
[0132] Examples of recombinant IgG-like dual-targeting molecules include, but are not limited to, dual-targeting (DT)-Ig molecules (WO2009058383), two-in-one antibodies (Genentech; Bostrom, et al 2009. Science 323, 1610–1614.), cross-linked Mabs (Karmanos Cancer Center), mAb2 (F-Star, WO2008003116), Zybody molecules (Zyngenia; LaFleur et al. MAbs. 2013 Mar-Apr;5(2):208-18), using a common light chain approach (Crucell / Merus, US7,262,028), κλBodies (NovImmune, WO2012023053), and CovX-bodies (CovX / Pfizer; Doppalapudi, VR, et al 2007. Bioorg.Med. Chem. Lett.). 17,501–506.
[0133] Examples of IgG fusion molecules include, but are not limited to, dual variable domain (DVD)-Ig molecules (Abbott, US7,612,181), dual domain biheaded antibodies (Unilever; Sanofi Aventis, WO20100226923), IgG-like bispecific molecules (ImClone / Eli Lilly, Lewis et al. Nat Biotechnol. 2014 Feb;32(2):191-8), Ts2Ab (MedImmune / AZ; Dimasi et al. J Mol Biol. 2009 Oct 30;393(3):672-92), BsAb molecules (Zymogenetics, WO2010111625), HERCULES molecules (Biogen Idec, US007951918), scFv fusion molecules (Novartis), and scFv fusion molecules (Changzhou Adam Biotech Inc, CN). 102250246) and TvAb molecules (Roche, WO2012025525, WO2012025530).
[0134] Examples of Fc fusion molecules include, but are not limited to, ScFv / Fc fusions (Pearce et al., Biochem MolBiol Int. 1997 Sep;42(6):1179-88), SCORPION molecules (Emergent BioSolutions / Trubion, Blankenship JW, et al. AACR 100th Annual meeting 2009 (Abstract # 5465); Zymogenetics / BMS, WO2010111625), dual affinity retargeting technology (Fc-DART) molecules (MacroGenics, WO2008157379, WO2010080538), and dual (ScFv) 2-Fab molecules (National Research Center for Antibody Medicine – China).
[0135] Examples of Fab fusion bispecific antibodies include, but are not limited to, F(ab)2 molecules (Medarex / AMGEN; Deo et al J Immunol. 1998 Feb 15;160(4):1677-86.), dual-acting or bi-Fab molecules (Genentech, Bostrom, et al 2009. Science 323, 1610–1614.), docking and locking (DNL) molecules (ImmunoMedics, WO2003074569, WO2005004809), bivalent bispecific molecules (Biotecnol, Schoonjans, J Immunol. 2000 Dec 15;165(12):7050-7.), and Fab-Fv molecules (UCB-Celltech, WO 2009040562 A1).
[0136] Examples of ScFv-, biantibody-, and domain-based antibodies include, but are not limited to, bispecific T-cell Engager (BiTE) molecules (Micromet, WO2005061547), tandem biantibody molecules (TandAb) (Affimed) Le Gallet al., Protein Eng Des Sel. 2004 Apr;17(4):357-66., Dual Affinity Retargeting Technology (DART) molecules (MacroGenics, WO2008157379, WO2010080538), single-chain biantibody molecules (Lawrence, FEBS Lett. 1998 Apr 3;425(3):479-84), TCR-like antibodies (AIT, ReceptorLogics), human serum albumin ScFv fusion (Merrimack, WO2010059315), and COMBODY molecules (Epigen Biotech, Zhu et al. Immunol Cell Biol.). 2010 Aug;88(6):667-75.), dual-targeting nanobodies (Ablynx, Hmila et al., FASEB J. 2010) and dual-targeting heavy chain domain-only antibodies.
[0137] In one aspect, the bispecific antibody of the present invention comprises a first Fc-region comprising a first CH3 region and a second Fc-region comprising a second CH3 region, wherein the sequences of the first and second CH3 regions are different, and such that the heterodimeric interaction between the first and second CH3 regions is stronger than the homodimeric interaction between each of the first and second CH3 regions. Further details regarding these interactions and how they can be achieved are provided in WO2011131746 and WO2013060867 (Genmab), which are incorporated herein by reference.
[0138] As further described herein, using specific methods, stable bispecific CD3xCD20 antibodies can be obtained in high yields based on a homodimer-initiated CD20 antibody and a homodimer-initiated CD3 antibody (containing only a small number of fairly conserved asymmetric mutations in the CH3 region). Asymmetric mutations mean that the sequences of the first and second CH3 regions contain amino acid substitutions at different positions.
[0139] In one aspect, the bispecific antibody defined in any of the embodiments disclosed herein comprises first and second heavy chains, wherein each of the first and second heavy chains comprises at least a hinge region, a CH2 region, and a CH3 region, wherein at least one amino acid in the first heavy chain corresponding to a position selected from the human IgG1 heavy chain T366, L368, K370, D399, F405, Y407, and K409 has been substituted, and at least one amino acid in the second heavy chain corresponding to a position selected from the human IgG1 heavy chain T366, L368, K370, D399, F405, Y407, and K409 has been substituted, and wherein the first and second heavy chains are not substituted at the same position.
[0140] In one embodiment, the bispecific antibody as defined in any of the embodiments disclosed herein comprises a first and a second heavy chain, wherein (i) the amino acid at position F405 of the human IgG1 heavy chain in the first heavy chain is L, and the amino acid at position K409 of the human IgG1 heavy chain in the second heavy chain is R, or (ii) the amino acid at position K409 of the human IgG1 heavy chain in the first heavy chain is R, and the amino acid at position F405 of the human IgG1 heavy chain in the second heavy chain is L.
[0141] In one embodiment of the bispecific antibody as defined in any of the embodiments disclosed herein, the first Fc-region has an amino acid substitution at a position selected from 366, 368, 370, 399, 405, 407, and 409, and the second Fc-region has an amino acid substitution at a position selected from 366, 368, 370, 399, 405, 407, and 409, and wherein the first and second Fc-regions are not substituted at the same position.
[0142] In one embodiment of the bispecific antibody defined in any of the embodiments disclosed herein, the first Fc-region has an amino acid substitution at position 366 and the second Fc-region has an amino acid substitution at position selected from 368, 370, 399, 405, 407, and 409. In one embodiment, the amino acid at position 366 is selected from Ala, Asp, Glu, His, Asn, Val, or Gln.
[0143] In one embodiment of the bispecific antibody as defined in any of the embodiments disclosed herein, the first Fc-region has an amino acid substitution at position 368 and the second Fc-region has an amino acid substitution at position selected from 366, 370, 399, 405, 407 and 409.
[0144] In one embodiment of the bispecific antibody as defined in any of the embodiments disclosed herein, the first Fc-region has an amino acid substitution at position 370 and the second Fc-region has an amino acid substitution at position selected from 366, 368, 399, 405, 407 and 409.
[0145] In one embodiment of the bispecific antibody as defined in any of the embodiments disclosed herein, the first Fc-region has an amino acid substitution at position 399 and the second Fc-region has an amino acid substitution at position selected from 366, 368, 370, 405, 407 and 409.
[0146] In one embodiment of the bispecific antibody as defined in any of the embodiments disclosed herein, the first Fc-region has an amino acid substitution at position 405 and the second Fc-region has an amino acid substitution at position selected from 366, 368, 370, 399, 407 and 409.
[0147] In one embodiment of the bispecific antibody as defined in any of the embodiments disclosed herein, the first Fc-region has an amino acid substitution at position 407 and the second Fc-region has an amino acid substitution at position selected from 366, 368, 370, 399, 405 and 409.
[0148] In one embodiment of the bispecific antibody defined in any of the embodiments disclosed herein, the first Fc-region has an amino acid substitution at position 409 and the second Fc-region has an amino acid substitution at position selected from 366, 368, 370, 399, 405 and 407.
[0149] Therefore, in one embodiment of the bispecific antibody defined in any of the embodiments disclosed herein, the sequences of the first and second CH3 regions contain asymmetric mutations, i.e., mutations at different positions in the two CH3 regions, for example, a mutation at position 405 in one CH3 region and a mutation at position 409 in the other CH3 region.
[0150] In one embodiment of the bispecific antibody as defined in any of the embodiments disclosed herein, the first Fc-region has an amino acid at position 409 that is not Lys, Leu, or Met, such as Gly, Ala, Val, Ile, Ser, Thr, Phe, Arg, His, Asp, Asn, Glu, Gln, Pro, Trp, Tyr, or Cys, and the second Fc-region has an amino acid substitution at a position selected from 366, 368, 370, 399, 405, and 407. In one such embodiment, the first Fc-region has an amino acid at position 409 that is not Lys, Leu, or Met, such as Gly, Ala, Val, Ile, Ser, Thr, Phe, Arg, His, Asp, Asn, Glu, Gln, Pro, Trp, Tyr, or Cys, and the second Fc-region has an amino acid at position 405 that is not Phe, such as Gly, Ala, Val, Ile, Ser, Thr, Lys, Arg, His, Asp, Asn, Glu, Gln, Pro, Trp, Tyr, Cys, Lys, or Leu. In a further embodiment, the first Fc-region has an amino acid at position 409 that is not Lys, Leu, or Met, such as Gly, Ala, Val, Ile, Ser, Thr, Phe, Arg, His, Asp, Asn, Glu, Gln, Pro, Trp, Tyr, or Cys, and the second Fc-region has an amino acid at position 405 that is not Phe, Arg, or Gly, such as Leu, Ala, Val, Ile, Ser, Thr, Met, Lys, His, Asp, Asn, Glu, Gln, Pro, Trp, Tyr, or Cys.
[0151] In another embodiment of the bispecific antibody as defined in any of the embodiments disclosed herein, the first Fc-region contains Phe at position 405 and an amino acid at position 409 that is not Lys, Leu, or Met, such as Gly, Ala, Val, Ile, Ser, Thr, Phe, Arg, His, Asp, Asn, Glu, Gln, Pro, Trp, Tyr, or Cys, and the second Fc-region contains an amino acid at position 405 that is not Phe, such as Gly, Ala, Val, Ile, Ser, Thr, Lys, Arg, His, Asp, Asn, Glu, Gln, Pro, Trp, Tyr, Leu, Met, or Cys and Lys at position 409. In a further embodiment, the first Fc-region contains Phe at position 405 and an amino acid at position 409 that is not Lys, Leu, or Met, such as Gly, Ala, Val, Ile, Ser, Thr, Phe, Arg, His, Asp, Asn, Glu, Gln, Pro, Trp, Tyr, or Cys, and the second Fc-region contains an amino acid at position 405 that is not Phe, Arg, or Gly, such as Leu, Ala, Val, Ile, Ser, Thr, Met, Lys, His, Asp, Asn, Glu, Gln, Pro, Trp, Tyr, or Cys and Lys at position 409.
[0152] In another embodiment of the bispecific antibody as defined in any of the embodiments disclosed herein, the first Fc-region comprises Phe at position 405 and an amino acid at position 409 that is not Lys, Leu, or Met, such as Gly, Ala, Val, Ile, Ser, Thr, Phe, Arg, His, Asp, Asn, Glu, Gln, Pro, Trp, Tyr, or Cys, and the second Fc-region comprises Leu at position 405 and Lys at position 409. In a further embodiment, the first Fc-region comprises Phe at position 405 and Arg at position 409, and the second Fc-region comprises an amino acid at position 405 that is not Phe, Arg, or Gly, such as Leu, Ala, Val, Ile, Ser, Thr, Lys, Met, His, Asp, Asn, Glu, Gln, Pro, Trp, Tyr, or Cys, and Lys at position 409. In another embodiment, the first Fc-region includes Phe at position 405 and Arg at position 409, and the second Fc-region includes Leu at position 405 and Lys at position 409.
[0153] In a further embodiment of the bispecific antibody defined in any of the embodiments disclosed herein, the first Fc-region contains an amino acid at position 409 that is not Lys, Leu, or Met, such as Gly, Ala, Val, Ile, Ser, Thr, Phe, Arg, His, Asp, Asn, Glu, Gln, Pro, Trp, Tyr, or Cys, and the second Fc-region contains Lys at position 409, Thr at position 370, and Leu at position 405. In a further embodiment, the first Fc-region contains Arg at position 409 and the second Fc-region contains Lys at position 409, Thr at position 370, and Leu at position 405.
[0154] In any embodiment of the bispecific antibody defined herein, or even a further embodiment thereof, the first Fc-region comprises Lys at position 370, Phe at position 405, and Arg at position 409, and the second Fc-region comprises Lys at position 409, Thr at position 370, and Leu at position 405.
[0155] In another embodiment of the bispecific antibody as defined in any of the embodiments disclosed herein, the first Fc-region contains an amino acid at position 409 that is not Lys, Leu, or Met, such as Gly, Ala, Val, Ile, Ser, Thr, Phe, Arg, His, Asp, Asn, Glu, Gln, Pro, Trp, Tyr, or Cys, and the second Fc-region contains Lys at position 409, and: a) Ile at position 350 and Leu at position 405, or b) Thr at position 370 and Leu at position 405.
[0156] In another embodiment of the bispecific antibody as defined in any of the embodiments disclosed herein, the first Fc region comprises Arg at position 409, and the second Fc region comprises Lys at position 409, and: a) Ile at position 350 and Leu at position 405, or b) Thr at position 370 and Leu at position 405.
[0157] In another embodiment of the bispecific antibody as defined in any of the embodiments disclosed herein, the first Fc region comprises Thr at position 350, Lys at position 370, Phe at position 405, and Arg at position 409, and the second Fc region comprises Lys at position 409, and: a) Ile at position 350 and Leu at position 405, or b) Thr at position 370 and Leu at position 405.
[0158] In another embodiment of the bispecific antibody as defined in any of the embodiments disclosed herein, the first Fc-region comprises Thr at position 350, Lys at position 370, Phe at position 405, and Arg at position 409, and the second Fc-region comprises Ile at position 350, Thr at position 370, Leu at position 405, and Lys at position 409.
[0159] In one embodiment of the bispecific antibody as defined in any of the embodiments disclosed herein, the first Fc-region has an amino acid at position 409 that is not Lys, Leu, or Met, and the second Fc-region has an amino acid at position 405 that is not Phe, for example, an amino acid at position 405 that is not Phe, Arg, or Gly; or the first CH3 region has an amino acid at position 409 that is not Lys, Leu, or Met, and the second CH3 region has an amino acid at position 407 that is not Tyr, Asp, Glu, Phe, Lys, Gln, Arg, Ser, or Thr.
[0160] In one embodiment, the bispecific antibody as defined in any of the embodiments disclosed herein comprises a first Fc-region having an amino acid at position 409 that is not Lys, Leu, or Met, and a second Fc-region having an amino acid at position 407 that is not Tyr, Asp, Glu, Phe, Lys, Gln, Arg, Ser, or Thr.
[0161] In one embodiment, the bispecific antibody as defined in any of the embodiments disclosed herein comprises a first Fc-region having a Tyr at position 407 and an amino acid at position 409 that is not Lys, Leu, or Met, and a second Fc-region having an amino acid at position 407 that is not Tyr, Asp, Glu, Phe, Lys, Gln, Arg, Ser, or Thr and a Lys at position 409.
[0162] In one embodiment, the bispecific antibody as defined in any of the embodiments disclosed herein comprises a first Fc-region having Tyr at position 407 and Arg at position 409, and a second Fc-region having an amino acid at position 407 that is not Tyr, Asp, Glu, Phe, Lys, Gln, Arg, Ser, or Thr and Lys at position 409.
[0163] In another embodiment, the first Fc-region has an amino acid at position 409 that is not Lys, Leu, or Met, such as Gly, Ala, Val, Ile, Ser, Thr, Phe, Arg, His, Asp, Asn, Glu, Gln, Pro, Trp, Tyr, or Cys, and the second Fc-region has an amino acid at position 407 that is not Tyr, Asp, Glu, Phe, Lys, Gln, Arg, Ser, or Thr, such as Leu, Met, Gly, Ala, Val, Ile, His, Asn, Pro, Trp, or Cys. In another embodiment, the first Fc-region has an amino acid at position 409 that is not Lys, Leu, or Met, such as Gly, Ala, Val, Ile, Ser, Thr, Phe, Arg, His, Asp, Asn, Glu, Gln, Pro, Trp, Tyr, or Cys, and the second Fc-region has an amino acid at position 407 that is Ala, Gly, His, Ile, Leu, Met, Asn, Val, or Trp.
[0164] In another embodiment of the bispecific antibody as defined in any of the embodiments disclosed herein, the first Fc-region has an amino acid at position 409 that is not Lys, Leu, or Met, such as Gly, Ala, Val, Ile, Ser, Thr, Phe, Arg, His, Asp, Asn, Glu, Gln, Pro, Trp, Tyr, or Cys, and the second Fc-region has Gly, Leu, Met, Asn, or Trp at position 407.
[0165] In another embodiment of the bispecific antibody as defined in any of the embodiments disclosed herein, the first Fc-region has Tyr at position 407 and an amino acid at position 409 that is not Lys, Leu, or Met, such as Gly, Ala, Val, Ile, Ser, Thr, Phe, Arg, His, Asp, Asn, Glu, Gln, Pro, Trp, Tyr, or Cys, and the second Fc-region has an amino acid at position 407 that is not Tyr, Asp, Glu, Phe, Lys, Gln, Arg, Ser, or Thr, such as Leu, Met, Gly, Ala, Val, Ile, His, Asn, Pro, Trp, or Cys, and Lys at position 409.
[0166] In another embodiment of the bispecific antibody as defined in any of the embodiments disclosed herein, the first Fc-region has Tyr at position 407 and an amino acid that is not Lys, Leu, or Met at position 409, such as Gly, Ala, Val, Ile, Ser, Thr, Phe, Arg, His, Asp, Asn, Glu, Gln, Pro, Trp, Tyr, or Cys, and the second Fc-region has Ala, Gly, His, Ile, Leu, Met, Asn, Val, or Trp at position 407 and Lys at position 409.
[0167] In another embodiment of the bispecific antibody as defined in any of the embodiments disclosed herein, the first Fc-region has Tyr at position 407 and an amino acid that is not Lys, Leu, or Met at position 409, such as Gly, Ala, Val, Ile, Ser, Thr, Phe, Arg, His, Asp, Asn, Glu, Gln, Pro, Trp, Tyr, or Cys, and the second Fc-region has Gly, Leu, Met, Asn, or Trp at position 407 and Lys at position 409.
[0168] In another embodiment of the bispecific antibody as defined in any of the embodiments disclosed herein, the first Fc-region has Tyr at position 407 and Arg at position 409, and the second Fc-region has an amino acid at position 407 that is not Tyr, Asp, Glu, Phe, Lys, Gln, Arg, Ser, or Thr, such as Leu, Met, Gly, Ala, Val, Ile, His, Asn, Pro, Trp, or Cys, and Lys at position 409.
[0169] In another embodiment of the bispecific antibody as defined in any of the embodiments disclosed herein, the first Fc-region has Tyr at position 407 and Arg at position 409, and the second Fc-region has Ala, Gly, His, Ile, Leu, Met, Asn, Val or Trp at position 407 and Lys at position 409.
[0170] In another embodiment of the bispecific antibody as defined in any of the embodiments disclosed herein, the first Fc-region has Tyr at position 407 and Arg at position 409, and the second Fc-region has Gly, Leu, Met, Asn or Trp at position 407 and Lys at position 409.
[0171] In another embodiment of the bispecific antibody as defined in any of the embodiments disclosed herein, the first Fc-region has an amino acid at position 409 that is not Lys, Leu, or Met, such as Gly, Ala, Val, Ile, Ser, Thr, Phe, Arg, His, Asp, Asn, Glu, Gln, Pro, Trp, Tyr, or Cys, and the second Fc-region has (i) The amino acid at position 368 is not Phe, Leu, or Met, for example, Gly, Ala, Val, Ile, Ser, Thr, Lys, Arg, His, Asp, Asn, Glu, Gln, Pro, Trp, Tyr, or Cys, or (ii) Trp at position 370, or (iii) The amino acid at position 399 is not Asp, Cys, Pro, Glu, or Gln, for example, Phe, Leu, Met, Gly, Ala, Val, Ile, Ser, Thr, Lys, Arg, His, Asn, Trp, Tyr, or Cys, or (iv) The amino acid at position 366 is not Lys, Arg, Ser, Thr, or Trp, for example, Phe, Leu, Met, Ala, Val, Gly, Ile, Asn, His, Asp, Glu, Gln, Pro, Tyr, or Cys.
[0172] In one implementation, the first Fc region has Arg, Ala, His, or Gly at position 409, and the second Fc region has (i) Lys, Gln, Ala, Asp, Glu, Gly, His, Ile, Asn, Arg, Ser,Thr, Val, or Trp at position 368, or (ii) Trp at position 370, or (iii) Ala, Gly, Ile, Leu, Met, Asn, Ser, Thr, Trp, Phe, His, Lys, Arg, or Tyr at position 399, or (iv) Ala, Asp, Glu, His, Asn, Val, Gln, Phe, Gly, Ile, Leu, Met, or Tyr at position 366.
[0173] In one implementation, the first Fc region has Arg at position 409 and the second Fc region has (i) Asp, Glu, Gly, Asn, Arg, Ser, Thr, Val or Trp at position 368, or (ii) Trp at position 370, or (iii) Phe, His, Lys, Arg, or Tyr at position 399, or (iv) Ala, Asp, Glu, His, Asn, Val, Gln at position 366.
[0174] In addition to the amino acid substitutions mentioned above, the first and second Fc regions may contain other amino acid substitutions, deletions, or insertions relative to the wild-type Fc sequence.
[0175] In a further embodiment, the first and second Fab-arms (or heavy chain constant domains) containing the first and second Fc regions, in addition to the specified mutations, contain CH3 sequences independently selected from the following: (IgG1m(a)) (SEQ ID NO:60), (IgG1m(f)) (SEQ ID NO:61) and (IgG1m(ax) (SEQ ID NO:62).
[0176] In one implementation, neither the first nor the second Fc-region contains the Cys-Pro-Ser-Cys sequence in the (core) hinge region.
[0177] In a further embodiment, both the first and second Fc-regions contain a Cys-Pro-Pro-Cys sequence in the (core) hinge region.
[0178] In individual and specific embodiments, one or both Fab arms contain heavy chain constant region sequences, independently selected from SEQ ID NO: 63, 64, 65, 66, 67, 68, 69, 70 and 71 (see Table 1).
[0179] In one embodiment of the bispecific antibody of any embodiment disclosed herein, (a) the first antigen-binding region comprises heavy chain variable (VH) regions CDR1, CDR2, and CDR3 having sequences shown in SEQ ID NO:1, 2, and 3, respectively, and light chain variable (VL) regions CDR1, CDR2, and CDR3 having sequences shown in SEQ ID NO:4, sequence GTN, and sequence shown in SEQ ID NO:5, respectively; and (b) the second antigen-binding region binding to human CD20 comprises the VH CDR1 region of SEQ ID NO:32, the VH CDR2 region of SEQ ID NO:33, the VH CDR3 region of SEQ ID NO:34, the VL CDR1 region of SEQ ID NO:35, the VL CDR2 region of DAS, and the VL CDR3 region of SEQ ID NO:36, respectively.
[0180] In one embodiment of the bispecific antibody of any of the embodiments disclosed herein, (a) the first antigen-binding region comprises the VH sequence shown in SEQ ID NO:6 and the VL sequence shown in SEQ ID NO:10, and (b) the second antigen-binding region comprises the VH sequence shown in SEQ ID NO:27 and the VL sequence shown in SEQ ID NO:28. In one embodiment of the bispecific antibody as defined in any of the embodiments disclosed herein, the first antigen-binding region is a Fab arm derived from IgG1-huCD3-H1L1-FEAL and the second antigen-binding region is a Fab arm derived from IgG1-7D8-FEAR.
[0181] In one embodiment of the bispecific antibody defined in any of the embodiments disclosed herein, the first binding arm is a half-molecule antibody derived from IgG1-huCD3-H1L1-FEAL (i.e., comprising a heavy chain and a light chain) and the second binding arm is a half-molecule antibody derived from IgG1-7D8-FEAR.
[0182] In one embodiment of the bispecific antibody defined in any of the embodiments disclosed herein, the first binding arm is a half-molecule antibody derived from IgG1-huCD3-H1L1-FEAR and the second binding arm is a half-molecule antibody derived from IgG1-7D8-FEAL.
[0183] Methods for preparing bispecific antibodies Conventional methods, such as hybridoma and chemical conjugation methods (Marvin and Zhu (2005) ActaPharmacol Sin 26:649), can be used to prepare the bispecific antibody of the present invention. Co-expression of two antibodies composed of different heavy and light chains in host cells produces a mixture of possible antibody products other than the desired bispecific antibody, which can then be separated by, for example, affinity chromatography or similar methods.
[0184] Strategies that facilitate the formation of functional bispecific products after co-expressing different antibody constructs can also be used, for example, as described in Lindhofer et al. .The method described in (1995 J Immunol 155:219) involves the fusion of rat and mouse hybridomas that produce different antibodies, resulting in a limited number of heterodimeric proteins due to species-restricted heavy / light chain pairing. Another strategy to promote heterodimer formation beyond homodimer formation is the "nodule-to-pore" strategy, in which a nodule is introduced onto the first heavy chain polypeptide and a corresponding pore is introduced into the second heavy chain polypeptide, such that the nodule can be localized into the pore at the interface between the two heavy chains to promote heterodimer formation and inhibit homodimer formation. The "nodule" is constructed by replacing a small amino acid side chain from the interface of the first polypeptide with a larger side chain. Compensatory "pores" of the same or similar size as the nodule are generated at the interface of the second polypeptide by replacing a large amino acid side chain with a smaller side chain (US patent 5,731,168). EP1870459 (Chugai) and WO2009089004 (Amgen) describe other strategies that facilitate heterodimer formation after co-expression of different antibody domains in host cells. In these methods, one or more residues constituting the CH3-CH3 interface in the two CH3 domains are replaced with charged amino acids, making homodimer formation electrostatically unfavorable and heterodimerization electrostatically favorable. WO2007110205 (Merck) describes yet another strategy in which the difference between the IgA and IgG CH3 domains is utilized to promote heterodimerization.
[0185] Another in vitro method for generating bispecific antibodies has been described in WO2008119353 (Genmab), in which bispecific antibodies are formed by a “Fab-arm” or “half-molecule” exchange (exchange of heavy chain and linked light chain) between two monospecific IgG4- or IgG4-like antibodies after incubation under reducing conditions. The resulting product is a bispecific antibody having two Fab arms that may contain different sequences.
[0186] Preferred methods for preparing the bispecific CD3xCD20 antibody of the present invention include the methods described in WO2011131746 and WO13060867 (Genmab), comprising the following steps: a) Provide a first antibody comprising an Fc region, wherein the Fc region comprises a first CH3 region; b) Provide a second antibody comprising a second Fc region, wherein the Fc region comprises a second CH3 region, wherein the first antibody is a CD3 antibody and the second antibody is a CD20 antibody, or vice versa; The sequences of the first and second CH3 regions are different and such that the heterodimer interaction between the first and second CH3 regions is stronger than the homodimer interaction between each of the first and second CH3 regions; c) Incubate the first antibody and the second antibody under reducing conditions; and d) Obtain the bispecific CD3xCD20 antibody.
[0187] In one embodiment, the first antibody and the second antibody are incubated together under reducing conditions sufficient to allow cysteine in the hinge region to undergo disulfide isomerization, wherein the heterodimeric interaction between the first and second antibodies in the resulting heterodimeric antibody results in no Fab-arm exchange occurring in 0.5 mM GSH after 24 hours at 37°C.
[0188] Unrestricted by theory, in step c), the heavy-chain disulfide bonds in the hinge region of the parent antibody are reduced, and the resulting cysteine residues are then able to form inter-heavy-chain disulfide bonds with cysteine residues of another parent antibody molecule (initially with different specificities). In one embodiment of the method, the reduction conditions in step c) include the addition of a reducing agent, for example, selected from the following reducing agents: 2-mercaptoethylamine (2-MEA), dithiothreitol (DTT), dithioerythritol (DTE), glutathione, tris(2-carboxyethyl)phosphine (TCEP), L-cysteine, and β-mercaptoethanol, preferably selected from the following reducing agents: 2-mercaptoethylamine, dithiothreitol, and tris(2-carboxyethyl)phosphine. In a further embodiment, step c) includes recovery conditions that are non-reducing or less reducing, for example, by removing the reducing agent, for example, by desalting.
[0189] For this method, any of the CD3 and CD20 antibodies described above can be used, including first and second CD3 and CD20 antibodies, each comprising a first and / or a second Fc region. Examples of such first and second Fc regions, including combinations of such first and second Fc regions, may include any of those described above. In specific embodiments, the first and second CD3 and CD20 antibodies may each be selected to obtain the bispecific antibody described herein.
[0190] In one embodiment of the method, the first and / or second antibody is a full-length antibody.
[0191] The Fc regions of the first and second antibodies may have any isotype, including but not limited to IgG1, IgG2, IgG3, or IgG4. In one embodiment of the method, the Fc regions of both the first and second antibodies have the IgG1 isotype. In another embodiment, one Fc region of the antibody has the IgG1 isotype and the other has the IgG4 isotype. In the latter embodiment, the resulting bispecific antibody comprises the Fc region of IgG1 and the Fc region of IgG4, and may therefore possess valuable intermediate properties in terms of activation of effector functions.
[0192] In a further embodiment, one of the antibody initiating proteins is engineered to not bind to protein A, thus allowing the heterodimeric protein to be separated from the homodimeric initiating protein by passing the product through a protein A column.
[0193] As described above, the sequences of the first and second CH3 regions of the homodimer-initiating antibody are distinct, such that the heterodimer interaction between the first and second CH3 regions is stronger than the homodimer interaction between each of the first and second CH3 regions. Further details regarding these interactions and how they can be achieved are provided in WO2011131746 and WO2013060867 (Genmab), which are incorporated herein by reference in their entirety.
[0194] In particular, stable bispecific CD3xCD20 antibodies can be obtained in high yield using the method described above in this invention, based on two homodimer initiating antibodies that respectively bind to CD3 and CD20 and contain only a small amount of fairly conserved asymmetric mutations in the CH3 region. Asymmetric mutations mean that the sequences of the first and second CH3 regions contain amino acid substitutions at different positions.
[0195] The bispecific antibody of the present invention can also be obtained by co-expression of constructs encoding first and second polypeptides in a single cell. Therefore, in a further aspect, the present invention relates to a method for generating bispecific antibodies, the method comprising the steps of: a) Provide a first nucleic acid construct encoding a first polypeptide comprising a first Fc region of a first antibody heavy chain and a first antigen-binding region, wherein the first Fc region comprises a first CH3 region. b) Provide a second nucleic acid construct encoding a second polypeptide comprising a second Fc region and a second antigen-binding region of a second antibody heavy chain, wherein the second Fc region comprises a second CH3 region. The sequences of the first and second CH3 regions are distinct, such that the heterodimeric interaction between the first and second CH3 regions is stronger than the homodimeric interaction between each of the first and second CH3 regions, and wherein the first homodimeric protein has an amino acid at position 409 that is not Lys, Leu, or Met, and the second homodimeric protein has amino acid substitutions selected from positions 366, 368, 370, 399, 405, and 407. Optionally, the first and second nucleic acid constructs encode the light chain sequences of the first and second antibodies. c) Co-expression of the first and second nucleic acid constructs in host cells, and d) Obtain the heterodimeric protein from cell culture.
[0196] Therefore, the present invention also relates to recombinant eukaryotic or prokaryotic host cells that produce the bispecific antibodies of the present invention.
[0197] In one embodiment of the invention, the bispecific antibody is obtained by any of the methods of the invention.
[0198] Suitable expression vectors for antibody production, including promoters, enhancers, etc., and suitable host cells, are well known in the art. Examples of host cells include yeast, bacteria, and mammalian cells, such as CHO or HEK cells.
[0199] In one embodiment, the bispecific antibody defined in any of the embodiments disclosed herein comprises first and second CH3 regions, and, in addition to the specified mutation, contains the sequence of SEQ ID NO:60 (IgG1m(a)).
[0200] In one embodiment, the bispecific antibody defined in any of the embodiments disclosed herein comprises a first Fc-region and a second Fc-region, wherein neither the first nor the second Fc-region contains a Cys-Pro-Ser-Cys sequence in its hinge region.
[0201] In one embodiment, the bispecific antibody as defined in any of the embodiments disclosed herein comprises a first Fc-region and a second Fc-region, wherein both the first and second Fc-regions contain a Cys-Pro-Pro-Cys sequence in their hinge regions.
[0202] In one embodiment, the bispecific antibody as defined in any of the embodiments disclosed herein comprises a first Fc region and a second Fc region, wherein the first and second Fc regions are human antibody Fc regions.
[0203] In one embodiment, the bispecific antibody defined in any of the embodiments disclosed herein comprises a first Fc-region and a second Fc-region, wherein the first and second Fc regions, except for the specified mutations, comprise sequences independently selected from SEQ ID NO: 63, 64, 65, 66, 67, 68, 69, 70 and 71.
[0204] In one embodiment, the bispecific antibody as defined in any of the embodiments disclosed herein comprises a first Fc-region and a second Fc-region, wherein the first and second antigen-binding regions comprise a human antibody VH sequence, and optionally, a human antibody VL sequence.
[0205] In one embodiment, the bispecific antibody as defined in any of the embodiments disclosed herein comprises a first Fc-region and a second Fc-region, wherein the first and second antigen-binding regions are derived from a heavy chain antibody.
[0206] In one embodiment, the bispecific antibody as defined in any of the embodiments disclosed herein comprises a first Fc-region and a second Fc-region, wherein the first and second antigen-binding regions comprise first and second light chains.
[0207] In a further embodiment, the co-expression method of the present invention includes any other features described in the above in vitro methods.
[0208] In a further aspect, the present invention relates to an expression vector comprising the first and second nucleic acid constructs specified above. In a further embodiment, the expression vector further comprises a nucleotide sequence encoding a constant region of a light chain, a heavy chain, or both a light chain and a heavy chain of an antibody (e.g., a human antibody).
[0209] In the context of this invention, the expression vector can be any suitable vector, including chromosomal, non-chromosomal, and synthetic nucleic acid vectors (containing a nucleic acid sequence of a suitable set of expression control elements). Examples of such vectors include derivatives of SV40, bacterial plasmids, phage DNA, baculoviruses, yeast plasmids, vectors derived from combinations of plasmids and phage DNA, and viral nucleic acid (RNA or DNA) vectors. In one embodiment, CD20 or CD3 antibody-encoding nucleic acid is contained in a naked DNA or RNA vector, including, for example, linear expression elements (described, for example, in Sykes and Johnston, Nat Biotech 17,355-59 (1997)), compact nucleic acid vectors (described, for example, in US 6,077, 835 and / or WO 00 / 70087), plasmid vectors such as pBR322, pUC 19 / 18, or pUC 118 / 119, and "midge" minimum-size nucleic acid vectors (described, for example, in Schakowski et al.). . , Mol Ther 3, 793-800 (2001)) or as a precipitated nucleic acid carrier construct, such as a CaPO4-precipitated construct (described, for example, WO200046147, Benvenisty and Reshef, PNAS USA 83,9551-55 (1986), Wigler et al. . , Cell 14, 725 (1978) and Coraro and Pearson, SomaticCell Genetics 7, 603 (1981)). Such nucleic acid vectors and their uses are well known in the art (see, for example, US 5,589,466 and US 5,973,972).
[0210] In one embodiment, the vector is suitable for expressing CD20 and / or CD3 antibodies in bacterial cells. Examples of such vectors include expression vectors such as BlueScript (Stratagene) and pIN vectors (Van Heeke & Schuster, J Biol Chem). 264 , 5503-5509 (1989), pET vector (Novagen, Madison WI, etc.).
[0211] The expression vector may also be, or alternatively, a vector suitable for expression in a yeast system. Any vector suitable for expression in a yeast system can be used. Suitable vectors include, for example, vectors containing constitutive or inducible promoters, such as α-factors, alcohol oxidases, and PGH (reviewed in: F. Ausubel et al.). . , ed. Current Protocols in Molecular Biology, Greene Publishing and Wiley InterScience New York (1987) and Grant et al. . Methods in Enzymol 153 , 516-544 (1987)).
[0212] The expression vector may also be, or alternatively, a vector suitable for expression in mammalian cells, for example, a vector containing glutamine synthase as a selectable marker, such as the vector described in Bebbington (1992) Biotechnology (NY) 10:169-175.
[0213] The nucleic acid and / or vector may also contain a nucleic acid sequence encoding a secretion / localization sequence that can target a polypeptide, such as a nascent polypeptide chain, to the periplasmic space or cell culture medium. Such sequences are known in the art and include secretion leader or signal peptides.
[0214] Expression vectors may contain or be associated with any suitable promoter, enhancer, and other expression-promoting elements. Examples of such elements include strong expression promoters (e.g., the human CMV IE promoter / enhancer, as well as RSV, SV40, SL3-3, MMTV, and HIV LTR promoters), efficient poly(A) termination sequences, origins of replication for plasmid products in *E. coli*, antibiotic resistance genes as selectable markers, and / or convenient cloning sites (e.g., polymer adapters). Nucleic acids may also contain inducible promoters, such as CMV IE, as opposed to constitutive promoters.
[0215] In one implementation, CD20 and / or CD3 antibody-encoding expression vectors can be located and / or delivered to host cells or host animals via viral vectors.
[0216] In an even further aspect, the present invention relates to host cells comprising the first and second nucleic acid constructs specified above.
[0217] Therefore, the present invention also relates to recombinant eukaryotic or prokaryotic host cells that produce the bispecific antibodies of the present invention, such as transfected tumors.
[0218] The first CD20-specific antibody can be expressed in recombinant eukaryotic or prokaryotic host cells, such as transfected tumors, which produce the antibody of the present invention as defined herein, or the bispecific antibody of the present invention as defined herein. Similarly, the CD3-specific antibody can be expressed in recombinant eukaryotic or prokaryotic host cells, such as transfected tumors, which produce the antibody of the present invention as defined herein, or the bispecific antibody of the present invention as defined herein.
[0219] Examples of host cells include yeast, bacteria, plant, and mammalian cells, such as CHO, CHO-S, HEK, HEK293, HEK-293F, Expi293F, PER.C6, or NSO cells or lymphocytes. For example, in one embodiment, the host cell may comprise first and second nucleic acid constructs stably integrated into the cell's genome. In another embodiment, the invention provides cells comprising non-integrated nucleic acids, such as plasmids, granules, phage particles, or linear expression elements, containing the first and second nucleic acid constructs specified above.
[0220] In an even further aspect, the present invention relates to transgenic non-human animals or plants comprising nucleic acids encoding one or two groups of human heavy chains and human light chains, wherein said animals or plants produce the bispecific antibodies of the present invention.
[0221] In a further aspect, the present invention relates to hybridomas that produce antibodies for the bispecific antibodies of the present invention as defined herein. In an even further aspect, the present invention relates to transgenic non-human animals or plants comprising nucleic acids encoding one or two sets of human heavy and light chains, wherein said animals or plants produce antibodies for bispecific antibodies or the bispecific antibodies of the present invention.
[0222] In one aspect, the present invention relates to nucleic acid constructs encoding one or more amino acid sequences listed in Table 1.
[0223] In one aspect, the present invention relates to an expression carrier comprising... (i) A nucleic acid sequence that encodes the heavy chain sequence of the first binding arm according to any of the embodiments disclosed herein; (ii) A nucleic acid sequence encoding the light chain sequence of the first binding arm according to any of the embodiments disclosed herein; (iii) A nucleic acid sequence encoding the heavy chain sequence of the second binding arm according to any of the embodiments disclosed herein; (iv) A nucleic acid sequence encoding the light chain sequence of the second binding arm according to any of the embodiments disclosed herein; Nucleic acids shown in (v)(i) and (ii); Nucleic acids shown in (vi), (iii) and (iv); Nucleic acids shown in (vii), (ii), (iii) and (iv).
[0224] In one aspect, the present invention relates to a method for generating a bispecific antibody according to any embodiment disclosed herein, comprising the following steps: a) Culturing the host cells disclosed herein, which contain the expression vector disclosed herein expressing the first antibody disclosed herein, and purifying the antibody from the culture medium; b) Culture the host cells disclosed herein, which contain the expression vector disclosed herein expressing the second antibody disclosed herein, and purify the antibody from the culture medium; c) Incubate the first antibody and the second antibody under reducing conditions sufficient to allow cysteine in the hinge region to undergo disulfide isomerization, and d) Obtain the bispecific antibody.
[0225] In one aspect, the present invention relates to host cells comprising the expression vector defined above. In one embodiment, the host cell is a recombinant eukaryotic, recombinant prokaryotic, or recombinant microbial host cell.
[0226] Fc area In one aspect of the invention, the bispecific CD3xCD20 antibody of the invention further comprises a first Fc region and a second Fc region, which may be contained in a first and a second Fab-arm, each of which also comprises the aforementioned first and second antigen-binding regions (or vice versa).
[0227] In another aspect of the invention, the bispecific CD3xCD20 antibody includes first and second Fab-arms, each comprising first and second antigen-binding regions. The bispecific CD3xCD20 antibody further includes first and second Fc regions. In another aspect of the invention, the bispecific CD3xCD20 antibody includes a first Fab-arm comprising a first antigen-binding region and a first Fc region, and a second Fab-arm comprising a second antigen-binding region and a second Fc region.
[0228] In another aspect of the invention, the bispecific CD3xCD20 antibody includes a second Fab-arm comprising a second antigen-binding region and a first Fc region, and a first Fab-arm comprising a first antigen-binding region and a second Fc region.
[0229] The first and second Fc regions may each have any isotype, including but not limited to IgG1, IgG2, IgG3, and IgG4, and may contain one or more mutations or modifications. In one embodiment, each of the first and second Fc regions has an IgG4 isotype or is derived therefrom, and optionally has one or more mutations or modifications. In another embodiment, one Fc region has an IgG1 isotype and the other has an IgG4 isotype, or is derived from each of such isotypes, and optionally has one or more mutations or modifications.
[0230] In one embodiment, one or both Fc regions contain a mutation that removes the Asn-linked glycosylation receptor site, or are otherwise manipulated to alter the glycosylation properties. For example, in the IgG1 Fc region, the N297Q mutation can be used to remove the Asn-linked glycosylation site. Therefore, in a specific embodiment, one or both Fc regions contain an IgG1 wild-type sequence with the N297Q mutation (SEQ ID NO: 66, see Table 1).
[0231] In one implementation, one or both Fc regions are effector-functionally defective. For example, the Fc regions may have an IgG4 isotype or a non-IgG4 type, such as IgG1, IgG2, or IgG3, which has been mutated to reduce or even eliminate the ability to mediate effector functions such as ADCC. Such mutations have been described, for example, in Dall'Acqua WF et al. . , JImmunol. 177 (2):1129-1138 (2006) and Hezareh M, J Virol.; 75 (24):12161-12168(2001). In one embodiment, one or both Fc-regions contain the IgG1 wild-type sequence (SEQ ID NO:63, see Table 1).
[0232] The bispecific antibodies of the present invention may contain modifications in the Fc region. When a bispecific antibody contains such modifications, it can become an inert or inactive bispecific antibody. As used herein, the terms "inert," "dormant," or "inactive" mean at least that the two Fc regions of a single antibody cannot bind to any Fcγ receptor, induce Fc-mediated FcR crosslinking, or induce FcR-mediated target antigen crosslinking, or cannot bind to the C1q Fc region. The inertness of the Fc region of a humanized or chimeric CD3 antibody is advantageous for use in monospecific antibody assays.
[0233] Several variants can be constructed to prepare the Fc region of antibodies inactive against interaction with the Fcγ (gamma) receptor and C1q, for use in the development of therapeutic antibodies. Examples of such variants are described herein.
[0234] Therefore, in one embodiment, the antibody comprises an Fc region that has been modified such that, compared with a wild-type antibody, the antibody-mediated Fc-mediated T-cell proliferation is reduced by at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 99%, or 100%, wherein the T-cell proliferation is measured in a peripheral blood mononuclear cell (PBMC)-based functional assay.
[0235] Therefore, amino acids in the Fc region that play a major role in the interaction with C1q and Fcγ receptors can be modified. Examples of amino acid positions that can be modified include positions L234, L235, and P331. Combinations of these, such as L234F / L235E / P331S, can cause a significant reduction in binding to human CD64, CD32A, CD16, and C1q.
[0236] Therefore, in one embodiment, the amino acids corresponding to at least one position of L234, L235, and P331 can be A, A, and S, respectively (Xu et al., 2000, Cell Immunol. 200(1):16-26; Oganesyan et al., 2008, Acta Cryst. (D64):700-4). Furthermore, amino acid substitutions of L234F and L235E can produce an Fc region with abolished interactions with the Fcγ receptor and C1q (Canfield et al., 1991, J. Exp.Med. (173):1483-91; Duncan et al., 1988, Nature (332):738-40). Therefore, in one embodiment, the amino acids corresponding to the positions of L234 and L235 can be F and E, respectively. The D265A amino acid substitution reduces binding to all Fcγ receptors and prevents ADCC (Shields et al., 2001, J. Biol. Chem. (276):6591-604). Therefore, in one embodiment, the amino acid corresponding to the D265 position can be A. Binding to C1q can be eliminated by mutations at positions D270, K322, P329, and P331. Mutating these positions to any one of D270A, K322A, P329A, or P331A can render the antibody lacking CDC activity (Idusogie EE, et al., 2000, J Immunol. 164: 4178-84). Therefore, in one embodiment, the amino acid corresponding to at least one position at D270, K322, P329, and P331 can be A, A, A, and A, respectively.
[0237] An alternative method to minimize the interaction between the Fc region and the Fcγ receptor and C1q is by removing the glycosylation site of the antibody. Mutation at position N297, for example, Q, A, or E, removes a glycosylation site that is critical for IgG-Fcγ receptor interaction. Therefore, in one embodiment, the amino acid corresponding to the N297 position can be G, Q, A, or E (Leabman et al., 2013, MAbs; 5(6):896-903). Another alternative method to minimize the interaction between the Fc region and the Fcγ receptor can be obtained by the following mutations: P238A, A327Q, P329A, or E233P / L234V / L235A / G236del (Shields et al., 2001, J. Biol. Chem. (276):6591-604).
[0238] Alternatively, although human IgG2 and IgG4 subclasses are considered to be naturally deficient in their interactions with C1q and Fcγ receptors, interactions with Fcγ receptors have been reported (Parren et al., 1992, J. ClinInvest. 90: 1537-1546; Bruhns et al.). ., (2009, Blood 113: 3716-3725). Mutations that eliminate these residual interactions can be performed in both isotypes, resulting in a reduction of unwanted side effects associated with FcR binding. For IgG2, these include L234A and G237A, and for IgG4, L235E. Thus, in one embodiment, the amino acids in the human IgG2 heavy chain corresponding to the L234 and G237 positions can be A and A, respectively. In one embodiment, the amino acid in the human IgG4 heavy chain corresponding to the L235 position can be E.
[0239] Other methods for further minimizing interactions with Fcγ receptors and C1q in IgG2 antibodies include those described in WO2011066501 and Lightle, S., et al., 2010, Protein Science (19):753-62.
[0240] The hinge region of an antibody may also be important in its interaction with the Fcγ receptor and complement (Brekke et al., 2006, J Immunol 177:1129-1138; Dall'Acqua WF, et al., 2006, J Immunol 177:1129-1138). Therefore, mutations or deletions in the hinge region can affect the effector function of the antibody.
[0241] As used herein, the term "crosslinking" refers to an indirect bridging via the Fab arm (monovalent or bivalent) of an antibody that binds to the target antigen through the Fc region of a cell-binding antibody carrying an FcR. Therefore, binding an antibody to the target antigen on a cell carrying the target antigen allows said cell to crosslink with another cell expressing the FcR.
[0242] As used in this article, "nonspecific killing" refers to the tumor-target antigen-independent activation of killing cells via the cytotoxic function of T cells or other effector cells. Therefore, nonspecific killing means that effector cells, such as cytotoxic T cells, are activated and induce cytotoxicity in a manner independent of tumor-target binding, for example, by enabling antibodies to bind to CD3 and FcγR.
[0243] Therefore, in one embodiment, the bispecific antibody comprises first and second immunoglobulin heavy chains, wherein in at least one of the first and second immunoglobulin heavy chains, one or more amino acids at positions L234, L235, D265, N297, and P331 of the human IgG1 heavy chain are not L, L, D, N, and P, respectively.
[0244] In one embodiment, in both the first and second heavy chains, one or more amino acids at positions L234, L235, D265, N297, and P331 corresponding to the human IgG1 heavy chain are not L, L, D, N, and P, respectively.
[0245] In another embodiment, in at least one of the first and second heavy chains, one or more amino acids at positions L234, L235 and D265 of the human IgG1 heavy chain are not L, L and D, respectively, and the amino acids at positions N297 and P331 of the human IgG1 heavy chain are N and P, respectively.
[0246] As used herein, the term "corresponding amino acid position" refers to the amino acid position number of the human IgG1 heavy chain. Corresponding amino acid positions in other immunoglobulins can be identified by comparison with human IgG1. Unless otherwise stated or contradicted by context, amino acids in constant region sequences are numbered herein according to the Eu numbering index (described in Kabat, EA et al., 1991, Sequences of proteins of immunological interest. 5th Edition - US Department of Health and Human Services, NIH publication No. 91-3242, pp 662, 680, 689). Therefore, an amino acid or segment in one sequence that "corresponds" to an amino acid or segment in another sequence is an amino acid or segment that, when aligned using standard sequence alignment programs such as ALIGN, ClustalW, or similar programs, typically with default settings, and has at least 50%, at least 80%, at least 90%, or at least 95% identity with the human IgG1 heavy chain. It is well known in the art how sequences or segments within sequences are aligned and thus positions in the sequence corresponding to the amino acid positions of the present invention are determined.
[0247] In the context of this invention, amino acids can be defined as described above.
[0248] The term "amino acid is not" or similar expressions, when referring to amino acids in the heavy chain, should be understood to mean that the amino acid is any other amino acid that is not the specific amino acid mentioned. For example, the amino acid at position L234 of the human IgG1 heavy chain is not L, meaning that the amino acid can be any other naturally occurring or non-naturally occurring amino acid other than L.
[0249] In one embodiment, in at least one of the first and second heavy chains, the amino acid at position D265 of the human IgG1 heavy chain is not D.
[0250] In one embodiment, in at least one of the first and second heavy chains, the amino acid at position D265 of the human IgG1 heavy chain is not D, and the amino acids at positions N297 and P331 of the human IgG1 heavy chain are N and P, respectively.
[0251] In one embodiment, in at least one of the first and second heavy chains, the amino acid at position D265 of the human IgG1 heavy chain is a hydrophobic or polar amino acid.
[0252] As used herein, the term "hydrophobic" for amino acid residues refers to amino acid residues selected from A, C, F, G, H, I, L, M, R, T, V, W, and Y. Therefore, in one embodiment, in at least one of the first and second heavy chains, the amino acid corresponding to position D265 of the human IgG1 heavy chain is selected from the amino acids composed of A, C, F, G, H, I, L, M, R, T, V, W, and Y.
[0253] As used herein, the term "polar" for amino acid residues refers to any amino acid residue selected from C, D, E, H, K, N, Q, R, S, and T. Therefore, in one embodiment, in at least one of the first and second heavy chains, the amino acid at position D265 of the human heavy chain is selected from C, E, H, K, N, Q, R, S, and T.
[0254] In another embodiment, in at least one of the first and second heavy chains, the amino acid at position D265 of the human IgG1 heavy chain is an aliphatic uncharged, aromatic, or acidic amino acid.
[0255] As used herein, the term "aliphatic uncharged" for amino acid residues refers to any amino acid residue selected from A, G, I, L, and V. Therefore, in one embodiment, in at least one of the first and second heavy chains, the amino acid at position D265 of the human IgG1 heavy chain is selected from A, G, I, L, and V.
[0256] As used herein, the term "aromatic" for amino acid residues refers to any amino acid residue selected from F, T, and W. Therefore, in one embodiment, in at least one of the first and second heavy chains, the amino acid at position D265 of the human IgG1 heavy chain is selected from F, T, and W.
[0257] As used herein, the term "acidic" with respect to amino acid residues refers to any amino acid residue selected from D and E. Therefore, in one embodiment, in at least one of the first and second heavy chains, the amino acid at position D265 of the human IgG1 heavy chain is selected from D and E.
[0258] In a specific implementation, in at least one of the first and second heavy chains, the amino acid at position D265 of the human IgG1 heavy chain is selected from A, E, F, G, I, L, T, V, and W.
[0259] In one embodiment, in both the first and second heavy chains, the amino acid at position D265 of the human IgG1 heavy chain is not D.
[0260] In one embodiment, in both the first and second heavy chains, the amino acid at position D265 of the human IgG1 heavy chain is not D, and the amino acids at positions N297 and P331 of the human IgG1 heavy chain are N and P, respectively.
[0261] In one embodiment, in both the first and second heavy chains, the amino acid at position D265 of the human IgG1 heavy chain is a hydrophobic or polar amino acid.
[0262] Therefore, in one embodiment, in both the first and second heavy chains, the amino acid at position D265 of the human IgG1 heavy chain is selected from amino acids composed of A, C, F, G, H, I, L, M, R, T, V, W, and Y.
[0263] Therefore, in one embodiment, in both the first and second heavy chains, the amino acid at position D265 of the human heavy chain is selected from C, E, H, K, N, Q, R, S, and T. In one embodiment, in both the first and second heavy chains, the amino acid at position D265 of the human IgG1 heavy chain is selected from amino acids composed of A, C, F, G, H, I, L, M, R, T, V, W, and Y.
[0264] In one embodiment, in both the first and second heavy chains, the amino acid at position D265 of the human heavy chain is selected from C, E, H, K, N, Q, R, S, and T.
[0265] In another embodiment, in both the first and second heavy chains, the amino acid at position D265 of the human IgG1 heavy chain is an aliphatic uncharged, aromatic, or acidic amino acid.
[0266] Therefore, in one embodiment, in both the first and second heavy chains, the amino acid at the position corresponding to position D265 of the human IgG1 heavy chain is selected from A, G, I, L, and V.
[0267] Therefore, in one embodiment, in both the first and second heavy chains, the amino acid at position D265 of the human IgG1 heavy chain is selected from F, T, and W.
[0268] Therefore, in one embodiment, in both the first and second heavy chains, the amino acid at the position corresponding to position D265 of the human IgG1 heavy chain is selected from D and E.
[0269] In a specific implementation, in both the first and second heavy chains, the amino acid at position D265 of the human IgG1 heavy chain is selected from A, E, F, G, I, L, T, V, and W.
[0270] In a further embodiment, in at least one of the first and second heavy chains, the amino acid at position N297 of the human IgG1 heavy chain is not N.
[0271] In one embodiment, in at least one of the first and second heavy chains, the amino acid at position N297 of the human IgG1 heavy chain is not N, and the amino acid at position P331 of the human IgG1 heavy chain is P.
[0272] In one embodiment, in both the first and second heavy chains, the amino acid at position N297 of the human IgG1 heavy chain is not N.
[0273] In one embodiment, in both the first and second heavy chains, the amino acid at position N297 of the human IgG1 heavy chain is not N, and the amino acid at position P331 of the human IgG1 heavy chain is P.
[0274] In a further embodiment, in at least one of the first and second heavy chains, the amino acids at positions L234 and L235 corresponding to the human IgG1 heavy chain are not L and L, respectively.
[0275] In one embodiment, in at least one of the first and second heavy chains, the amino acids at positions L234 and L235 of the human IgG1 heavy chain are not L and L, respectively, and the amino acids at positions N297 and P331 of the human IgG1 heavy chain are N and P, respectively.
[0276] In one embodiment, in at least one of the first and second heavy chains, the amino acids corresponding to positions L234 and L235 of the human IgG1 heavy chain are selected from A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, Y, and V.
[0277] In one embodiment, in at least one of the first and second heavy chains, the amino acids at positions L234 and L235 of the human IgG1 heavy chain are hydrophobic or polar amino acids.
[0278] Therefore, in one embodiment, in at least one of the first and second heavy chains, the amino acids at positions L234 and L235 corresponding to the human IgG1 heavy chain are each selected from A, C, F, G, H, I, M, R, T, V, W, and Y.
[0279] Therefore, in one embodiment, in at least one of the first and second heavy chains, the amino acids corresponding to positions L234 and L235 of the human IgG1 heavy chain are each selected from amino acids composed of C, D, E, H, K, N, Q, R, S and T.
[0280] In a specific implementation, in at least one of the first and second heavy chains, the amino acids corresponding to positions L234 and L235 of the human IgG1 heavy chain are each selected from A, C, D, E, F, G, H, I, K, M, N, Q, R, S, T, V, W, and Y.
[0281] In one embodiment, in both the first and second heavy chains, the amino acids at positions L234 and L235 corresponding to the human IgG1 heavy chain are not L and L, respectively.
[0282] In one embodiment, in both the first and second heavy chains, the amino acids at positions L234 and L235 of the human IgG1 heavy chain are not L and L, respectively, and the amino acids at positions N297 and P331 of the human IgG1 heavy chain are N and P, respectively.
[0283] In one embodiment, in both the first and second heavy chains, the amino acids at positions corresponding to L234 and L235 of the human IgG1 heavy chain are hydrophobic or polar amino acids.
[0284] In one embodiment, in both the first and second heavy chains, the amino acids at positions L234 and L235 corresponding to the human IgG1 heavy chain are each selected from A, C, F, G, H, I, M, R, T, V, W, and Y.
[0285] In one embodiment, in both the first and second heavy chains, the amino acids at positions L234 and L235 corresponding to the human IgG1 heavy chain are each selected from amino acids composed of C, D, E, H, K, N, Q, R, S, and T.
[0286] In a specific implementation, in both the first and second heavy chains, the amino acids at positions L234 and L235 corresponding to the human IgG1 heavy chain are each selected from A, C, D, E, F, G, H, I, K, M, N, Q, R, S, T, V, W, and Y.
[0287] In another embodiment, in at least one of the first and second heavy chains, the amino acids at positions L234 and L235 of the human IgG1 heavy chain are aliphatic uncharged, aromatic, or acidic amino acids.
[0288] Therefore, in one embodiment, in at least one of the first and second heavy chains, the amino acids at positions L234 and L235 corresponding to the human IgG1 heavy chain are each selected from A, G, I and V.
[0289] Therefore, in one embodiment, in at least one of the first and second heavy chains, the amino acids at positions L234 and L235 corresponding to the human IgG1 heavy chain are each selected from F, T, and W.
[0290] Therefore, in one embodiment, in at least one of the first and second heavy chains, the amino acids at positions L234 and L235 of the human IgG1 heavy chain are each selected from D and E.
[0291] In a specific embodiment, in at least one of the first and second heavy chains, the amino acids corresponding to positions L234 and L235 are each selected from A, D, E, F, G, I, T, V, and W.
[0292] In one embodiment, in at least one of the first and second heavy chains, the amino acids at positions L234 and L235 of the human IgG1 heavy chain are F and E, or A and A, respectively.
[0293] In one embodiment, in at least one of the first and second heavy chains, the amino acids at positions L234 and L235 of the human IgG1 heavy chain are F and E, or A and A, respectively, and the amino acids at positions N297 and P331 of the human IgG1 heavy chain are N and P, respectively.
[0294] In one embodiment, in both the first and second heavy chains, the amino acids at positions L234 and L235 of the human IgG1 heavy chain are F and E, or A and A, respectively.
[0295] In one embodiment, in both the first and second heavy chains, the amino acids corresponding to positions L234 and L235 of the human IgG1 heavy chain are F and E, or A and A, respectively, and the amino acids corresponding to positions N297 and P331 of the human IgG1 heavy chain are N and P, respectively.
[0296] In a specific implementation, in at least one of the first and second heavy chains, the amino acids at positions L234 and L235 of the human IgG1 heavy chain are F and E, respectively.
[0297] In one embodiment, in both the first and second heavy chains, the amino acids at positions L234 and L235 of the human IgG1 heavy chain are F and E, respectively.
[0298] In one embodiment, in at least one of the first and second heavy chains, the amino acids at positions L234 and L235 of the human IgG1 heavy chain are A and A, respectively.
[0299] In one embodiment, in both the first and second heavy chains, the amino acids at positions L234 and L235 corresponding to the human IgG1 heavy chain are A and A, respectively.
[0300] In one embodiment, in at least one of the first and second heavy chains, the amino acids at positions L234, L235, and D265 of the human IgG1 heavy chain are not L, L, and D, respectively.
[0301] In one embodiment, in at least one of the first and second heavy chains, the amino acids at positions L234, L235, and D265 of the human IgG1 heavy chain are not L, L, and D, respectively, and the amino acids at positions N297 and P331 of the human IgG1 heavy chain are N and P, respectively.
[0302] In one embodiment, in at least one of the first and second heavy chains, the amino acids corresponding to positions L234 and L235 of the human IgG1 heavy chain are selected from A, C, D, E, F, G, H, I, K, M, N, P, Q, R, S, T, Y, V and W, and the amino acid corresponding to position D265 is selected from A, C, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, Y, V and W.
[0303] In one embodiment, in at least one of the first and second heavy chains, the amino acids at positions L234, L235, and D265 of the human IgG1 heavy chain are hydrophobic or polar amino acids.
[0304] Therefore, in one embodiment, in at least one of the first and second heavy chains, the amino acid at position D265 of the human IgG1 heavy chain is selected from A, C, F, G, H, I, L, M, R, T, V, W and Y, and the amino acids at positions L234 and L235 of the human IgG1 heavy chain are each selected from A, C, F, G, H, I, M, R, T, V, W and Y.
[0305] Therefore, in one embodiment, in at least one of the first and second heavy chains, the amino acids at positions L234 and L235 of the human IgG1 heavy chain are each selected from C, D, E, H, K, N, Q, R, S and T, and the amino acid at position D265 of the human heavy chain is selected from C, E, H, K, N, Q, R, S and T.
[0306] In a specific embodiment, in at least one of the first and second heavy chains, the amino acids corresponding to positions L234 and L235 of the human IgG1 heavy chain are each selected from A, C, D, E, F, G, H, I, K, M, N, Q, R, S, T, V, W, and Y, and the amino acid corresponding to position D265 of the human IgG1 heavy chain is selected from A, C, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, and Y.
[0307] In one embodiment, in both the first and second heavy chains, the amino acids at positions corresponding to L234, L235, and D265 of the human IgG1 heavy chain are hydrophobic or polar amino acids.
[0308] In one embodiment, in both the first and second heavy chains, the amino acid at position D265 of the human IgG1 heavy chain is selected from A, C, F, G, H, I, L, M, R, T, V, W, and Y, and the amino acids at positions L234 and L235 of the human IgG1 heavy chain are each selected from A, C, F, G, H, I, M, R, T, V, W, and Y.
[0309] In one embodiment, in both the first and second heavy chains, the amino acids at positions L234 and L235 of the human IgG1 heavy chain are each selected from C, D, E, H, K, N, Q, R, S, and T, and the amino acid at position D265 of the human heavy chain is selected from C, E, H, K, N, Q, R, S, and T.
[0310] In a specific implementation, in both the first and second heavy chains, the amino acids corresponding to positions L234 and L235 of the human IgG1 heavy chain are each selected from A, C, D, E, F, G, H, I, K, M, N, Q, R, S, T, V, W, and Y, and the amino acid corresponding to position D265 of the human IgG1 heavy chain is selected from A, C, E, F, G, H, I, K, L, M, N, Q, R, S, T, V, W, and Y.
[0311] In another embodiment, in at least one of the first and second heavy chains, the amino acids at positions L234, L235, and D265 of the human IgG1 heavy chain are aliphatic uncharged, aromatic, or acidic amino acids.
[0312] Therefore, in one embodiment, in at least one of the first and second heavy chains, the amino acid at position D265 of the human IgG1 heavy chain is selected from A, G, I, L and V, and the amino acids at positions L234 and L235 of the human IgG1 heavy chain are each selected from A, G, I and V.
[0313] Therefore, in one embodiment, in at least one of the first and second heavy chains, the amino acids at positions L234, L235 and D265 of the human IgG1 heavy chain are each selected from F, T and W.
[0314] Therefore, in one embodiment, in at least one of the first and second heavy chains, the amino acids at positions L234, L235 and D265 of the human IgG1 heavy chain are each selected from D and E.
[0315] In a specific embodiment, in at least one of the first and second heavy chains, the amino acid at position D265 of the human IgG1 heavy chain is selected from A, E, F, G, I, L, T, V and W, and the amino acids at positions L234 and L235 are each selected from A, D, E, F, G, I, T, V and W.
[0316] In one embodiment, in both the first and second heavy chains, the amino acids at positions L234, L235, and D265 of the human IgG1 heavy chain are not L, L, and D, respectively.
[0317] In one embodiment, in both the first and second heavy chains, the amino acids at positions L234, L235, and D265 of the human IgG1 heavy chain are not L, L, and D, respectively, and the amino acids at positions N297 and P331 of the human IgG1 heavy chain are N and P, respectively.
[0318] In one embodiment, in both the first and second heavy chains, the amino acids at positions corresponding to L234, L235, and D265 of the human IgG1 heavy chain are aliphatic uncharged, aromatic, or acidic amino acids.
[0319] In one embodiment, in both the first and second heavy chains, the amino acid at position D265 of the human IgG1 heavy chain is selected from A, G, I, L, and V, and the amino acids at positions L234 and L235 of the human IgG1 heavy chain are each selected from A, G, I, and V.
[0320] In one embodiment, in both the first and second heavy chains, the amino acids at positions L234, L235, and D265 of the human IgG1 heavy chain are each selected from D and E.
[0321] In a specific implementation, in both the first and second heavy chains, the amino acid at position D265 of the human IgG1 heavy chain is selected from A, E, F, G, I, L, T, V and W, and the amino acids at positions L234 and L235 are each selected from A, D, E, F, G, I, T, V and W.
[0322] In one embodiment, in at least one of the first and second heavy chains, the amino acids at positions L234, L235, and D265 of the human IgG1 heavy chain are F, E, and A, respectively; or A, A, and A.
[0323] In one embodiment, in at least one of the first and second heavy chains, the amino acids corresponding to positions L234, L235, and D265 of the human IgG1 heavy chain are F, E, and A, respectively; or A, A, and A, and the amino acids corresponding to positions N297 and P331 of the human IgG1 heavy chain are N and P, respectively.
[0324] In one embodiment, in both the first and second heavy chains, the amino acids at positions L234, L235, and D265 of the human IgG1 heavy chain are F, E, and A, respectively; or A, A, and A.
[0325] In one embodiment, in both the first and second heavy chains, the amino acids corresponding to positions L234, L235, and D265 of the human IgG1 heavy chain are F, E, and A, respectively; or A, A, and A, and the amino acids corresponding to positions N297 and P331 of the human IgG1 heavy chain are N and P, respectively.
[0326] In a specific implementation, in at least one of the first and second heavy chains, the amino acids at positions L234, L235, and D265 of the human IgG1 heavy chain are F, E, and A, respectively.
[0327] In a particularly preferred embodiment, in both the first and second heavy chains, the amino acids at positions L234, L235, and D265 of the human IgG1 heavy chain are F, E, and A, respectively.
[0328] In one embodiment, in at least one of the first and second heavy chains, the amino acids at positions L234, L235, and D265 of the human IgG1 heavy chain are A, A, and A, respectively.
[0329] In one embodiment, in both the first and second heavy chains, the amino acids at positions L234, L235, and D265 of the human IgG1 heavy chain are A, A, and A, respectively.
[0330] In another embodiment, in at least one of the first and second heavy chains, the amino acids at positions L234, L235, D265, N297 and P331 of the human IgG1 heavy chain are F, E, A, Q and S, respectively.
[0331] In one embodiment, in both the first and second heavy chains, the amino acids at positions L234, L235, D265, N297, and P331 of the human IgG1 heavy chain are F, E, A, Q, and S, respectively.
[0332] In a specific embodiment, the antibody of the present invention comprises the VH sequence shown in SEQ ID NO:8, the VL sequence shown in SEQ ID NO:10, and amino acids F, E, and A at positions L234, L235, and D265 of the human IgG1 heavy chain in at least one heavy chain.
[0333] In another embodiment, the antibody of the present invention comprises the VH sequence shown in SEQ ID NO:8, the VL sequence shown in SEQ ID NO:12, and amino acids F, E, and A at positions L234, L235, and D265 of the human IgG1 heavy chain in at least one heavy chain.
[0334] In another embodiment, the antibody of the present invention comprises the VH sequence shown in SEQ ID NO:6, the VL sequence shown in SEQ ID NO:10, and amino acids F, E, and A at positions L234, L235, and D265 of the human IgG1 heavy chain in at least one heavy chain.
[0335] In another embodiment, the antibody of the present invention comprises the VH sequence shown in SEQ ID NO:6, the VL sequence shown in SEQ ID NO:12, and amino acids F, E, and A at positions L234, L235, and D265 of the human IgG1 heavy chain in at least one heavy chain.
[0336] In another embodiment, the antibody of the present invention comprises the VH sequence shown in SEQ ID NO:9, the VL sequence shown in SEQ ID NO:10, and amino acids F, E, and A at positions L234, L235, and D265 of the human IgG1 heavy chain in at least one heavy chain.
[0337] In another embodiment, the antibody of the present invention comprises the VH sequence shown in SEQ ID NO:9, the VL sequence shown in SEQ ID NO:12, and amino acids F, E, and A at positions L234, L235, and D265 of the human IgG1 heavy chain in at least one heavy chain.
[0338] In one aspect, the bispecific antibody of the present invention comprises a light chain with a constant structural domain λ of human IgLC2 / IgLC3 as described in SEQ ID NO:29.
[0339] Several antibody variants are generated by replacing one or more amino acids in the Fc region. An inactivated Fc region prevents the antibody from interacting with Fc-receptors present in blood cells (e.g., monocytes) or from interacting with C1q to activate the classical complement pathway. Reduced Fc activity is tested in antibody variants containing different combinations of amino acid replacements in the Fc region. Up to five amino acid replacements are introduced, including mutations in N297Q, L234A, L235A, L234F, L235E, D265A, and P331S. Replacements at one or more of these five amino acid positions are introduced into the K409R and / or F405L IgG1 backbone. The following Fc region variants produce huCLB-T3 / 4 antibodies: N297Q (referring to the N297Q substitution, called IgG1-huCLB-T3 / 4-N297Q), LFLE (referring to the L234F / L235E substitution, called IgG1-huCLB-T3 / 4-LFLE), LALA (referring to the L234A / L235A substitution, called IgG1-huCLB-T3 / 4-LALA), LFLENQ (referring to the L234F / L235E / N297Q substitution, called IgG1-huCLB-T3 / 4-LFLENQ), LFLEDA (referring to the L234F / L235E / D265A substitution, called IgG1-huCLB-T3 / 4-LFLEDA), DA (referring to the D265A substitution, called IgG1-huCLB-T3 / 4-DA), DAPS (Refers to D265A / P331S replacement, called IgG1-huCLB-T3 / 4-DAPS), DANQ (refers to D265A / N297Q replacement, called IgG1-huCLB-T3 / 4-DANQ), LFLEPS (refers to L234F / L235E / P331S replacement, called IgG1-huCLB-T3 / 4-LFLEPS), and LFLEDANQPS (refers to L234F / L235E / D265A / N297Q / P331S replacement, called IgG1-huCLB-T3 / 4-LFLEDANQPS).
[0340] In particular, a combination of three amino acid substitutions in IgG1-huCD3 antibody variants, including mutants L234F, L235E, and D265A and referred to as LFLEDA or FEA, was introduced into the K409R and F405L IgG1 backbones to produce antibodies with an inactive Fc region. The resulting inactive antibody variants are designated with the suffixes “FEAR” or “FEAL”, respectively.
[0341] In one aspect, the bispecific antibody of the present invention may be modified in the light chain and / or heavy chain to increase expression levels and / or production yield. In one embodiment, the antibody of the present invention may be modified in the light chain. Such modification is known in the art and can be performed according to the methods described, for example, in Zheng, L., Goddard, J.-P., Baumann, U., & Reymond, J.-L. (2004). Expression improvement and mechanistic study of theretro-Diels-Alderase catalytic antibody 10F11 by site-directed mutagenesis. Journal of Molecular Biology, 341(3), 807–14.
[0342] In one embodiment, the bispecific antibody as defined in any of the embodiments disclosed herein comprises a first heavy chain and a first light chain, wherein the amino acid of the first light chain corresponding to position T41 of the λ light chain in SEQ ID NO:10 is not T.
[0343] In one embodiment of the bispecific antibody defined in any of the embodiments disclosed herein, the amino acid corresponding to position T41 of the λ light chain in SEQ ID NO:10 is selected from H, I, K, L, Q, R, and V.
[0344] In one embodiment of the bispecific antibody defined in any of the embodiments disclosed herein, the amino acid at position T41 of the λ light chain of SEQ ID NO:10 is H, K, or R.
[0345] In one embodiment of the bispecific antibody defined in any of the embodiments disclosed herein, the amino acid at position T41 of the λ light chain of the first light chain corresponding to SEQ ID NO:10 is K.
[0346] In one embodiment of the bispecific antibody defined in any of the embodiments disclosed herein, the amino acid at position F10 of the λ light chain of SEQ ID NO:10 is not F, and one or more amino acids at positions T41, K55 and L97 of the λ light chain of SEQ ID NO:10 are not T, K and L, respectively.
[0347] In one embodiment of the bispecific antibody as defined in any of the embodiments disclosed herein, the amino acids at positions F10, T41, K55, and L97 of the first light chain corresponding to the λ light chain of SEQ ID NO:10 are not F, T, K, and L, respectively.
[0348] In one embodiment of the bispecific antibody as defined in any of the embodiments disclosed herein, the amino acids of the first light chain corresponding to positions F10, T41, K55 and L97 of the λ light chain of SEQ ID NO:10 are L, K, N and H, respectively.
[0349] In one embodiment of the bispecific antibody as defined in any of the embodiments disclosed herein, the amino acids at positions R23 and A35 of the λ light chain of the first light chain corresponding to SEQ ID NO:10 are not R and A, respectively.
[0350] In one embodiment of the bispecific antibody as defined in any of the embodiments disclosed herein, the amino acids of the first light chain corresponding to positions R23 and A35 of the λ light chain in SEQ ID NO:10 are A and P, respectively.
[0351] In one embodiment of the bispecific antibody as defined in any of the embodiments disclosed herein, the amino acids at positions F10, R23, A35, R47, D71, A82, D83, S86, I87 and F89 of the first light chain corresponding to the λ light chain of SEQ ID NO:10 are not F, R, A, R, D, A, D, S, I and F, respectively.
[0352] In one embodiment of the bispecific antibody defined in any of the embodiments disclosed herein, the amino acids at positions F10, R23, A35, R47, D71, A82, D83, S86, I87 and F89 of the first light chain corresponding to the λ light chain of SEQ ID NO:10 are L, A, P, T, G, P, E, A, E and Y, respectively.
[0353] In one embodiment of the bispecific antibody as defined in any of the embodiments disclosed herein (i) The amino acid at position F10 of the λ light chain in the first light chain corresponding to SEQ ID NO:10 is not F, or (ii) The amino acid at position K55 of the λ light chain in SEQ ID NO:10 is not K, or (iii) The amino acid at position F10 of the first light chain corresponding to position F10 of the λ light chain in SEQ ID NO:10 is not F, and the amino acid at position K55 of the first light chain corresponding to position K55 of the λ light chain in SEQ ID NO:10 is not K.
[0354] In one embodiment of the bispecific antibody as defined in any of the embodiments disclosed herein (i) The amino acid at position F10 of the λ light chain in the first light chain corresponding to SEQ ID NO:10 is L, or (ii) The amino acid at position K55 of the λ light chain in SEQ ID NO:10 of the first light chain is N, or (iii) The amino acid at position F10 of the λ light chain of the first light chain corresponding to SEQ ID NO:10 is L, and the amino acid at position K55 of the λ light chain of the first light chain corresponding to SEQ ID NO:10 is N.
[0355] In one embodiment, the bispecific antibody of the present invention comprises a first light chain, wherein the amino acid corresponding to position T41 is selected from H, I, K, L, Q, R, or V, for example, selected from H, K, and R, such as K. In one embodiment, the bispecific antibody of the present invention comprises a first light chain having amino acids L, K, N, and H at positions F10, T41, K55, and L97 corresponding to the λ light chain of SEQ ID NO: 10, respectively. In one embodiment, the bispecific antibody of the present invention comprises a first light chain, wherein the amino acid corresponding to position R23 is selected from A, G, H, K, Q, S, and T, for example, selected from A and G, and wherein the amino acid corresponding to position A35 is selected from I, L, M, P, V, G, F, and W, for example, selected from I, L, M, P, and V.
[0356] In one embodiment, the bispecific antibody of the present invention comprises a first light chain, wherein the amino acid corresponding to position R23 is A or G, for example A, and the amino acid corresponding to position A35 is P.
[0357] In one embodiment, the bispecific antibody of the present invention comprises a first light chain, wherein the amino acids at positions F10, R23, A35, R47, D71, A82, D83, S86, I87 and F89 of the λ light chain corresponding to SEQ ID NO: 10 are not F, R, A, R, D, A, D, S, I and F, respectively.
[0358] In one embodiment, the bispecific antibody of the present invention comprises a first light chain, wherein the amino acid corresponding to position R23 is selected from A, G, H, K, Q, S and T, for example, selected from A and G; wherein the amino acid corresponding to position A35 is selected from I, L, M, P, V, G, F and W, for example, selected from I, L, M, P; and wherein the amino acids corresponding to positions F10, R47, D71, A82, D83, S86, I87 and F89 of the λ light chain of SEQ ID NO:10 are L, T, G, P, E, A, E and Y, respectively.
[0359] In one embodiment, the bispecific antibody of the present invention comprises a first light chain, wherein the amino acid corresponding to position R23 is A or G, and wherein the amino acids corresponding to positions F10, A35, R47, D71, A82, D83, S86, I87 and F89 of the λ light chain of SEQ ID NO:10 are L, P, T, G, P, E, A, E and Y, respectively.
[0360] In one aspect, the bispecific antibody of the present invention may be modified in the first and / or second light chain to increase the antibody affinity.
[0361] In one aspect, the bispecific antibody of the present invention may be modified in the light chain of the first and / or second binding arm to reduce antibody affinity. This may be advantageous and lead to increased efficacy in some cases. In particular, the low affinity of the first binding arm (binding to human CD3ε (epsilon)) can have an effect on T cell motility in circulation and tumor sites, thus leading to better binding of T cells to tumor cells, see Mølhøj et al., Molecular Immunology 44 (2007). In particular, this can be used in the bispecific form, where the CD3 antibody is used as one of the binding arms. Modifications that lead to reduced antibody affinity are known in the art, see, for example, Webster et al. Int J Cancer Suppl. 1988;3:13-6.
[0362] In one embodiment, the bispecific antibody of the present invention comprises a first light chain, wherein (i) The amino acid at position F10 of the λ light chain corresponding to SEQ ID NO:10 is not F, or (ii) The amino acid at position K55 of the λ light chain corresponding to SEQ ID NO:10 is not K, or (iii) The amino acid at position F10 of the λ light chain corresponding to SEQ ID NO:10 is not F and the amino acid at position K55 of the λ light chain corresponding to SEQ ID NO:10 is not K.
[0363] In one embodiment, the antibody of the present invention comprises a constant light chain (LC), wherein (i) The amino acid at position F10 of the λ light chain corresponding to SEQ ID NO:10 is L, or (ii) The amino acid at position K55 of the λ light chain corresponding to SEQ ID NO:10 is N, or (iii) The amino acid at position F10 of the λ light chain in SEQ ID NO:10 is L and the amino acid at position K55 of the λ light chain in SEQ ID NO:10 is N.
[0364] In one embodiment, the bispecific antibody of the present invention comprises a light chain wherein the amino acids corresponding to positions F10, T41, K55, and L97 of the λ light chain in SEQ ID NO:10 are not F, T, K, and L, respectively. This modification serves to both increase expression levels and reduce affinity.
[0365] In one embodiment, the bispecific antibody of the present invention comprises a first light chain, wherein the amino acids corresponding to positions F10, T41, K55, and L97 of the λ light chain in SEQ ID NO: 10 are L, K, N, and H, respectively. This modification serves to both increase expression levels and reduce affinity.
[0366] In a further aspect of the invention, mutations have been performed on the CDR region of huCD3 to optimize the binding affinity of the CD3 binding arm, for example, by reducing the binding affinity of the CD3 arm.
[0367] Therefore, in one embodiment, the CD3 binding arm of the bispecific antibody of the present invention comprises six CDR sequences selected from the CDR sequences described in Table 2 below.
[0368] Table 2 In one implementation, six CDR sequences can be inserted into any of the huCD3 VH and VL frame sequences VH1, VH2, VH3 and VH4, and VL1, VL2 and VL3, respectively, replacing the huCD3 CDR sequence. In one implementation, the six CDR sequences are inserted into the huCD3 frame sequences VH1 and VL1.
[0369] In a further embodiment, the CD3 binding arm comprises six CDR sequences selected from Table 2, wherein X1 of SEQ ID NO:72 is selected from V, H, F, T, P, L, Q, D, K, W, G, A, C, and R; X2 of SEQ ID NO:73 is selected from N, A, H, Q, P, F, M, Y, L, W, D, E, and C; X4 of SEQ ID NO:75 is selected from Y, Q, W, L, A, I, M, D, T, K, R, G, F, E, V, C, and P; X5 of SEQ ID NO:76 is selected from N, L, Y, W, H, M, G, F, K, S, V, R, Q, D, C, E, and P; X of SEQ ID NO:81 10 Selected from A, G, R, V, F, E, M, H, N, Y, P, Q, D, K, and L; X of SEQ ID NO:83 12 Selected from D, K, Q, G, V, E, T, N, Y, S, P, W, F and M.
[0370] Compared to the wild-type huCD3 CDR sequence, such huCD3 CDR variant sequences have reduced binding affinity. Six CDR sequences can be inserted into any of the huCD3 VH and VL framework sequences VH1, VH2, VH3 and VH4, and VL1, VL2 and VL3, respectively, replacing the huCD3 CDR sequence. In one embodiment, the six CDR sequences are inserted into the huCD3 framework sequences VH1 and VL1. In a further embodiment, the six CDR sequences are inserted into the huCD3 framework sequences VH1 and VL1, wherein the amino acid T at position 41 of VL1 (SEQ ID NO:10) has been mutated to K.
[0371] In a further embodiment, the CD3 binding arm comprises six CDR sequences selected from Table 2, wherein X1 of SEQ ID NO:72 is selected from L, P, Q, D, K, W, S, G, A, C, and R; X2 of SEQ ID NO:73 is selected from S, N, G, A, K, V, R, H, Q, P, I, F, M, Y, L, W, D, E, and C; X3 of SEQ ID NO:74 is selected from M, W, G, Q, V, T, S, L, P, I, A, K, R, and C; X4 of SEQ ID NO:75 is selected from W, L, A, I, M, D, T, K, R, G, F, E, V, C, and P; X5 of SEQ ID NO:76 is selected from C, E, P and T; X6 of SEQ ID NO:77 is selected from A, S, V, N, K, L, T, I, P, Q, C, G, Y, W, F and R; X7 of SEQ ID NO:78 is selected from P, C, S and T; X8 of SEQ ID NO:79 is selected from A, T, G, L, N, C, P, F, Q, H, R, K, E, W and Y; X9 of SEQ ID NO:80 is selected from P, L, T, C, A, I, L, Q, V, E, M, K, R, G and P; X of SEQ ID NO:81 10 Selected from E, H, I, M, N, Y, P, Q, D, K, and L; X of SEQ ID NO:82 11 Selected from F, Y, I, T, V, M, A, S, N, G, W, E, K, P, R, and D; and X of SEQ ID NO:83 12 Selected from G, Y, V, N, T, S, H, E, P, W, F and M.
[0372] Compared to the wild-type huCD3 CDR sequence, such HuCD3 CDR variant sequences have reduced binding affinity. Six CDR sequences can be inserted into any one of the huCD3 VH and VL framework sequences VH1, VH2, VH3, and VH4, and VL1, VL2, and VL3, respectively, replacing the huCD3 CDR sequence. In one embodiment, the six CDR sequences are inserted into the huCD3 framework sequences VH1 and VL1. In a further embodiment, the six CDR sequences are inserted into the huCD3 framework sequences VH1 and VL1, wherein the amino acid T at position 41 of VL1 (SEQ ID NO: 10) has been mutated to K.
[0373] In yet another embodiment, the CD3 binding arm comprises six CDR sequences selected from the CDR sequences described in Table 3 below, wherein... X2 of SEQ ID NO:73 is selected from M and P; X3 of SEQ ID NO:74 is A; X4 of SEQ ID NO:75 is E; X6 of SEQ ID NO:77 is selected from F, G, I, K, L and N; X7 of SEQ ID NO:78 is P; X8 of SEQ ID NO:79 is selected from A and G; and X9 of SEQ ID NO:80 is selected from M, R and V.
[0374] Table 3 Compared to the wild-type huCD3 CDR sequence, such HuCD3 CDR variant sequences have reduced binding affinity. Six CDR sequences can be inserted into any one of the huCD3 VH and VL framework sequences VH1, VH2, VH3, and VH4, and VL1, VL2, and VL3, respectively, replacing the huCD3 CDR sequence. In one embodiment, the six CDR sequences are inserted into the huCD3 framework sequences VH1 and VL1. In a further embodiment, the six CDR sequences are inserted into the huCD3 framework sequences VH1 and VL1, wherein the amino acid T at position 41 of VL1 (SEQ ID NO: 10) has been mutated to K.
[0375] In a further embodiment of the bispecific antibody as defined in any of the embodiments disclosed herein, the first binding arm is derived from a CD3 antibody having a diameter greater than 3.4 x 10⁻⁶. -8 The binding affinity of M for human CD3ε (K) D ), such as that determined by Bio-Layer interferometry, for example 3.5 x 10 -8 M to 9.9x10 -8 M, or 1.0x10 -7 M to 9.9x10 -7 M, as determined by the Bio-Layer interferometry method.
[0376] In a further embodiment of the invention, one or both antibodies forming the bispecific antibody portion have been engineered to reduce or increase binding to the nascent Fc receptor (FcRn) to manipulate the serum half-life of the bispecific antibody. Techniques for increasing or decreasing serum half-life are well known in the art. See, for example, Dall'Acqua et al. 2006, J. Biol. Chem., 281:23514-24; Hinton et al. 2006, J. Immunol., 176:346-56; and Zalevsky et al. 2010 Nat. Biotechnol., 28:157-9.
[0377] In one aspect, the bispecific antibody defined in any of the embodiments disclosed herein comprises a first constant heavy chain (HC) and a first constant light chain (LC), wherein the positions of the first heavy chain and the second heavy chain corresponding to positions L234, L235 and D265 of the human IgG1 heavy chain in SEQ ID NO:15 are F, E and A, respectively.
[0378] In one embodiment, the bispecific antibody as defined in any of the embodiments disclosed herein comprises first and second constant heavy chains (HC) and first and second constant light chains (LC), wherein the positions of the first heavy chain and the second heavy chain corresponding to positions L234 and L235 of the human IgG1 heavy chain in SEQ ID NO:15 are F and E, respectively.
[0379] In one embodiment of the bispecific antibody defined in any of the embodiments disclosed herein, the first binding arm is a Fab arm derived from IgG1-huCD3-H1L1-FEAR, and the second binding arm is a Fab arm derived from IgG1-7D8-FEAL.
[0380] In this document, huCD3-H1L1 refers to a humanized SP34 anti-CD3 antibody having VH1 and VL1 as shown in Table 1 as SEQ ID NO: 6 and 10. FEAL refers to the L234F, L235E, D265A, and F405L mutations in the constant region of the antibody, while FEAR refers to the L234F, L235E, D265A, and K409R mutations in the constant region of the antibody, where the amino acid positions correspond to the amino acid positions of human IgG1. “IgG1” means that the antibody constant region is derived from human IgG1 other than the specified mutation. 7D8 refers to an anti-CD20 antibody having the VH and VL sequences shown in Table 1 as SEQ ID NO: 27 and 28.
[0381] In one embodiment of the bispecific antibody defined in any of the embodiments disclosed herein, the first binding arm is a half-molecule antibody derived from IgG1-huCD3-H1L1-FEAR, and the second binding arm is a half-molecule antibody derived from IgG1-7D8-FEAL.
[0382] In one embodiment of the bispecific antibody defined in any of the embodiments disclosed herein, the first binding arm is a Fab arm derived from IgG1-huCD3-H1L1-FEAL, and the second binding arm is a Fab arm derived from IgG1-7D8-FEAR.
[0383] In one embodiment of the bispecific antibody defined in any of the embodiments disclosed herein, the first binding arm is a half-molecule antibody derived from IgG1-huCD3-H1L1-FEAL (i.e., comprising a heavy chain and a light chain), and the second binding arm is a half-molecule antibody derived from IgG1-7D8-FEAR (Fab arm and Fc arm).
[0384] In one embodiment, the bispecific antibody as defined in any of the embodiments disclosed herein comprises first and second constant heavy chains (HC) and first and second constant light chains (LC), wherein the positions L234, L235 and D265 of the first and second constant heavy chains corresponding to the human IgG1 heavy chain in SEQ ID NO:15 are F, E and A, respectively, and wherein the position F405 of the first constant heavy chain corresponding to the human IgG1 heavy chain in SEQ ID NO:15 is L and the position K409 of the second constant heavy chain corresponding to the human IgG1 heavy chain in SEQ ID NO:15 is R, and wherein (i) the positions F10, T41, K55 and L97 of the first constant light chain corresponding to the λ light chain in SEQ ID NO:10 are L, K, N and H, respectively, or (ii) the position T41 of the first constant light chain corresponding to the λ light chain in SEQ ID NO:10 is K.
[0385] Other implementation schemes for bispecific antibodies The bispecific antibodies of the present invention can have any isotype. The choice of isotype is typically guided by the desired effector function, such as ADCC induction. Exemplary isotypes are IgG1, IgG2, IgG3, and IgG4. Either the human light chain constant region κ or λ can be used. For various therapeutic uses, the effector function of the antibodies of the present invention can be altered by isotype exchange with, for example, IgG1, IgG2, IgG3, IgG4, IgD, IgA, IgE, or IgM antibodies. In one embodiment, the two Fc-regions of the antibody of the present invention have the IgG1 isotype, such as IgG1,κ. In one embodiment, the two Fc-regions of the bispecific antibody have the IgG1 and IgG4 isotypes, respectively. Optionally, the Fc-regions may be modified in the hinge region and / or CH3 region, as described elsewhere herein.
[0386] In one embodiment, the bispecific antibody of the present invention is a full-length antibody, preferably an IgG1 antibody, particularly an IgG1,κ antibody or a variant thereof. In another embodiment, the bispecific antibody of the present invention comprises an antibody fragment or a single-chain antibody. The antibody fragment can be obtained, for example, by fragmentation using conventional techniques, and the utility of the fragment can be screened in the same manner as described herein for the whole antibody. For example, the F(ab')2 fragment can be produced by treating the antibody with pepsin. The resulting F(ab')2 fragment can be treated with a reducing agent, such as dithiothreitol, to reduce the disulfide bridge to produce the Fab' fragment. The Fab fragment can be obtained by treating the antibody with papain. The F(ab')2 fragment can also be produced by binding the Fab' fragment via a thioether bond or a disulfide bond. The antibody fragment can also be produced by expression of a nucleic acid encoding such a fragment in recombinant cells (see, for example, Evanset al). . , J. Immunol. Meth. 184 , 123-38 (1995)). For example, a chimeric gene encoding a portion of the F(ab')2 segment may include a C gene encoding the H chain. H The DNA sequence of the 1st domain and hinge region is then translated to the stop codon to obtain such a truncated antibody fragment molecule.
[0387] The bispecific CD3xCD20 antibody of the present invention can also be prepared from a single-chain antibody. A single-chain antibody is a peptide in which the heavy chain and light chain Fv regions are linked. In one embodiment, the bispecific antibody of the present invention comprises a single-chain Fv (scFv), wherein the heavy chain and light chain of the Fv of the CD20 antibody of the present invention are linked in a single peptide chain by a flexible peptide linker (typically having about 10, 12, 15 or more amino acid residues). Methods for producing such antibodies are described, for example, in US 4,946,778, Pluckthunin 'The Pharmacology of Monoclonal Antibodies', vol. 113, Rosenburg and Mooreeds. Springer-Verlag, New York, pp. 269-315 (1994), Bird et al. . Science 242 ,423-426 (1988), Huston et al . PNAS USA 85 , 5879-5883 (1988) and McCafferty et al. . Nature 348 , 552-554 (1990). Bispecific antibodies can then be derived from two V antibodies derived from single-chain CD20 and single-chain CD3 antibodies. H and V L Formation, or multivalent antibodies, from two or more V H and V L Chain formation.
[0388] In one embodiment, one or both Fc regions of the CD3 and CD20 monoclonal antibodies used to generate the specific antibodies of the present invention are effector functionally defective.
[0389] Conjugate In a further aspect, the present invention provides bispecific CD3xCD20 antibodies linked to or conjugated to one or more therapeutic components, such as cytokines, immunosuppressants, immunostimulatory molecules, and / or radioisotopes. Such conjugates are referred to herein as “immunoconjugates” or “pharmaceutical conjugates.” Immunoconjugates comprising one or more cytotoxins are referred to as “immunotoxins.”
[0390] In one embodiment, the first and / or second Fc-regions are conjugated to a drug or prodrug, or contain a receptor group for said drug or prodrug. Such a receptor group may, for example, be a non-natural amino acid.
[0391] Composition In a further aspect, the present invention relates to compositions comprising a bispecific antibody according to any embodiment disclosed herein.
[0392] In a further aspect, the present invention relates to a pharmaceutical composition comprising: - Bispecific CD3xCD20 antibodies as defined in any of the embodiments disclosed herein; and - A pharmaceutically acceptable carrier.
[0393] The pharmaceutical compositions of the present invention may comprise one bispecific antibody of the present invention or a combination of different bispecific antibodies of the present invention.
[0394] The pharmaceutical compositions can be formulated using conventional techniques, such as those disclosed in Remington: The Science and Practice of Pharmacy, 19th Edition, Gennaro, Ed., Mack Publishing Co., Easton, PA, 1995. The pharmaceutical compositions of the present invention may, for example, include diluents, fillers, salts, buffers, detergents (e.g., nonionic detergents, such as Tween-20 or Tween-80), stabilizers (e.g., sugars or protein-free amino acids), preservatives, tissue fixatives, solubilizers, and / or other materials suitable for inclusion in the pharmaceutical composition.
[0395] Pharmaceutically acceptable carriers include any and all suitable solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic agents, antioxidants, and absorption delay agents, which are physiologically compatible with the bispecific antibodies of the present invention. Examples of suitable aqueous and non-aqueous carriers that can be used in the pharmaceutical compositions of the present invention include water, saline, phosphate-buffered saline, ethanol, glucose, polyols (e.g., glycerol, propylene glycol, polyethylene glycol, etc.) and suitable mixtures thereof, vegetable oils, carboxymethyl cellulose colloidal solutions, tragacanth gum, and injectable organic esters, such as ethyl oleate, and / or various buffers. Pharmaceutically acceptable carriers include sterile aqueous solutions or dispersions, and sterile powders for the ad hoc preparation of sterile injectable solutions or dispersions. Suitable flowability can be maintained, for example, by using coating materials, such as lecithin, in the case of dispersions, by maintaining the desired particle size and by using surfactants.
[0396] The pharmaceutical bispecific antibody of the present invention may also contain pharmaceutically acceptable antioxidants, such as (1) water-soluble antioxidants, such as ascorbic acid, cysteine hydrochloride, sodium bisulfate, sodium metabisulfite, sodium sulfite, etc.; (2) oil-soluble antioxidants, such as ascorbate palmitate, butylated hydroxyanisole, butylated hydroxytoluene, lecithin, propyl gallate, α-tocopherol, etc.; and (3) metal chelating agents, such as citric acid, ethylenediaminetetraacetic acid (EDTA), sorbitol, tartaric acid, phosphoric acid, etc.
[0397] The pharmaceutical bispecific antibody of the present invention may also contain an isotonic agent in the composition, such as sugar, polyol such as mannitol, sorbitol, glycerol or sodium chloride.
[0398] The pharmaceutical bispecific antibodies of the present invention may also contain one or more excipients suitable for the selected route of administration, such as preservatives, humectants, emulsifiers, dispersants, or buffers, which may improve the shelf life or efficacy of the pharmaceutical composition. The bispecific antibodies of the present invention can be prepared using carriers that protect the bispecific antibodies from rapid release, such as controlled-release formulations, including implants, transdermal patches, and microencapsulation delivery systems. Such carriers may include gelatin, glyceryl monostearate, glyceryl distearate, biodegradable and biocompatible polymers such as ethylene vinyl acetate, polyanhydride, polyglycolic acid, collagen, polyorthoesters, and polylactic acid, alone or with waxes, or other materials well known in the art. Methods for preparing such formulations are generally known to those skilled in the art.
[0399] Sterile injectable solutions can be prepared by incorporating the required amount of active compound into a suitable solvent, containing, as needed, one or a combination of components listed above, followed by sterile microfiltration. Typically, dispersions are prepared by incorporating the active compound into a sterile solvent containing a base dispersion medium and other desired components (e.g., selected from those listed above). Examples of preparation methods for sterile powders used to prepare sterile injectable solutions include vacuum drying and freeze-drying (lyophilization), which yield a powder containing the active ingredient plus any other desired components from a previously sterile filtered solution.
[0400] The actual dose level of the active ingredient in a pharmaceutical composition can be varied to obtain an amount of active ingredient sufficient to achieve the therapeutic response required for a particular patient, composition, and route of administration, without toxicity to the patient. The selected dose level depends on various pharmacokinetic factors, including the activity of the specific component or its amide used in this invention, the route of administration, the frequency of administration, the excretion rate of the specific compound used, the duration of treatment, other drugs, compounds, and / or substances used in combination with the specific composition used, the patient's age, sex, weight, condition, general health, and previous medical history, and similar factors well known in the medical field.
[0401] The pharmaceutical composition may be administered via any suitable route and manner. In one embodiment, the pharmaceutical composition of the present invention is administered parenterally. As used herein, "parenterally" means a route of administration that is not enteric or local, typically by injection, and including injection and infusion via the epidermis, intravenous, intramuscular, intraarterial, intrasheath, intracapsular, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, intratendonal, tracheal, subcutaneous, subepidermal, intra-articular, subcapsular, subarachnoid, intravertebral, intracranial, intrathoracic, epidural, and intrasternal routes.
[0402] In one embodiment, the pharmaceutical composition is administered via intravenous or subcutaneous injection or infusion.
[0403] use In one aspect, the present invention relates to bispecific antibodies, compositions disclosed herein, or pharmaceutical compositions disclosed herein, according to any embodiment disclosed herein, for use as pharmaceuticals.
[0404] In one aspect, the present invention relates to bispecific antibodies, compositions, or pharmaceutical compositions disclosed herein according to any embodiment disclosed herein for the treatment of a disease.
[0405] In one aspect, the present invention relates to a method of treating a disease, comprising administering a bispecific antibody, a composition disclosed herein, or a pharmaceutical composition disclosed herein according to any embodiment disclosed herein to a subject in need.
[0406] In one implementation, the disease is a mature B-cell malignancy.
[0407] In one implementation, the disease is cancer, such as NHL or B-cell leukemia.
[0408] The bispecific antibodies of this invention can be used for a variety of purposes. In particular, the bispecific antibodies of this invention can be used to treat various forms of cancer, including metastatic and refractory cancers.
[0409] In particular, the bispecific antibodies of the present invention can be used in therapeutic contexts where specific targeting of CD20-expressing cells and T-cell-mediated killing are required, and may be more effective than conventional CD20 antibodies in certain such indications and contexts.
[0410] The bispecific antibodies of this invention also have additional uses in the treatment and diagnosis of various CD20-related diseases. For example, the bispecific antibodies can be used to induce one or more of the following biological activities in vivo or in vitro: inhibiting the growth and / or differentiation of CD20-expressing cells; killing CD20-expressing cells; mediating phagocytosis or ADCC of CD20-expressing cells in the presence of human effector cells; mediating CDC of CD20-expressing cells in the presence of complement; mediating apoptosis of CD20-expressing cells; and / or inducing translocation to lipid rafts upon binding to CD20.
[0411] In another embodiment, the bispecific antibody of the present invention can be used to achieve T cell-mediated immune responses, inflammation, and microenvironment remodeling.
[0412] In specific implementations, the bispecific antibody is used in vivo to treat, prevent, or diagnose various CD20-related diseases. Examples of CD20-related diseases include, in particular, B-cell lymphomas, such as non-Hodgkin's lymphoma (NHL), B-cell leukemia, and immune diseases, such as autoimmune diseases, as listed below.
[0413] In one embodiment, the bispecific antibody of the present invention is used to treat NHL or B-cell leukemia.
[0414] In one embodiment, the bispecific antibody of the present invention is used to treat CD20 antibody-resistant NHL or B-cell leukemia, such as rituximab- or ofamumumab-resistant NHL or B-cell leukemia, such as rituximab-resistant non-aggressive B-cell lymphoma.
[0415] In one embodiment, the bispecific antibody of the present invention is used to treat acute lymphoblastic leukemia (ALL), such as relapsed or refractory ALL.
[0416] In one embodiment, the bispecific antibody of the present invention is used to treat CLL, such as relapsed or refractory CLL.
[0417] In one embodiment, the bispecific antibody of the present invention is used to treat FL, such as relapsed or refractory FL.
[0418] In one embodiment, the bispecific antibody of the present invention is used to treat adult grade III lymphomatoid granulomatosis; adult nasal extranodular NK / T-cell lymphoma; anaplastic large cell lymphoma; angioimmunoblastic T-cell lymphoma; sequential stage II adult Burkitt lymphoma; sequential stage II adult diffuse large cell lymphoma; sequential stage II adult diffuse mixed cell lymphoma; sequential stage II adult diffuse small lytic cell lymphoma; sequential stage II adult immunoblastic large cell lymphoma; sequential stage II adult lymphocytic lymphoma; sequential stage II grade I follicular lymphoma; sequential stage II grade 2 follicular lymphoma; sequential stage II grade 3 follicular lymphoma; sequential stage II Mantle cell lymphoma; Continuous stage II marginal zone lymphoma; Continuous stage II small lymphocytic lymphoma; Cutaneous B-cell non-Hodgkin lymphoma; Epstein-Barr virus infection; Mucosa-associated lymphoid tissue extranodal marginal zone B-cell lymphoma; Hepatocellular T-cell lymphoma; Intraocular lymphoma; Nodular marginal zone B-cell lymphoma; Discontinuous stage II adult Burkitt lymphoma; Discontinuous stage II adult diffuse large cell lymphoma; Discontinuous stage II adult diffuse mixed cell lymphoma; Discontinuous stage II adult diffuse small lytic cell lymphoma; Discontinuous stage II adult immunoblastic large cell lymphoma; Discontinuous stage II adult lymphocytic lymphoma; Discontinuous stage II grade 1. Follicular lymphoma; Discontinuous stage II 2. Follicular lymphoma; Discontinuous stage II 3. Follicular lymphoma; Discontinuous stage II mantle cell lymphoma; Discontinuous stage II marginal zone lymphoma; Discontinuous stage II small lymphocytic lymphoma; Non-cutaneous extranodular lymphoma; Peripheral T-cell lymphoma; Post-transplant lymphoproliferative disorder; Progressive hairy cell leukemia, initial treatment; Recurrent adult Burkitt lymphoma; Recurrent adult diffuse mixed cell lymphoma; Recurrent adult diffuse small lytic cell lymphoma; Recurrent adult stage III lymphomatoid granulomatosis; Recurrent adult Hodgkin lymphoma; Recurrent adult immunoblastic large cell lymphoma; Recurrent adult lymphocytic lymphoma; Recurrent adult T-cell leukemia / lymphoma; recurrent cutaneous T-cell non-Hodgkin lymphoma; recurrent grade 1 follicular lymphoma; recurrent grade 2 follicular lymphoma; recurrent grade 3 follicular lymphoma; recurrent mantle cell lymphoma; recurrent marginal zone lymphoma; recurrent mycosis fungoides / Cezari syndrome; recurrent small lymphocytic lymphoma; refractory hairy cell leukemia; small intestinal lymphoma; splenic marginal zone lymphoma; stage I adult Burkitt lymphoma; stage I adult diffuse large cell lymphoma; stage I adult diffuse mixed cell lymphoma; stage I adult diffuse small lytic cell lymphoma; stage I adult Hodgkin lymphoma; stage I adult immunoblastic large cell lymphoma; stage I adult lymphocytic lymphoma;Stage I Adult T-cell leukemia / lymphoma; Stage I Cutaneous T-cell non-Hodgkin lymphoma; Stage I Grade 1 Follicular lymphoma; Stage I Grade 2 Follicular lymphoma; Stage I Grade 3 Follicular lymphoma; Stage I Mantle cell lymphoma; Stage I Marginal zone lymphoma; Stage I Small lymphocytic lymphoma; Stage IA Mycosis fungoides / Cezari syndrome; Stage IB Mycosis fungoides / Cezari syndrome; Stage II Adult Hodgkin lymphoma; Stage II Adult T-cell leukemia / lymphoma; Stage II Cutaneous T-cell non-Hodgkin lymphoma; Stage IIA Mycosis fungoides / Cezari syndrome Cezari syndrome; Stage IIB mycosis fungoides / Cezari syndrome; Stage III adult Burkitt lymphoma; Stage III adult diffuse large cell lymphoma; Stage III adult diffuse mixed cell lymphoma; Stage III adult diffuse small lytic cell lymphoma; Stage III adult Hodgkin lymphoma; Stage III adult immunoblastic large cell lymphoma; Stage III adult lymphoblastic lymphoma; Stage III adult T-cell leukemia / lymphoma; Stage III cutaneous T-cell non-Hodgkin lymphoma; Stage III grade 1 follicular lymphoma; Stage III grade 2 Follicular lymphoma; Stage III grade 3 follicular lymphoma; Stage III mantle cell lymphoma; Stage III marginal zone lymphoma; Stage III small lymphocytic lymphoma; Stage IIIA mycosis fungoides / Cezari syndrome; Stage IIIB mycosis fungoides / Cezari syndrome; Stage IV adult Burkitt lymphoma; Stage IV adult diffuse large cell lymphoma; Stage IV adult diffuse mixed cell lymphoma; Stage IV adult diffuse small lytic cell lymphoma; Stage IV adult Hodgkin lymphoma; Stage IV adult immunoblastic large cell lymphoma; Stage IV adult lymphoblastic lymphoma. Stage IV T-cell lymphoma; Stage IV adult T-cell leukemia / lymphoma; Stage IV cutaneous T-cell non-Hodgkin lymphoma; Stage IV Grade 1 follicular lymphoma; Stage IV Grade 2 follicular lymphoma; Stage IV Grade 3 follicular lymphoma; Stage IV mantle cell lymphoma; Stage IV marginal zone lymphoma; Stage IV small lymphocytic lymphoma; Stage IVA mycosis fungoides / Cezari syndrome; Stage IVB mycosis fungoides / Cezari syndrome; T-cell large granular lymphocytic leukemia; testicular lymphoma; untreated hairy cell leukemia; or Waldenström macroglobulinemia.
[0419] In a specific implementation, the antibody of the present invention is used to treat or prevent NHL because the antibody depletes tumor cells carrying CD20.
[0420] NHL is a type of B-cell lymphoma. Lymphomas, such as B-cell lymphomas, are a group of related cancers that arise when lymphocytes (blood cells) become malignant. The normal function of lymphocytes is to defend the body against invading substances: bacteria, viruses, fungi, and even cancer. Lymphocytes exist in many subtypes and stages of maturation, and therefore there are many types of lymphomas. Like normal cells, malignant lymphocytes can migrate to many parts of the body. Normally, lymphoma cells form tumors in the lymphatic system: bone marrow, lymph nodes, spleen, and blood. However, these cells can migrate to other organs. Some types of lymphomas tend to grow in locations where the normally formed cells reside. For example, follicular NHL tumors often occur in lymph nodes.
[0421] CD20 is typically expressed at elevated levels on tumor (i.e., tumorigenic) B cells associated with NHL. Therefore, the CD20-binding antibody of the present invention can be used to deplete CD20-carrying tumor cells (which lead to NHL), and thus can be used for the prevention or treatment of the disease.
[0422] The bispecific antibody of this invention can also be used to block or inhibit other functions of CD20. For example, CD20 is known to be expressed on B lymphocytes and involved in the proliferation and / or differentiation of these cells. Because B lymphocytes function as immunomodulators, CD20 is an important target for antibody-mediated therapies targeting B lymphocytes, for example, to inactivate or kill B lymphocytes involved in autoimmune diseases. Such autoimmune diseases include, for example, the diseases listed above.
[0423] Similarly, the present invention relates to a method for killing tumor cells expressing CD20, comprising administering an effective amount of the bispecific antibody of the present invention to an individual in need.
[0424] The present invention also relates to a method for inhibiting the growth and / or proliferation of one or more CD20-expressing tumor cells, including administering the bispecific antibody of the present invention to an individual in need.
[0425] The present invention also relates to a method for treating cancer, including a) Select subjects with cancer, which includes tumor cells expressing CD20; and b) Administer the subject the bispecific antibody of the present invention or the pharmaceutical composition of the present invention.
[0426] Furthermore, the present invention relates to the use of a bispecific antibody combining human CD3 and human CD20 for the preparation of a medicament for treating cancer (e.g., one of the specific cancer indications mentioned above).
[0427] This invention also relates to bispecific antibodies for the treatment of cancer, such as one of the cancer indications mentioned above.
[0428] In one embodiment, the bispecific antibody is used to treat mature B-cell malignancies. In one embodiment, the bispecific antibody is used to treat CD20-expressing tumors. In one embodiment, the bispecific antibody is used to treat B-cell lymphoma. In one embodiment, the bispecific antibody is used to treat B-cell lymphoma, such as NHL. In one embodiment, the bispecific antibody is used to treat precursor B-cell lymphoblastic leukemia. In one embodiment, the bispecific antibody is used to treat B-cell chronic lymphocytic leukemia (CLL).
[0429] In one implementation scheme, the bispecific antibody is used to treat small lymphocytic lymphoma (SLL).
[0430] In one implementation scheme, the bispecific antibody is used to treat B-cell prelymphocytic leukemia.
[0431] In one implementation, a bispecific antibody is used to treat lymphoplasmacytic lymphoma.
[0432] In one implementation scheme, the bispecific antibody is used to treat mantle cell lymphoma (MCL).
[0433] In one implementation, the bispecific antibody is used to treat follicular lymphoma (FL), including low-grade, intermediate-grade, and high-grade FL.
[0434] In one implementation scheme, a bispecific antibody is used to treat B-cell Hodgkin lymphoma.
[0435] In one implementation, a bispecific antibody is used to treat an immune disorder, involving B cells that express CD20.
[0436] In one implementation scheme, bispecific antibodies are used to treat psoriasis.
[0437] In one implementation, bispecific antibodies are used to treat sclerosis.
[0438] In one implementation scheme, bispecific antibodies are used to treat inflammatory bowel disease.
[0439] For the above-mentioned uses, the antibody is preferably bsIgG1-huCD3-H1L1-FEALxCD20-7D8-FEAR, however it can be any bispecific CD3xCD20 antibody disclosed herein.
[0440] The bispecific antibody of the present invention has numerous in vitro and in vivo diagnostic and therapeutic applications, relating to the diagnosis and treatment of conditions involving cells expressing CD20. For example, the antibody can be administered to cultured cells, e.g., in vitro or ex vivo, or to human subjects, e.g., in vivo, to treat, prevent, and diagnose various conditions. As used herein, the term "subject" is intended to include human and non-human animals that respond to the bispecific antibody against CD3 and CD20. Preferred subjects include human patients with conditions that can be corrected or improved by inhibiting or controlling B cells (normal or malignant).
[0441] In one aspect, the present invention relates to diagnostic compositions comprising a bispecific antibody according to any embodiment disclosed herein.
[0442] In one embodiment, the diagnostic composition is a companion diagnostic used to screen and select patients who will benefit from treatment with bispecific antibodies.
[0443] In one embodiment, the bispecific antibody of the present invention can be used to treat a subject with a tumorigenic condition, for example, a condition characterized by the presence of tumor cells expressing CD20, including, for example, B-cell lymphoma, such as NHL. Examples of treatable and / or preventable oncogenic diseases include B-cell lymphomas, such as NHL, including precursor B-cell lymphoblastic leukemia / lymphoma and mature B-cell tumors such as B-cell chronic lymphocytic leukemia (CLL) / small lymphocytic lymphoma (SLL), B-cell prolymphocytic leukemia, lymphoplasmacytic lymphoma, mantle cell lymphoma (MCL), follicular lymphoma (FL) including low-grade, intermediate-grade and high-grade FL, cutaneous follicular center lymphoma, marginal zone B-cell lymphoma (MALT type, nodular and splenic type), hairy cell leukemia, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma, plasmacytoma, plasmacytic myeloma, post-transplant lymphoproliferative disorders, Waldenström's macroglobulinemia, malignant melanoma, and anaplastic large cell lymphoma (ALCL).
[0444] Other examples of B-cell non-Hodgkin's lymphoma include lymphomatoid granulomatosis, primary exudative lymphoma, intravascular large B-cell lymphoma, mediastinal large B-cell lymphoma, heavy chain diseases (including γ, μ, and α diseases), and lymphomas induced by immunosuppressant therapy, such as cyclosporine-induced lymphoma and methotrexate-induced lymphoma.
[0445] In a further embodiment, the bispecific antibody of the present invention can be used to treat B-cell Hodgkin lymphoma.
[0446] Examples of treatable and / or preventable immune disorders involving CD20-expressing B cells include autoimmune diseases such as psoriasis, psoriatic arthritis, dermatitis, systemic scleroderma and sclerosis, inflammatory bowel disease (IBD), Crohn's disease, ulcerative colitis, acute respiratory distress syndrome, meningitis, encephalitis (including chronic fatigue syndrome / myalgic encephalitis (CFS / ME) and chronic fatigue syndrome / myalgic encephalitis (CFS / ME)), uveitis, glomerulonephritis, eczema, asthma, atherosclerosis, leukocyte adhesion defects, multiple sclerosis, Raynaud's syndrome, Sjögren's syndrome, juvenile diabetes mellitus, Wright's disease, Bechtel's disease, immune complex nephritis, IgA nephropathy, IgM polyneuropathy, and other immune disorders. Epidemiologically mediated thrombocytopenic purpura (ITP) includes acute and chronic ITP, hemolytic anemia, myasthenia gravis, lupus nephritis, systemic lupus erythematosus, rheumatoid arthritis (RA), atopic dermatitis, pemphigus, Graves' disease, Hashimoto's thyroiditis, Wegener's granulomatosis, Omenn's syndrome, chronic renal failure, acute infectious mononucleosis, HIV, and herpes virus-related diseases. Other examples include severe acute respiratory distress syndrome (ARDS) and choroidoretinitis. Furthermore, other diseases and conditions include those caused or mediated by viruses such as Epstein-Barr virus (EBV) infection of B cells.
[0447] Other examples of inflammatory, immune, and / or autoimmune disorders in which autoantibodies and / or excessive B lymphocyte activity are predominant and can be treated and / or prevented include the following: Vasculitis and other vascular diseases Examples include microscopic polyangiitis, Churg-Strauss syndrome and other ANCA-related vasculitis, polyarteritis nodosa, idiopathic cryoglobulinemia vasculitis, cutaneous leukocytic vasculitis, Kawasaki disease, Takayasu arteritis, giant cell arthritis, allergic purpura, primary or solitary cerebral vasculitis, erythema nodosum, thromboangiitis obliterans, thrombotic thrombocytopenic purpura (including hemolytic uremic syndrome), and secondary vasculitis, including cutaneous leukocytic vasculitis (e.g. secondary to hepatitis B, hepatitis C, Waldenström's macroglobulinemia, B-cell tumor formation, rheumatoid arthritis, Sjögren's syndrome, or systemic lupus erythematosus); other examples are erythema nodosum, allergic vasculitis, panniculitis, Weber-Claystein disease, purpuric hyperglobulinemia, and Bougé's disease. Skin conditionsExamples include contact dermatitis, linear IgA dermatitis, vitiligo, pyoderma gangrenosa, acquired epidermolysis bullosa, pemphigus vulgaris (including cicatricial pemphigoid and bullous pemphigoid), alopecia areata (including generalized alopecia and total alopecia), herpetiform dermatitis, erythema multiforme, and chronic autoimmune urticaria (including angioedema and urticarial vasculitis). Immune-mediated cytopenia For example, autoimmune neutropenia and pure red cell aplasia; Connective tissue diseases Examples include CNS lupus, discoid lupus erythematosus, CREST syndrome, mixed connective tissue disease, polymyositis / dermatomyositis, inclusion body myositis, secondary amyloidosis, type I and type II cryoglobulinemia, fibromyalgia, phospholipid antibody syndrome, secondary hemophilia, relapsing polychondritis, sarcoidosis, stiff neck syndrome, and rheumatic fever; other examples include eosinophilic fasciitis, myositis, and juvenile dermatomyositis. joint disease, Examples include ankylosing spondylitis, juvenile chronic arthritis, adult Still's disease, and SAPHO syndrome; other examples include sacroileitis, reactive arthritis, Still's disease, and gout. Hematological disorders Examples include aplastic anemia, primary hemolytic anemia (including cold agglutinin syndrome), hemolytic anemia secondary to CLL or systemic lupus erythematosus; POEMS syndrome, pernicious anemia, and Waldenström's purpura hyperglobulinaemica; other examples include agranulocytosis, autoimmune neutropenia, Franklin's disease, Seligman's disease, μ-chain disease, paraneoplastic syndromes secondary to thymoma and lymphoma, and factor VIII inhibitor formation; endocrinopathy, Examples include multiple endocrine disorders and Addison's disease; other examples include autoimmune hypoglycemia, autoimmune hypothyroidism, autoimmune insulin syndrome, DeQuiver's thyroiditis, and insulin receptor antibody-mediated insulin resistance. Liver-gastrointestinal diseases Examples include celiac disease, Whipple's disease, primary biliary cirrhosis, chronic active hepatitis, and primary sclerosing cholangitis; another example is autoimmune gastritis. Kidney disease Examples include rapidly progressive glomerulonephritis, post-streptococcal nephritis, Goodpasser syndrome, membranous glomerulonephritis, and cryoglobulinemia nephritis; another example is minimal change disease. Neurological disordersExamples include autoimmune neuropathy, polyneuritis, Lambert-Eton's myasthenia gravis, Sidney's chorea, tabes dorsalis, and Guillain-Barré syndrome; other examples include myelopathy / tropical spastic paralysis, myasthenia gravis, acute inflammatory demyelinating polyneuropathy, and chronic inflammatory demyelinating polyneuropathy. Heart and lung diseases Examples include fibrotic alveolitis, obliterative bronchiolitis, allergic aspergillosis, cystic fibrosis, Ibuprofen syndrome, myocarditis, and pericarditis; other examples include allergic pneumonia and paraneoplastic syndromes secondary to lung cancer. Allergic conditions Examples include bronchial asthma and hyperIgE syndrome; another example is transient amaurosis. Eye diseases, For example, idiopathic chorioretinitis; infectious disease, For example, parvovirus B infection (including hand-and-stocking syndrome); and Gynecological and obstetric conditions Examples include recurrent miscarriage, recurrent pregnancy loss, and intrauterine growth retardation; another example is paraneoplastic syndrome secondary to gynecological tumors. Male reproductive disorders For example, paraneoplastic syndromes secondary to testicular tumors; and Transplant-related diseases Examples include allogeneic and xenograft rejection, as well as graft-versus-host disease (including chronic graft-versus-host disease).
[0448] In one implementation, the disease is an inflammatory, immune, and / or autoimmune condition selected from ulcerative colitis, Crohn's disease, juvenile diabetes, multiple sclerosis, immune-mediated thrombocytopenic purpura such as acute idiopathic thrombocytopenic purpura and chronic idiopathic thrombocytopenic purpura, hemolytic anemia (including autoimmune hemolytic anemia), myasthenia gravis, systemic sclerosis, and pemphigus vulgaris.
[0449] In a further embodiment of the treatment method of the present invention, the efficacy of the treatment is monitored during treatment, for example, at predetermined time points, by measuring the tumor burden or CD20 expression level on the relevant tumor cells.
[0450] The dosage regimens for the above-described treatment methods and uses are adjusted to provide the optimal response (e.g., therapeutic response). For example, a single bolus injection may be given, several fractions may be given over time, or the dose may be proportionally reduced or increased depending on the urgency of the treatment situation. Parenteral compositions may be formulated in unit dosage forms for ease of administration and uniform dosing.
[0451] The effective dose and dosing regimen of the bispecific antibody depend on the disease or condition to be treated and can be determined by those skilled in the art. An exemplary, non-limiting range of therapeutically effective amounts of the compounds of the present invention is about 0.001-10 mg / kg, for example about 0.001-5 mg / kg, for example about 0.001-2 mg / kg, for example about 0.001-1 mg / kg, for example about 0.001, about 0.01, about 0.1, about 1, or about 10 mg / kg. Another exemplary, non-limiting range of therapeutically effective amounts of the bispecific antibody of the present invention is about 0.1-100 mg / kg, for example about 0.1-50 mg / kg, for example about 0.1-20 mg / kg, for example about 0.1-10 mg / kg, for example about 0.5, about, for example 0.3, about 1, about 3, about 5, or about 8 mg / kg.
[0452] Physicians or veterinarians with ordinary skills in the art can readily determine and prescribe the effective amount of the desired pharmaceutical composition. For example, a physician or veterinarian may start with a dose of the bispecific antibody used in the pharmaceutical composition at a level below what is required to achieve the desired therapeutic effect, and gradually increase the dose until the desired effect is achieved. Typically, a suitable daily dose of the bispecific antibody of the present invention is the amount of the lowest dose of the compound that effectively produces a therapeutic effect. Administration may be, for example, parenteral, such as intravenous, intramuscular, or subcutaneous. In one embodiment, the bispecific antibody may be administered via mg / m². 2 The calculated weekly dose is administered by infusion. Such a dose may be based, for example, on the mg / kg dose provided above, according to the following formula: dose (mg / kg) x 70: 1.8. Such administration may be repeated, for example, 1-8 times, or, for example, 3-5 times. Administration may be carried out by continuous infusion over a period of 2-24 hours, for example, 2-12 hours. In one embodiment, the bispecific antibody may be administered by slow, continuous infusion over a period of time, for example, longer than 24 hours, to reduce toxic side effects.
[0453] In one implementation, when administered once weekly, the bispecific antibody can be administered at a fixed weekly dose, up to eight times, for example, four to six times. Such a regimen can be repeated once or more as needed, for example, after six or twelve months. Such a fixed dose can be, for example, based on the mg / kg dose provided above, where the body weight is estimated to be 70 kg. The dose can be determined or adjusted after administration by, for example, obtaining a biological sample and using an anti-individual genotype antibody targeting the CD20 antigen-binding region of the bispecific antibody of the present invention, by measuring the amount of the bispecific antibody of the present invention in the blood.
[0454] In one implementation, the bispecific antibody may be given as maintenance therapy, for example, once a week for 6 months or longer.
[0455] Bispecific antibodies can also be administered prophylactically to reduce the risk of developing cancer, delay the occurrence of cancer progression events, and / or reduce the risk of recurrence when cancer is in remission.
[0456] The bispecific antibody of the present invention can also be administered in combination therapy, i.e., in combination with other therapeutic agents related to the disease or condition being treated. Therefore, in one embodiment, a drug comprising a bispecific antibody is combined with one or more other therapeutic agents, such as cytotoxic agents, chemotherapeutic agents, or anti-angiogenic agents.
[0457] Such combined administration can be simultaneous, separate, or sequential. For simultaneous administration, the agents can be administered as a single composition or as separate compositions, where appropriate. The present invention therefore also provides a method for treating conditions involving CD20-expressing cells as described above, the method comprising administering a combination of the bispecific antibody of the present invention with one or more additional therapeutic agents as described below.
[0458] In one embodiment, the present invention provides a method for treating a condition involving CD20-expressing cells in a subject, the method comprising administering a therapeutically effective amount of the bispecific antibody of the present invention and optionally at least one additional therapeutic agent, or an antibody that binds to a CD20 epitope different from the antibody, to a subject in need.
[0459] In one embodiment, the present invention provides a method for treating or preventing cancer, the method comprising administering a therapeutically effective amount of the bispecific antibody of the present invention and at least one additional therapeutic agent to a subject in need.
[0460] In one implementation, such additional therapeutic agents may be selected from tyrosine kinase inhibitors (TKIs), such as imatinib (Glivec, Gleevec STI571), ibrutinib (PCI-32765, Imbruvica), or lapatinib (PTK787 / ZK222584).
[0461] In one implementation, such an additional therapeutic agent may be selected from Bruton's tyrosine kinase (BTK) inhibitors, such as ibrutinib.
[0462] In one implementation, such an additional therapeutic agent may be selected from proteasome inhibitors (PIs), such as carfilzomib.
[0463] In one implementation, such additional therapeutic agents may be selected from immunomodulatory agents (IMIDs), such as pomalidomide, thalidomide, or lenalidomide.
[0464] In one implementation, such additional therapeutic agents may be selected from phosphoinositol 3-kinase inhibitors, such as idelalisib or duvelisib.
[0465] In one implementation, such an additional therapeutic agent may be an aurora A kinase inhibitor, such as alisertib.
[0466] In one implementation, such additional therapeutic agents may be selected from B-cell lymphoma-2 (Bcl-2) inhibitors, such as venetoclax.
[0467] In one implementation, such an additional therapeutic agent may be selected from histone deacylase (HDAC) inhibitors, such as panobinostat.
[0468] The pharmaceutical compositions of the present invention can also be administered in combination therapy, i.e., in combination with other pharmaceutical agents. In one embodiment, such a therapeutic agent comprises one or more chemotherapeutic agents selected from the following categories: alkylating agents, antimetabolites, mitotic inhibitors, antitumor antibiotics, topoisomerase inhibitors, or platinum analogs. Examples of such chemotherapeutic agents are doxorubicin, cisplatin, bleomycin, carmustine, cyclophosphamide (Cytoxan, Procytox, Neosar), bendamustine, and chlorambucil.
[0469] In another embodiment, the bispecific antibody of the present invention may be administered in combination with: chlorambucil; CHOP (cyclophosphamide, daunorubicin, vincristine, prednisone, or prednisolone); cyclophosphamide and prednisolone; cyclophosphamide, vincristine, and prednisone; cyclophosphamide, vincristine, doxorubicin, and prednisone; fludarabine and an alkylating agent; dose-adjusted EPOCH (etoposide, prednisolone, vincristine, cyclophosphamide, and doxorubicin); GemOx (gemcitabine and oxaliplatin); GDP (gemcitabine, dexamethasone, and cisplatin) or in combination with other common multidrug regimens for NHL, such as those disclosed in Non-Hodgkin's Lymphomas: Making sense of Diagnosis, Treatment, and Options, Lorraine Johnston, 1999, O'Reilly and Associates, Inc.
[0470] In one implementation, such additional therapeutic agents may be selected from antimetabolites, such as methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, fludarabine, 5-fluorouracil, aminopyrimidine, hydroxyurea, asparaginase, gemcitabine, or cladribine. In another embodiment, such additional therapeutic agents may be selected from alkylating agents, such as nitrogen mustard, thiotepa, chlorambucil, melphalan, carmustine (BSNU), lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozomycin, dacarbazine (DTIC), procarbazine, mitomycin C, cisplatin, and other platinum derivatives, such as carboplatin.
[0471] In another embodiment, such additional therapeutic agents may be selected from antimitotic agents, such as taxanes, such as docetaxel and paclitaxel, and vinblastines, such as vincristine, vinblastine, vinorelbine, and vinorelbine.
[0472] In another implementation, such additional therapeutic agents may be selected from topoisomerase inhibitors, such as topotecan or irinotecan, or cell growth inhibitors such as etoposide and teniposide.
[0473] In another embodiment, the present invention provides a method for treating a condition involving CD20-expressing cells in a subject, the method comprising administering a therapeutically effective amount of the bispecific antibody of the present invention and at least one inhibitor of angiogenesis, neovascularization and / or other vascularization to the subject in need.
[0474] Examples of such angiogenesis inhibitors include urokinase inhibitors, matrix metalloproteinase inhibitors (e.g., marimustastat, neovastastat, BAY 12-9566, AG 3340, BMS-275291 and similar agents), inhibitors of endothelial cell migration and proliferation (e.g., TNP-470, squalamine, 2-methoxyestradiol, cobustatin, endostatin, angiostatin, penicillamine, SCH66336 (Schering-Plough Corp, Madison, NJ), R115777 (JanssenPharmaceutica, Inc, Titusville, NJ) and similar agents), antagonists of angiogenic growth factors (e.g., ZD6474, SU6668, antibodies against angiogenic agents and / or their receptors (e.g., VEGF (e.g., bevacizumab), bFGF and angiopoietin-1), thalidomide, thalidomide analogs (e.g., CC-5013), and similar agents. Sugen 5416, SU5402, anti-angiogenic ribozymes (e.g., angiozyme), interferon α (e.g., interferon α2a), suramin and similar agents), VEGF-R kinase inhibitors and other anti-angiogenic tyrosine kinase inhibitors (e.g., SU011248), endothelial-specific integrin / survival signal transduction inhibitors (e.g., vitaxin and similar agents), copper antagonists / chelators (e.g., tetrathiomolybdate, captopril and similar agents), formamide-triazole (CAI), ABT-627, CM101, interleukin-12 (IL-12), IM862, PNU145156E, and nucleotide molecules that inhibit angiogenesis (e.g., antisense-VEGF-cDNA, cDNA encoding angiostatin, cDNA encoding p53, and cDNA encoding defective VEGF receptor-2).
[0475] Other examples of such inhibitors of angiogenesis, neovascularization, and / or other vascularization include anti-angiogenic heparin derivatives (e.g., heparinase III), temozolomide, NK4, macrophage migration inhibitory factor, cyclooxygenase-2 inhibitors, hypoxia-inducible factor 1 inhibitors, anti-angiogenic soy isoflavones, otepralatrexate, nicotinic acid and its analogues, somatostatin analogues, polysulfated pentosans, tecogallan sodium, dalteparin, tumstatin, thromboretin, NM-3, combrestatin, canstatin, avastatin, and antibodies against other targets, such as anti-α-v / β-3 integrin and anti-kininostatin antibodies.
[0476] In one embodiment, the therapeutic agent used in combination with the bispecific antibody to treat the condition as described above can be an anti-cancer immunogen, such as a cancer antigen / tumor-associated antigen (e.g., epithelial cell adhesion molecule (EpCAM / TACSTD1), mucin 1 (MUC1), carcinoembryonic antigen (CEA), tumor-associated glycoprotein 72 (TAG-72), gp100, Melan-A, MART-1, KDR, RCAS1, MDA7, cancer-associated viral vaccine (e.g., human papillomavirus vaccine) or tumor-derived heat shock protein.
[0477] In one implementation, the therapeutic agent used in combination with the bispecific antibody to treat the condition as described above can be an anti-cancer cytokine, a chemokine, or a combination thereof. Examples of suitable cytokines and growth factors include IFNγ, IL-2, IL-4, IL-6, IL-7, IL-10, IL-12, IL-13, IL-15, IL-18, IL-23, IL-24, IL-27, IL-28a, IL-28b, IL-29, KGF, IFNα (e.g., INFα2b), IFNβ, GM-CSF, CD40L, Flt3 ligand, stem cell factor, ansistatin, and TNFα. Suitable chemokines may include Glu-Leu-Arg (ELR)-negative chemokines such as IP-10, MCP-3, MIG, and SDF-1α, derived from the human CXC and CC chemokine families. Suitable cytokines include cytokine derivatives, cytokine variants, cytokine fragments, and cytokine fusion proteins.
[0478] In one embodiment, the therapeutic agent used in combination with a bispecific antibody to treat the condition as described above can be a cell cycle control / apoptosis regulator (or "regulator"). The cell cycle control / apoptosis regulator may include molecules that target and regulate cell cycle control / apoptosis, such as (i) cdc-25 (e.g., NSC 663284), (ii) cyclin-dependent kinases that overstimulate the cell cycle (e.g., flavopiriridol (L868275, HMR1275), 7-hydroxysalicylic acid (UCN-01, KW-2401), and roscovitine (R-roscovitine, CYC202)), and (iii) telomere-terminal transferase regulators (e.g., BIBR1532, SOT-095, GRN163, and compositions described in, for example, US 6,440,735 and US 6,713,055). Non-limiting examples of molecules that interfere with the apoptosis pathway include TNF-associated apoptosis-inducing ligand (TRAIL) / apoptosis-2 ligand (Apo-2L), antibodies that activate the TRAIL receptor, interferon-γ (IFN-γ), and anti-sense Bcl-2.
[0479] In one implementation, the therapeutic agent used in combination with the bispecific antibody to treat the condition as described above can be a hormone modulator, such as agents used for anti-androgen and anti-estrogen therapy. Examples of such hormone modulators include tamoxifen, edoxifene, fulvestrant, droloxifen, toremifene, raloxifene, diethylstilbestrol, ethinylestradiol / ethinylestradiol, anti-androgens (e.g., flutaminde / eulexin), progesterone (e.g., progesterone caproate, medroxyprogesterone acetate / previa, medroxyprogesterone acetate / megsi), corticosteroids (e.g., hydrocortisone, prednisone), luteinizing hormone-releasing hormone (and its analogues and other LHRH agonists such as busherin and goserelin), aromatase inhibitors (e.g., anastrazole / renin, ammonia glutide / cytraden, exemestane), or hormone inhibitors (e.g., octreotide / sandretin).
[0480] In one embodiment, the therapeutic agent used in combination with the bispecific antibody to treat the condition as described above can be an immune checkpoint inhibitor, such as a molecule that blocks the activity of CTLA-4, for example, ipilimumab, PD-1, for example, pembrolizumab, PD-L1, TIM3, TIGIT, BTLA, VISTA, or LAG-3.
[0481] In one implementation, the therapeutic agent used in combination with the bispecific antibody to treat the condition as described above can be an anti-cancer nucleic acid or an anti-cancer inhibitory RNA molecule.
[0482] Examples of other anticancer agents that can be used in combination with the bispecific antibody of the present invention for the treatment of the conditions described above are differentiation inducers, retinoic acid analogs (e.g., all-trans retinoic acid, 13-cis retinoic acid and similar agents), vitamin D analogs (e.g., ciscalciferol and similar agents), ErbB3, ErbB4, IGF-IR, insulin receptor, PDGFRa, PDGFRbeta, Flk2, Flt4, FGFR1, FGFR2, FGFR3, FGFR4, TRKA, TRKC, RON (e.g., anti-RON antibody), inhibitors of Sea, Tie, Tie2, Eph, Ret, Ros, Alk, LTK, PTK7 and similar agents.
[0483] Other examples of anticancer agents that can be used in combination with the bispecific antibody of the present invention to treat the conditions described above are estrustin and epirubicin.
[0484] Examples of other anticancer agents that can be used in combination with the bispecific antibodies of the present invention to treat the conditions described above are HSP90 inhibitors, such as 17-allylaminogerdromycin, antibodies against tumor antigens such as PSA, CA125, KSA, integrins such as integrin β1, or VCAM inhibitors.
[0485] Examples of other anticancer agents that can be used in combination with bispecific antibodies to treat the conditions described above include neurotrophin inhibitors (e.g., vasopord, PSC 833, and other MDR-1 or p-glycoprotein inhibitors), TOR inhibitors (e.g., sirolimus, everolimus, and rapamycin), inhibitors of the "lymphocyte homing" mechanism (e.g., FTY720), and agents that affect cell signaling, such as adhesion molecule inhibitors (e.g., anti-LFA).
[0486] In yet another implementation, the bispecific antibody may be administered in combination with radiotherapy and / or autologous or allogeneic peripheral stem cell or bone marrow transplantation.
[0487] In yet another embodiment, the bispecific antibody may be administered in combination with one or more antibodies selected from anti-CD25 antibody, anti-CD19 antibody, anti-CD20 antibody (e.g., ofamumab or rituximab), anti-CD21 antibody, anti-CD22 antibody, anti-CD37 antibody, anti-CD38 antibody, anti-IL6R antibody, anti-IL8 antibody, anti-IL15 antibody, anti-IL15R antibody, anti-CD4 antibody, anti-CD11a antibody (e.g., efalizumab), anti-α-4 / β-1 integrin (VLA4) antibody (e.g., nastatinumab), and CTLA4-Ig.
[0488] In a further embodiment, the bispecific antibody may be administered in combination with one or more antibodies that block immune checkpoints, such as anti-CTLA-4 (CD152) antibody, anti-PD-1 (CD279) antibody, anti-PD-L1 (CD274) antibody, anti-LAG-3 (CD223) antibody, anti-TIM3 antibody, anti-CEACAM1 (CD66a) antibody, anti-VISTA antibody, anti-TIGIT antibody, and anti-BTLA (CD272) antibody.
[0489] In a further embodiment, the bispecific antibody may be administered in combination with one or more antagonistic antibodies that are specific to co-stimulatory receptors on immune cells, such as anti-4-1BB (CD137) antibody (e.g., urelumab), anti-OX40 (CD134) antibody, anti-CD40 antibody, and anti-CD27 antibody.
[0490] In a further embodiment, the bispecific antibody may be administered in combination with one or more type II macrophage depletion or polarization antibodies, such as anti-CSF-1R (CD115) antibody.
[0491] In a further embodiment, the bispecific antibody may be administered in combination with one or more antibodies that bind to molecules involved in regulating the innate immune system, such as anti-CD47 antibody, anti-CD200 antibody, anti-CD200R antibody, antibody against killer cell inhibitory receptors (KIRs), antibody against CD94 / NKG2 receptor, and anti-CD305 (LAIR1).
[0492] In another specific implementation, the bispecific antibody is administered in combination with one or more antibodies selected from anti-CD19 antibody, anti-CD21 antibody, anti-CD22 antibody, anti-CD37 antibody, and anti-CD38 antibody for the treatment of malignant diseases.
[0493] In another specific implementation, the bispecific antibody is administered in combination with an anti-CD20 antibody, such as oflambumab.
[0494] In yet another specific implementation, the bispecific antibody is administered in combination with one or more antibodies selected from anti-IL6R antibody, anti-IL8 antibody, anti-IL15 antibody, anti-IL15R antibody, anti-CD4 antibody, anti-CD11a antibody (e.g., efalizumab), anti-α-4 / β-1 integrin (VLA4) antibody (e.g., nastatinumab), and CTLA4-Ig for the treatment of inflammatory diseases.
[0495] In one embodiment, the bispecific antibody of the present invention is used in combination with one or more other therapeutic antibodies, such as zanolimumab, daratumumab (Darzalex), ranibizumab, nimotuzumab, panitumumab, hu806, daclizumab (Zenapax), basiliximab (Simulect), infliximab (Remicade), adalimumab (Humira), natalizumab (Tysabri), omalizumab (Xolair), and / or efalizumab (Raptiva).
[0496] In another embodiment, the bispecific antibody of the present invention is used in combination with one or more antibody-drug conjugates (ADCs), such as brentuximab-vedotin (Adcetris), inotuzumab ozogamicin (CMC-544), polatuzumab vedotin (RG7593), coltuximab ravtansine (SAR3419), indatuximab ravtansine (BT-062), inotuzumab ozogamicin (CMC-544), denintuzumab mafodotin (SGN-CD19), polatuzumab vedotin (RG7596), or a conjugated CD37-specific antibody drug (e.g., IMGN529 or AGS67E).
[0497] In another embodiment, the bispecific antibody of the present invention may be used in combination with an anti-inflammatory agent or an immunosuppressant. For example, combination therapy may include the composition of the present invention with at least one anti-inflammatory agent or at least one immunosuppressant. In one embodiment, such a therapeutic agent includes one or more anti-inflammatory agents, such as steroidal drugs or NSAIDs (nonsteroidal anti-inflammatory drugs). Preferred agents include, for example, aspirin and other salicylates, Cox-2 inhibitors, such as celecoxib (Celebrex), NSAIDs such as ibuprofen (Motrin, Advil), fenprofen (Nalfon), naproxen (Naprosyn), sulindac (Clinoril), diclofenac (Voltaren), piroxicam (Feldene), ketoprofen (Orudis), diflunisal (Dolobid), nabumetone (Relafen), lodine, oxapazine (Daypro), and indomethacin (Indocin).
[0498] In another implementation, such therapeutic agents include one or more DMARDs, such as methotrexate (Rheumatrex), hydroxychloroquine (Plaquenil), sulfasalazine (Asulfidine), pyrimidine synthesis inhibitors, such as leflunomide (Arava), IL-1 receptor blockers, such as kinetin, and TNF-α blockers, such as etanercept (Enbrel), infliximab (Remicade), and adalimumab.
[0499] In another implementation, such therapeutic agents include one or more immunosuppressants, such as cyclosporine (Sandimmune, Neoral) and azathioprine (Imural).
[0500] In a specific implementation plan, a combination of bispecific antibodies and anti-CD25 antibodies is administered to treat bullous pemphigoid, for example, in patients with graft-versus-host disease.
[0501] Radiation therapy – surgery In one embodiment, the present invention provides a method for treating a condition involving CD20-expressing cells in a subject, the method comprising administering a therapeutically effective amount of the present invention's CD3xCD20 bispecific antibody and radiotherapy to the subject in need.
[0502] In one embodiment, the present invention provides a method for treating or preventing cancer, the method comprising administering a therapeutically effective amount of the present invention’s CD3xCD20 bispecific antibody and radiotherapy to a subject in need.
[0503] In one embodiment, the present invention provides the use of the bispecific antibody of the present invention for the preparation of a pharmaceutical composition for the treatment of cancer, administered in combination with radiotherapy.
[0504] Radiation therapy may involve radiation or be administered to the patient concurrently with radiopharmaceuticals. The source of radiation can be external or internal to the patient being treated (radiotherapy can take the form of, for example, external beam radiotherapy (EBRT) or short-range radiotherapy (BT)). Radioactive elements that can be used to perform such methods include, for example, radium, cesium-137, iridium-192, americium-241, gold-198, cobalt-57, copper-67, technetium-99, iodine-123, iodine-131, and indium-111.
[0505] In a further embodiment, the present invention provides a method for treating or preventing cancer, the method comprising administering, in combination with surgery, a therapeutically effective amount of the bispecific antibody of the present invention to a subject in need.
[0506] Diagnostic uses Therefore, in one aspect, the present invention relates to diagnostic compositions comprising a bispecific CD3xCD20 antibody as defined herein and their use therein.
[0507] In another aspect, the present invention relates to a kit for detecting crosslinks between cells expressing CD3 and CD20 in patient-derived samples, such as blood samples, lymph node samples, or bone marrow samples, comprising... i) A bispecific antibody according to any of the embodiments disclosed herein; and ii) The instructions for use of the kit.
[0508] In one embodiment, the present invention provides a diagnostic kit for cancer, comprising a container containing a bispecific CD3xCD20 antibody and one or more reagents for detecting cross-linking of CD20-expressing cells and CD3-expressing cells. The reagents may include, for example, fluorescent tags, enzyme tags, or other detectable tags. The reagents may also include a second or third antibody or reagents for an enzyme reaction, wherein the enzyme reaction produces a visible product.
[0509] In a further aspect, the present invention relates to a method for detecting whether cross-linking occurs between cells expressing CD3 and CD20 in a patient-derived sample, such as a blood sample, lymph node sample, or bone marrow sample, after administration of a bispecific antibody according to any embodiment disclosed herein, comprising the following steps: (i) Contacting the sample with a bispecific antibody according to any embodiment disclosed herein under conditions that allow the bispecific antibody to form a complex with cells expressing CD3 and CD20; and (ii) Analyze whether a complex is formed.
[0510] The complex can be detected by methods known in the art, such as the method disclosed in Example 5.
[0511] In a further aspect, the present invention relates to anti-individual genotype antibodies, which bind to a first antigen-binding region as defined in any of the embodiments disclosed herein, or to a second antigen-binding region as defined in any of the embodiments disclosed herein. Detailed Implementation
[0512] The present invention also relates to the following embodiments: 1. A bispecific antibody comprising (i) a first binding arm comprising a first antigen-binding region for binding human CD3ε (epsilon), wherein the first antigen-binding region comprises (a) heavy chain variable (VH) regions CDR1, CDR2, and CDR3 having sequences shown in SEQ ID NO:1, 2, and 3, respectively, and light chain variable (VL) regions CDR1, CDR2, and CDR3 having sequences shown in SEQ ID NO:4, GTN, and SEQ ID NO:5, respectively, or (b) heavy chain variable (VH) regions CDR1, CDR2, and CDR3 having sequences shown in SEQ ID NO:55, 56, and 57, respectively, and light chain variable (VL) regions CDR1, CDR2, and CDR3 having sequences shown in SEQ ID NO:58, DTS, and SEQ ID NO:59, respectively, and (ii) a second binding arm comprising a second antigen-binding region for binding human CD20.
[0513] 2. The bispecific antibody of embodiment 1, comprising a first binding arm, the first binding arm comprising a first antigen-binding region binding to human CD3ε (epsilon), wherein the first antigen-binding region comprises heavy chain variable (VH) regions CDR1, CDR2 and CDR3 having sequences shown in SEQ ID NO:1, 2 and 3 respectively, and light chain variable (VL) regions CDR1, CDR2 and CDR3 having sequences shown in SEQ ID NO:4, sequence GTN and sequences shown in SEQ ID NO:5 respectively.
[0514] 3. A bispecific antibody according to embodiment 1 or 2, wherein the first antigen-binding region comprises a first heavy chain variable sequence (VH) and a first light chain variable sequence (VL), and the second antigen-binding region comprises a second heavy chain variable sequence (VH) and a second light chain variable sequence (VL), and wherein each of the variable sequences comprises three CDR sequences, namely CDR1, CDR2 and CDR3, and four frame sequences, namely FR1, FR2, FR3 and FR4.
[0515] 4. A bispecific antibody according to any of the foregoing embodiments, wherein (i) the first binding arm comprises a first heavy chain and a first light chain, the first heavy chain comprising a first heavy chain variable sequence (VH) and a first heavy chain constant sequence (CH), and the first light chain comprising a first light chain variable sequence (VL) and a first light chain constant sequence (CL); and (ii) the second binding arm comprises a second heavy chain and a second light chain, the second heavy chain comprising a second heavy chain variable sequence (VH) and a second heavy chain constant sequence (CH), and the second light chain comprising a second light chain variable sequence (VL) and a second light chain constant sequence (CL).
[0516] 5. A bispecific antibody according to any of the foregoing embodiments, wherein the VH sequence of the first antigen-binding region has at least 90%, at least 95%, at least 97%, or at least 99% amino acid sequence identity with an amino acid sequence selected from the following VH sequences: a) The VH sequence shown in SEQ ID NO:6; b) The VH sequence shown in SEQ ID NO:7; c) The VH sequence shown in SEQ ID NO:8; d) The VH sequence shown in SEQ ID NO:9; and e) The VH sequence shown in SEQ ID NO:17.
[0517] 6. A bispecific antibody according to any of the foregoing embodiments, wherein the VL sequence of the first antigen-binding region has at least 90%, at least 95%, at least 97%, or at least 99% amino acid sequence identity with an amino acid sequence selected from the following VL sequences: a) The VL sequence shown in SEQ ID NO:10; b) The VL sequence shown in SEQ ID NO:11; c) The VL sequence shown in SEQ ID NO:12; and d) The VL sequence shown in SEQ ID NO:18.
[0518] 7. A bispecific antibody according to any of the foregoing embodiments, wherein the framework sequence of the VH sequence in the first antigen-binding region has at least 90%, at least 95%, at least 97%, or at least 99% amino acid sequence identity with the framework amino acid sequence of a VH sequence selected from the following: a) The VH sequence shown in SEQ ID NO:6; b) The VH sequence shown in SEQ ID NO:7; c) The VH sequence shown in SEQ ID NO:8; d) The VH sequence shown in SEQ ID NO:9; and e) The VH sequence shown in SEQ ID NO:17.
[0519] 8. A bispecific antibody according to any of the foregoing embodiments, wherein the framework sequence of the VL sequence in the first antigen-binding region has at least 90%, at least 95%, at least 97%, or at least 99% amino acid sequence identity with the framework amino acid sequence of a VL sequence selected from the following: a) The VL sequence shown in SEQ ID NO:10; b) The VL sequence shown in SEQ ID NO:11; c) The VL sequence shown in SEQ ID NO:12; and d) The VL sequence shown in SEQ ID NO:18.
[0520] 9. A bispecific antibody according to any one of embodiments 5-8, wherein the CDR sequences of the VH and VL sequences are not mutated, but are as shown in Table 1.
[0521] 10. A bispecific antibody according to any one of implementation schemes 5-7, wherein the VH and VL sequences deviate only from the frame sequence.
[0522] 11. A bispecific antibody according to any one of embodiments 5-8, wherein the FR1, FR2, FR3 and FR4 framework sequences of the VH and VL sequences of the first antigen binding region have at least 90%, at least 95%, at least 97% or at least 99% amino acid sequence identity with the FR1, FR2, FR3 and FR4 framework sequences of the VH and VL sequences, and wherein the CDR sequence is not mutated.
[0523] 12. The bispecific antibody of any of the foregoing embodiments, wherein the VH sequence of the first antigen-binding region is selected from: a) The VH sequence shown in SEQ ID NO:6; b) The VH sequence shown in SEQ ID NO:7; c) The VH sequence shown in SEQ ID NO:8; d) The VH sequence shown in SEQ ID NO:9; e) The VH sequence shown in SEQ ID NO:17.
[0524] 13. The bispecific antibody of any of the foregoing embodiments, wherein the VL sequence of the first antigen-binding region is selected from: a) The VL sequence shown in SEQ ID NO:10; b) The VL sequence shown in SEQ ID NO:11; c) The VL sequence shown in SEQ ID NO:12; and d) The VL sequence shown in SEQ ID NO:18.
[0525] 14. The bispecific antibody of any of the foregoing embodiments, wherein the VH and VL sequences of the first antigen-binding region are selected from: a) The VH sequence shown in SEQ ID NO:6 and the VL sequence shown in SEQ ID NO:10; b) The VH sequence shown in SEQ ID NO:8 and the VL sequence shown in SEQ ID NO:10; c) The VH sequence shown in SEQ ID NO:9 and the VL sequence shown in SEQ ID NO:10; d) The VH sequence shown in SEQ ID NO:6 and the VL sequence shown in SEQ ID NO:11; e) The VH sequence shown in SEQ ID NO:6 and the VL sequence shown in SEQ ID NO:12; f) The VH sequence shown in SEQ ID NO:7 and the VL sequence shown in SEQ ID NO:10; g) The VH sequence shown in SEQ ID NO:7 and the VL sequence shown in SEQ ID NO:11; h) The VH sequence shown in SEQ ID NO:7 and the VL sequence shown in SEQ ID NO:12; i) The VH sequence shown in SEQ ID NO:8 and the VL sequence shown in SEQ ID NO:11; j) The VH sequence shown in SEQ ID NO:8 and the VL sequence shown in SEQ ID NO:12; k) The VH sequence shown in SEQ ID NO:9 and the VL sequence shown in SEQ ID NO:11; l) The VH sequence shown in SEQ ID NO:9 and the VL sequence shown in SEQ ID NO:12; and m) The VH sequence shown in SEQ ID NO:17 and the VL sequence shown in SEQ ID NO:18.
[0526] 15. A bispecific antibody according to any of the foregoing embodiments, wherein the first antigen-binding region comprises a VH sequence and a VL sequence selected from: a) The VH sequence shown in SEQ ID NO:6 and the VL sequence shown in SEQ ID NO:10; b) The VH sequence shown in SEQ ID NO:17 and the VL sequence shown in SEQ ID NO:18.
[0527] 16. The bispecific antibody of any of the foregoing embodiments, wherein the first antigen-binding region comprises a VH sequence having at least 90% sequence identity with the VH sequence shown in SEQ ID NO:6, and a VL sequence having at least 90% sequence identity with the VL sequence shown in SEQ ID NO:10.
[0528] 17. A bispecific antibody according to any of the foregoing embodiments, wherein the first antigen-binding region comprises a VH sequence having at least 95% sequence identity with the VH sequence shown in SEQ ID NO:6, and a VL sequence having at least 95% sequence identity with the VL sequence shown in SEQ ID NO:10.
[0529] 18. A bispecific antibody of any of the foregoing embodiments, wherein the first antigen-binding region comprises a VH sequence having at least 97% sequence identity with the VH sequence shown in SEQ ID NO:6, and a VL sequence having at least 97% sequence identity with the VL sequence shown in SEQ ID NO:10.
[0530] 19. A bispecific antibody of any of the foregoing embodiments, wherein the first antigen-binding region comprises the VH sequence shown in SEQ ID NO:6 and the VL sequence shown in SEQ ID NO:10.
[0531] 20. A bispecific antibody of any of the foregoing embodiments, wherein the first binding arm is derived from a mouse antibody.
[0532] 21. The bispecific antibody of any of the foregoing embodiments, wherein the first binding arm is derived from a humanized antibody.
[0533] 22. A bispecific antibody of any of the foregoing embodiments, wherein the first binding arm is derived from a full-length antibody.
[0534] 23. The bispecific antibody of any of the foregoing embodiments, wherein the first binding arm is derived from a full-length IgG1,λ (lambda) or IgG1,κ (kappa) antibody.
[0535] 24. A bispecific antibody of any of the foregoing embodiments, wherein the second antigen-binding region is derived from an antibody that binds to an epitope on human CD20, said epitope not containing or requiring the amino acid residue alanine at position 170 or the amino acid residue proline at position 172.
[0536] 25. The bispecific antibody of embodiment 21, wherein the second antigen-binding region is derived from an antibody that binds to an epitope on human CD20, said epitope further comprising or requiring asparagine amino acid residues at position 163 and 166.
[0537] 26. The bispecific antibody of any of the foregoing embodiments, wherein the second antigen-binding region binding to human CD20 comprises: (i) VH CDR1 region of SEQ ID NO:32, VH CDR2 region of SEQ ID NO:33, and VHCDR3 region of SEQ ID NO:34. (ii) VH CDR1 region of SEQ ID NO:38, VH CDR2 region of SEQ ID NO:39, and VHCDR3 region of SEQ ID NO:34. (iii) VH CDR1 region of SEQ ID NO:42, VH CDR2 region of SEQ ID NO:43, VH CDR3 region of SEQ ID NO:44, or (iv) VH CDR1 region of SEQ ID NO:49, VH CDR2 region of SEQ ID NO:50, and VHCDR3 region of SEQ ID NO:51.
[0538] 27. The bispecific antibody of any of the foregoing embodiments, wherein the second antigen-binding region binding to human CD20 comprises: (i) VL CDR1 region of SEQ ID NO:35, VL CDR2 region of DAS, and VL CDR3 region of SEQ ID NO:36. (ii) VL CDR1 region of SEQ ID NO:45, VL CDR2 region of DAS, and VL CDR3 region of SEQ ID NO:46. (iii) VL CDR1 region of SEQ ID NO:52, VL CDR2 region of DAS, and VL CDR3 region of SEQ ID NO:53.
[0539] 28. The bispecific antibody of any of the foregoing embodiments, wherein the second antigen-binding region binding to human CD20 comprises: (i) VH CDR1 region of SEQ ID NO:32, VH CDR2 region of SEQ ID NO:33, VHCDR3 region of SEQ ID NO:34, VL CDR1 region of SEQ ID NO:35, VL CDR2 region of DAS, and VL CDR3 region of SEQ ID NO:36. (ii) VH CDR1 region of SEQ ID NO:38, VH CDR2 region of SEQ ID NO:39, VHCDR3 region of SEQ ID NO:34, VL CDR1 region of SEQ ID NO:35, VL CDR2 region of DAS, and VL CDR3 region of SEQ ID NO:36. (iii) VH CDR1 region of SEQ ID NO:42, VH CDR2 region of SEQ ID NO:43, VH CDR3 region of SEQ ID NO:44, VL CDR1 region of SEQ ID NO:45, VL CDR2 region of DAS, and VL CDR3 region of SEQ ID NO:46. (iv) VH CDR1 region of SEQ ID NO:49, VH CDR2 region of SEQ ID NO:50, VHCDR3 region of SEQ ID NO:51, VL CDR1 region of SEQ ID NO:52, VL CDR2 region of DAS, and VL CDR3 region of SEQ ID NO:53. (v) VH CDR1 region of SEQ ID NO:32, VH CDR2 region of SEQ ID NO:33, VHCDR3 region of SEQ ID NO:34, VL CDR1 region of SEQ ID NO:45, VL CDR2 region of DAS, and VL CDR3 region of SEQ ID NO:46. (vi) VH CDR1 region of SEQ ID NO:32, VH CDR2 region of SEQ ID NO:33, VHCDR3 region of SEQ ID NO:34, VL CDR1 region of SEQ ID NO:52, VL CDR2 region of DAS, and VL CDR3 region of SEQ ID NO:53. (vii) VH CDR1 region of SEQ ID NO:38, VH CDR2 region of SEQ ID NO:39, VH CDR3 region of SEQ ID NO:34, VL CDR1 region of SEQ ID NO:45, VL CDR2 region of DAS, and VL CDR3 region of SEQ ID NO:46. (viii) VH CDR1 region of SEQ ID NO:38, VH CDR2 region of SEQ ID NO:39, VH CDR3 region of SEQ ID NO:34, VL CDR1 region of SEQ ID NO:52, VL CDR2 region of DAS, and VL CDR3 region of SEQ ID NO:53. (ix) VH CDR1 region of SEQ ID NO:42, VH CDR2 region of SEQ ID NO:43, VHCDR3 region of SEQ ID NO:44, VL CDR1 region of SEQ ID NO:35, VL CDR2 region of DAS, and VL CDR3 region of SEQ ID NO:36. (x) VH CDR1 region of SEQ ID NO:42, VH CDR2 region of SEQ ID NO:43, VHCDR3 region of SEQ ID NO:44, VL CDR1 region of SEQ ID NO:52, VL CDR2 region of DAS, and VL CDR3 region of SEQ ID NO:53. (xi) VH CDR1 region of SEQ ID NO:49, VH CDR2 region of SEQ ID NO:50, VHCDR3 region of SEQ ID NO:51, VL CDR1 region of SEQ ID NO:35, VL CDR2 region of DAS, and VL CDR3 region of SEQ ID NO:36, or (xii) VH CDR1 region of SEQ ID NO:49, VH CDR2 region of SEQ ID NO:50, VH CDR3 region of SEQ ID NO:51, VL CDR1 region of SEQ ID NO:45, VL CDR2 region of DAS and VL CDR3 region of SEQ ID NO:46.
[0540] 29. The bispecific antibody of any of the foregoing embodiments, wherein the second antigen-binding region binding to human CD20 comprises the VH CDR1 region of SEQ ID NO:32, the VH CDR2 region of SEQ ID NO:33, the VH CDR3 region of SEQ ID NO:34, the VL CDR1 region of SEQ ID NO:35, the VL CDR2 region of DAS, and the VL CDR3 region of SEQ ID NO:36.
[0541] 30. The bispecific antibody of any of the foregoing embodiments, wherein the second antigen-binding region binding to human CD20 comprises: (i) a VH sequence having at least 90%, at least 95%, at least 97%, or at least 99% amino acid sequence identity with the amino acid sequence shown in SEQ ID NO:27, and a VL sequence having at least 90%, at least 95%, at least 97%, or at least 99% amino acid sequence identity with the amino acid sequence shown in SEQ ID NO:28. (ii) A VH sequence having at least 90%, at least 95%, at least 97%, or at least 99% amino acid sequence identity with the amino acid sequence shown in SEQ ID NO:37, and a VL sequence having at least 90%, at least 95%, at least 97%, or at least 99% amino acid sequence identity with the amino acid sequence shown in SEQ ID NO:28. (iii) A VH sequence having at least 90%, at least 95%, at least 97%, or at least 99% amino acid sequence identity with the amino acid sequence shown in SEQ ID NO:40, and a VL sequence having at least 90%, at least 95%, at least 97%, or at least 99% amino acid sequence identity with the amino acid sequence shown in SEQ ID NO:41. (iv) A VH sequence having at least 90%, at least 95%, at least 97%, or at least 99% amino acid sequence identity with the amino acid sequence shown in SEQ ID NO:47, and a VL sequence having at least 90%, at least 95%, at least 97%, or at least 99% amino acid sequence identity with the amino acid sequence shown in SEQ ID NO:48. (v) A VH sequence having at least 90%, at least 95%, at least 97%, or at least 99% amino acid sequence identity with the amino acid sequence shown in SEQ ID NO:27, and a VL sequence having at least 90%, at least 95%, at least 97%, or at least 99% amino acid sequence identity with the amino acid sequence shown in SEQ ID NO:41. (vi) A VH sequence having at least 90%, at least 95%, at least 97%, or at least 99% amino acid sequence identity with the amino acid sequence shown in SEQ ID NO:27, and a VL sequence having at least 90%, at least 95%, at least 97%, or at least 99% amino acid sequence identity with the amino acid sequence shown in SEQ ID NO:48. (vii) A VH sequence having at least 90%, at least 95%, at least 97%, or at least 99% amino acid sequence identity with the amino acid sequence shown in SEQ ID NO:37, and a VL sequence having at least 90%, at least 95%, at least 97%, or at least 99% amino acid sequence identity with the amino acid sequence shown in SEQ ID NO:41. (viii) A VH sequence having at least 90%, at least 95%, at least 97%, or at least 99% amino acid sequence identity with the amino acid sequence shown in SEQ ID NO:37, and a VL sequence having at least 90%, at least 95%, at least 97%, or at least 99% amino acid sequence identity with the amino acid sequence shown in SEQ ID NO:48. (ix) A VH sequence having at least 90%, at least 95%, at least 97%, or at least 99% amino acid sequence identity with the amino acid sequence shown in SEQ ID NO:40, and a VL sequence having at least 90%, at least 95%, at least 97%, or at least 99% amino acid sequence identity with the amino acid sequence shown in SEQ ID NO:28. (x) A VH sequence having at least 90%, at least 95%, at least 97%, or at least 99% amino acid sequence identity with the amino acid sequence shown in SEQ ID NO:40, and a VL sequence having at least 90%, at least 95%, at least 97%, or at least 99% amino acid sequence identity with the amino acid sequence shown in SEQ ID NO:48. (xi) A VH sequence having at least 90%, at least 95%, at least 97%, or at least 99% amino acid sequence identity with the amino acid sequence shown in SEQ ID NO:47, and a VL sequence having at least 90%, at least 95%, at least 97%, or at least 99% amino acid sequence identity with the amino acid sequence shown in SEQ ID NO:28, or (xii) A VH sequence having at least 90%, at least 95%, at least 97%, or at least 99% amino acid sequence identity with the amino acid sequence shown in SEQ ID NO:47, and a VL sequence having at least 90%, at least 95%, at least 97%, or at least 99% amino acid sequence identity with the amino acid sequence shown in SEQ ID NO:41.
[0542] 31. The bispecific antibody of any of the foregoing embodiments, wherein the second antigen-binding region binding to human CD20 comprises: (i) The VH sequence of SEQ ID NO:27 and the VL sequence of SEQ ID NO:28, (ii) The VH sequence of SEQ ID NO:37 and the VL sequence of SEQ ID NO:28, (iii) The VH sequence of SEQ ID NO:40 and the VL sequence of SEQ ID NO:41, (iv) The VH sequence of SEQ ID NO:47 and the VL sequence of SEQ ID NO:48, (v) The VH sequence of SEQ ID NO:27 and the VL sequence of SEQ ID NO:41, (vi) The VH sequence of SEQ ID NO:27 and the VL sequence of SEQ ID NO:48, (vii) The VH sequence of SEQ ID NO:37 and the VL sequence of SEQ ID NO:41, (viii) The VH sequence of SEQ ID NO:37 and the VL sequence of SEQ ID NO:48, (ix) The VH sequence of SEQ ID NO:40 and the VL sequence of SEQ ID NO:28, (x) The VH sequence of SEQ ID NO:40 and the VL sequence of SEQ ID NO:48, (xi) The VH sequence of SEQ ID NO:47 and the VL sequence of SEQ ID NO:28, or (xii) The VH sequence of SEQ ID NO:47 and the VL sequence of SEQ ID NO:41.
[0543] 32. The bispecific antibody of any of the foregoing embodiments, wherein the second antigen-binding region binding to human CD20 comprises the VH sequence of SEQ ID NO:27 and the VL sequence of SEQ ID NO:28.
[0544] 33. The bispecific antibody of any of the foregoing embodiments, wherein the second binding arm is derived from a human antibody.
[0545] 34. A bispecific antibody of any of the foregoing embodiments, wherein the second binding arm is derived from a full-length antibody.
[0546] 35. The bispecific antibody of any of the foregoing embodiments, wherein the second binding arm is derived from a full-length IgG1,κ(kappa) antibody.
[0547] 36. A bispecific antibody according to any of the foregoing embodiments, wherein (a) the first antigen-binding region comprises heavy chain variable (VH) regions CDR1, CDR2 and CDR3 having sequences shown in SEQ ID NO:1, 2 and 3 respectively, and light chain variable (VL) regions CDR1, CDR2 and CDR3 having sequences shown in SEQ ID NO:4, sequence GTN and sequence shown in SEQ ID NO:5 respectively, and (b) the second antigen-binding region binding to human CD20 comprises the VH CDR1 region of SEQ ID NO:32, the VH CDR2 region of SEQ ID NO:33, the VH CDR3 region of SEQ ID NO:34, the VL CDR1 region of SEQ ID NO:35, the VL CDR2 region of DAS and the VL CDR3 region of SEQ ID NO:36 respectively.
[0548] 37. A bispecific antibody of any of the foregoing embodiments, wherein (a) the first antigen-binding region comprises the VH sequence shown in SEQ ID NO:6 and the VL sequence shown in SEQ ID NO:10, and (b) the second antigen-binding region comprises the VH sequence shown in SEQ ID NO:27 and the VL sequence shown in SEQ ID NO:28.
[0549] 38. The bispecific antibody of any of the foregoing embodiments, wherein the first antigen-binding region is a half-molecule antibody derived from IgG1-huCD3-H1L1-FEAL and the second antigen-binding region is a half-molecule antibody derived from IgG1-7D8-FEAR.
[0550] 39. The bispecific antibody of any of the foregoing embodiments, wherein the first binding arm is a half-molecule antibody derived from IgG1-huCD3-H1L1-FEAR and the second binding arm is a half-molecule antibody derived from IgG1-7D8-FEAL.
[0551] 40. A bispecific antibody according to any one of embodiments 1-37, wherein each of the first and second heavy chains comprises at least a hinge region, a CH2 region, and a CH3 region, wherein at least one amino acid in the first heavy chain corresponding to a position selected from T366, L368, K370, D399, F405, Y407, and K409 of the human IgG1 heavy chain has been substituted, and at least one amino acid in the second heavy chain corresponding to a position selected from T366, L368, K370, D399, F405, Y407, and K409 of the human IgG1 heavy chain has been substituted, and wherein the first heavy chain and the second heavy chain are not substituted at the same position.
[0552] 41. The bispecific antibody of embodiment 40, wherein (i) the amino acid at position F405 of the human IgG1 heavy chain in the first heavy chain is L, and the amino acid at position K409 of the human IgG1 heavy chain in the second heavy chain is R, or (ii) the amino acid at position K409 of the human IgG1 heavy chain in the first heavy chain is R, and the amino acid at position F405 of the human IgG1 heavy chain in the second heavy chain is L.
[0553] 42. A bispecific antibody according to any one of embodiments 1-41, wherein the bispecific antibody comprises a first constant heavy chain (HC) and a first constant light chain (LC), wherein the positions of the first heavy chain and the second heavy chain corresponding to positions L234, L235 and D265 of the human IgG1 heavy chain in SEQ ID NO:15 are F, E and A, respectively.
[0554] 43. A bispecific antibody according to any one of embodiments 1-41, wherein the bispecific antibody comprises a first and a second constant heavy chain (HC) and a first and a second constant light chain (LC), wherein the positions L234 and L235 of the first heavy chain and the second heavy chain corresponding to the human IgG1 heavy chain in SEQ ID NO:15 are F and E, respectively.
[0555] 44. A bispecific antibody of any one of embodiments 1-43, wherein the first binding arm is a half-molecule antibody derived from IgG1-huCD3-H1L1-FEAL and the second binding arm is a half-molecule antibody derived from IgG1-7D8-FEAR.
[0556] 45. A bispecific antibody of any one of embodiments 1-43, wherein the first binding arm is a half-molecule antibody derived from IgG1-huCD3-H1L1-FEAR and the second binding arm is a half-molecule antibody derived from IgG1-7D8-FEAL.
[0557] 46. A bispecific antibody according to any one of embodiments 1-45, wherein the bispecific antibody comprises a first and a second constant heavy chain (HC) and a first and a second constant light chain (LC), wherein the positions L234, L235 and D265 of the first and second constant heavy chains corresponding to the human IgG1 heavy chain in SEQ ID NO:15 are F, E and A, respectively, and wherein the position F405 of the first constant heavy chain corresponding to the human IgG1 heavy chain in SEQ ID NO:15 is L, and the position K409 of the second constant heavy chain corresponding to the human IgG1 heavy chain in SEQ ID NO:15 is R.
[0558] 47. A bispecific antibody according to any one of embodiments 1-45, wherein the bispecific antibody comprises a constant heavy chain (HC) and a constant light chain (LC), wherein the positions L234 and L235 of the first heavy chain and the second heavy chain corresponding to the human IgG1 heavy chain in SEQ ID NO:15 are F and E, respectively, and wherein the position of F405 of the first heavy chain corresponding to the human IgG1 heavy chain in SEQ ID NO:15 is L, and the position of K409 of the second heavy chain corresponding to the human IgG1 heavy chain in SEQ ID NO:15 is R.
[0559] 48. A bispecific antibody according to any of the foregoing embodiments, wherein the antibody comprises an Fc region that has been modified such that the binding of C1q to the antibody is reduced by at least 70%, at least 80%, at least 90%, at least 95%, at least 97%, or 100% compared to a wild-type antibody, wherein C1q binding is determined by ELISA.
[0560] 49. A nucleic acid construct encoding one or more amino acid sequences of implementation schemes 1-48.
[0561] 50. Encode the nucleic acid construct of the bispecific antibody as defined in any of Implementation Schemes 1-48.
[0562] 51. A vehicle for expression, which includes: (i) The nucleic acid sequence encoding the heavy chain sequence of the first binding arm as defined in any of the aforementioned embodiments 1-23; (ii) A nucleic acid sequence encoding the light chain sequence of the first binding arm as defined in any of the aforementioned embodiments 1-23; (iii) A nucleic acid sequence encoding the heavy chain sequence of the second binding arm as defined in any of the aforementioned embodiments 24-32; (iv) A nucleic acid sequence encoding the light chain sequence of the second binding arm as defined in any of embodiments 24-32 above; (v) Nucleic acids shown in (i) and (ii); Nucleic acids shown in (vi) and (iii) and (iv); Nucleic acids shown in (vii), (ii), (iii) and (iv).
[0563] 52. A host cell containing the expression vector of implementation scheme 51.
[0564] 53. The host cell of embodiment 52, wherein the host cell is a recombinant eukaryotic host cell, a recombinant prokaryotic host cell, or a recombinant microbial host cell.
[0565] 54. A composition comprising a bispecific antibody of any one of the preceding embodiments 1-48.
[0566] 55. A pharmaceutical composition comprising a bispecific antibody of any one of the preceding embodiments 1-48 and a pharmaceutically acceptable carrier.
[0567] 56. A bispecific antibody of any one of embodiments 1-48, a composition of embodiment 54, or a pharmaceutical composition of embodiment 55, which is used as a pharmaceutical.
[0568] 57. A bispecific antibody of any one of embodiments 1-48, a composition of embodiment 54, or a pharmaceutical composition of embodiment 55, for the treatment of a disease.
[0569] 58. The bispecific antibody used according to embodiment 57, wherein the use is for the treatment of cancer.
[0570] 59. The bispecific antibody used according to embodiment 58, wherein the use is for the treatment of B-cell malignancies.
[0571] 60. A bispecific antibody used according to embodiment 58 or 59, wherein the use is for the treatment of NHL or B-cell leukemia.
[0572] 61. A method of treating a disease, comprising administering to a subject in need a bispecific antibody of any one of embodiments 1-48, a composition of embodiment 54, or a pharmaceutical composition of embodiment 55.
[0573] 62. Use of the bispecific antibody of any one of Implementation Schemes 1-48 in the preparation of a drug.
[0574] 63. Use of the bispecific antibody of any one of embodiments 1-48 in the preparation of a medicament for the treatment of cancer.
[0575] 64. The use of embodiment 63, wherein the use is for the treatment of B-cell malignancies.
[0576] 65. The use of embodiment 63 or 64, wherein the use is for the treatment of NHL or B-cell leukemia.
[0577] 66. The method or use of any one of embodiments 56-65, wherein the method or use of the bispecific antibody of any one of embodiments 1-48 is used in combination with one or more other therapeutic agents, such as chemotherapeutic agents.
[0578] 67. A method for generating a bispecific antibody according to any one of the preceding embodiments 1-48, comprising the following steps: a) Culture host cells containing the expression vector of embodiment 51(v), and purify the antibody from the culture medium; b) Culture host cells containing the expression vector of embodiment 51(vi) and purify the antibody from the culture medium; c) Incubate the first antibody and the second antibody under reducing conditions sufficient to allow cysteine in the hinge region to undergo disulfide isomerization, and d) Obtain the bispecific antibody.
[0579] 68. A diagnostic composition comprising a bispecific antibody of any one of the aforementioned embodiments 1-48.
[0580] 69. A method for detecting whether cross-linking occurs between cells expressing CD3 and CD20 in a patient-derived sample, such as a blood sample, lymph node sample, or bone marrow sample, after administration of the bispecific antibody of any one of the aforementioned embodiments 1-48, comprising the following steps: (i) Contacting the sample with the bispecific antibody of any one of embodiments 1-48 described above, under conditions that allow for the formation of a complex between the bispecific antibody and cells expressing CD3 and CD20; and (ii) Analyze whether a complex has been formed.
[0581] 70. A kit for detecting crosslinks between cells expressing CD3 and CD20 in patient-derived samples, such as blood samples, lymph node samples, or bone marrow samples, comprising... (i) the bispecific antibody of any one of the aforementioned implementation schemes 1-48; and (ii) Instructions for use of the kit.
[0582] 71. An anti-individual genotype antibody, which binds to a first antigen-binding region as defined in any one of the aforementioned embodiments 1-23, or binds to a second antigen-binding region as defined in any one of the aforementioned embodiments 24-32.
[0583] The present invention is further illustrated by the following embodiments, which should not be construed as limiting the scope of the invention. Example
[0584] Example 1 - Generation of humanized CD3 antibodies and inactivated antibody variants Humanization of CD3 antibody Humanization of the mouse CD3 antibody SP34 (US8236,308, referred to herein as IgG1-CD3) was performed by Antitope (Cambridge, UK) using its modified form of germline humanization (CDR-transplantation) technology (EP0629240). Using this technology, four different VH chains (SEQ ID NO:6, 7, 8, and 9) and three different VL chains (SEQ ID NO:10, 11, and 12) were designed. By combining these four VH chains with the three VL chains, twelve different antibodies were generated. The humanized variant is referred to herein as huCD3. Thus, according to the invention, a humanized variant comprising VH and VL is referred to, for example, IgG1-huCD3-H1L1, meaning that the specific variant has an IgG1 isotype, is a humanized SP34 CD3-specific antibody, and comprises a VH amino acid sequence referred to as “H1” and defined according to SEQ ID NO:6, and a VL amino acid sequence referred to as “L1” and defined according to SEQ ID NO:10. Therefore, H1 refers to the variable heavy chain region VH1, L1 refers to the variable light chain region VL1, and so on.
[0585] Specifically, the variants IgG1-huCD3-H1L1 (humanized CD3, containing the VH1 sequence shown in SEQ ID NO:6 and the VL1 sequence shown in SEQ ID NO:10), IgG1-huCD3-H1L2 (humanized CD3, containing the VH1 sequence shown in SEQ ID NO:6 and the VL2 sequence shown in SEQ ID NO:11), IgG1-huCD3-H1L3 (humanized CD3, containing the VH1 sequence shown in SEQ ID NO:6 and the VL3 sequence shown in SEQ ID NO:12), IgG1-huCD3-H3L3 (humanized CD3, containing the VH3 sequence shown in SEQ ID NO:8 and the VL3 sequence shown in SEQ ID NO:12), IgG1-huCD3-H4L1 (humanized CD3, containing the VH4 sequence shown in SEQ ID NO:9 and the VL1 sequence shown in SEQ ID NO:10), and IgG1-huCD3-H3L1 (humanized CD3, containing the VH1 sequence shown in SEQ ID NO:6 and the VL1 sequence shown in SEQ ID NO:10), contain the VH1 sequence shown in SEQ ID NO:6 and the VL1 sequence shown in SEQ ID NO:10), contain the VH1 sequence shown in SEQ ID NO:6 and the VL1 sequence shown in SEQ ID NO:10, contain the VH1 sequence shown in SEQ ID NO:11 and the VL2 sequence shown in SEQ ID NO:1 ..., contain the VH1 sequence shown in SEQ ID NO:11 and the VL2 sequence shown in SEQ ID NO:11, contain the VH1 sequence shown in SEQ ID NO:11 and the VL2 sequence shown in SEQ ID NO:11, contain the V The VH3 sequence shown in SEQ ID NO:8 and the VL1 sequence shown in SEQ ID NO:10), IgG1-huCD3-H3L3 (humanized CD3, comprising the VH3 sequence shown in SEQ ID NO:8 and the VL3 sequence shown in SEQ ID NO:12) and IgG1-huCD3-H4L3 (humanized CD3, comprising the VH4 sequence shown in SEQ ID NO:9 and the VL3 sequence shown in SEQ ID NO:12) have been used as the first antigen-binding region of the bispecific antibody of the present invention. Here, "IgG1-huCD3" refers to IgG1-huCD3-H1L1 unless otherwise defined.
[0586] In some instances, CD3 antibodies containing the heavy and light chain variable region sequences of huCLB-T3 / 4 (SEQ ID NO: 17 and 18, respectively) are used as the first antigen-binding region of the bispecific antibody of the present invention. huCLB-T3 / 4 is a humanized form of the mouse CD3 antibody CLB-T3 / 4 (Parren et al., Res Immunol. 1991, 142(9):749-63). The two sequences (SEQ ID NO: 17 and 18) were cloned into the associated pcDNA3.3 (Invitrogen) expression vector and expressed by co-transfection in HEK293F cells. The resulting CD3 antibody is called IgG1-huCLB-T3 / 4.
[0587] The humanized CD3 antibody was further disclosed in WO2015001085.
[0588] CD20 antibody The CD20 antibody used as the second binding arm of the bispecific antibody of the present invention is further disclosed in WO2004035607 (Genmab) and WO2005103081 (Genmab).
[0589] Comparison The following antibodies were used as controls in the examples: CD3 antibody IgG1-CD3 (parental CD3 antibody SP34, possessing the VH and VL sequences shown in SEQ ID NO:25 and SEQ ID NO:26, respectively) IgG1-huCD3 (H1L1) (possessing the VH and VL sequences shown in SEQ ID NO:6 and SEQ ID NO:10, respectively) IgG1-huCLB-T3 / 4 bsIgG1-huCD3-H1L1-FEALxb12-FEAR (Bispecific antibody, using antibody b12 as the second arm, which is a gp120 specific antibody (Barbas, CF. J Mol Biol. 1993 Apr 5; 230(3):812-23) IgG1-huCD3-H1L1-FEAL IgG1-huCLB-T3 / 4-FEAL CD20 antibody IgG1-7D8 (containing the VH and VL sequences shown in SEQ ID NO:27 and SEQ ID NO:28, respectively) IgG1-11B8 (possessing the VH and VL sequences shown in SEQ ID NO:40 and SEQ ID NO:41, respectively) IgG1-2F2 (containing the VH and VL sequences shown in SEQ ID NO:37 and SEQ ID NO:28, respectively) IgG1-RTX (containing the VH and VL sequences of rituximab) IgG1-GA101 (containing the VH and VL sequences of obinutuzumab, CHEMBL1743048, US8883980, and containing the Fc domain of wild-type human IgG1) IgG1-2C6 (containing the VH and VL sequences shown in SEQ ID NO:47 and SEQ ID NO:48, respectively) IgG1-7D8-FEAR IgG1-11B8-FEAR IgG1-2F2-FEAR IgG1-GA101-FEAR IgG1-2C6-FEAR Table 4: Quantitative analysis of 7D8 CD20 antibody binding on different B cell lines Quantitative flow cytometry (QIFIKIT®, Dako; cat. no K0078) was performed as described (Poncelet and Calayon, 1985, J. Immunol. Meth. 85: 65-74) to quantify the binding of 7D8 CD20 antibodies on the different human B-cell lines used in the examples, as an indicator of CD20 expression. For this purpose, the human B-cell lines were incubated with a saturated concentration of 7D8, and the number of bound 7D8 molecules was determined using quantitative flow cytometry.
[0590] Anti-human CD20 antibody 7D8, engineered to express the mouse Fc domain (10 µg / mL, mmIgG1-7D8 (Overdijk et al. 2012, J. Immunol. 189: 3430-3438), was used in this assay. B-ALL: B-cell acute lymphoblastic leukemia; ABC-DLBCL: activated B-cell diffuse large B-cell lymphoma; GC-DLBCL: germinal center diffuse large B-cell lymphoma; FL: follicular lymphoma.
[0591] Example 2 - Generation of bispecific antibodies via 2-MEA-induced Fab-arm exchange An in vitro method for generating bispecific antibodies is described in WO2008119353 (Genmab) and by van der Neut-Kolfschoten et al. . (Science. 2007 Sep 14; 317(5844):1554-7) reported. In this paper, bispecific antibodies are formed by “Fab-arm” or “half-molecule” exchange (exchange of heavy chain and linked light chain) between two monospecific IgG4- or IgG4-like antibodies after incubation under mild reducing conditions. Without being bound by theory, this Fab-arm exchange reaction is a result of disulfide isomerization, in which the inter-heavy chain disulfide bonds in the hinge region of the monospecific antibody are reduced, and the resulting free cysteine residues form new inter-heavy chain disulfide bonds with cysteine residues of another antibody molecule having different specificities. The resulting product is a bispecific antibody with two Fab arms having different sequences.
[0592] This knowledge of natural IgG4 Fab-arm exchange has been adapted to obtain a method for generating stable IgG1-based bispecific antibodies (WO2011131746 (Genmab)). The bispecific antibody product generated by this method no longer participates in IgG4 Fab-arm exchange. This method is based on the use of complementary CH3 domains, which, under specific assay conditions, promote the formation of heterodimers. To generate bispecific antibodies by this method, IgG1 molecules with certain mutations in the CH3 domain are produced: T350I, K370T, and F405L mutations (or at least F405L) in one parental IgG1 antibody, and K409R mutation in another parental IgG1 antibody.
[0593] To generate bispecific antibodies, the two parental antibodies, each at a final concentration of 0.5 mg / mL (equimolar concentration), were incubated with 25 mM 2-mercaptoethylamine-HCl (2-MEA) in a total volume of 100 µL Tris-EDTA (TE) at 37°C for 90 min. The reduction reaction was terminated when the reducing agent 2-MEA was removed using a centrifugal column (Microcon centrifuge filter, 30k, Millipore) according to the manufacturer's instructions.
[0594] Example 3 – Generating mutants to optimize the production of humanized CD3 antibodies Production of huCD3-L1 mutant plasmid Several IgG1-huCD3-H1L1 variants with L1 light chain mutations were generated to enhance IgG1-huCD3-H1L1 expression levels in transient transfection assays (see Table 5). Residue selection was based on comparison with germline sequences or screening for the presence of rare residues in the huCD3-L1 sequence in combination with crystal structures derived from homologous antibodies. Selected sequences were analyzed using GeneArt (Life Technologies, Germany). p33L encodes the constant domain of the IgLC2 / IgLC3 λ light chain of human SEQ ID NO:29. p33G1f encodes the constant region of the IgG1m(f) heavy chain of SEQ ID NO:15.
[0595] Table 5 Transient expression in Expi293F cells For single antibodies, plasmids encoding both the heavy chain (HC) and light chain (LC) were transiently transfected into Freestyle Expi293F cells (Life Technologies, USA) using ExpiFectamine 293 (Lifetechnologies). A total of 1.5 µg of HC-encoding plasmid and 1.5 µg of LC-encoding plasmid (Table 5) were diluted in 150 µL of Opti-MEM (Gibco, USA). To prepare the transfection mixture, 8 µL of ExpiFectamine 293 was diluted in 150 µL of Opti-MEM and incubated at room temperature for 5 minutes. Next, the DNA / Opti-MEM and ExpiFectamine 293 / Opti-MEM solutions were mixed, incubated at room temperature for 20 minutes, and then added to 2.55 mL of Expi293 expression medium containing 7.5 x 10⁻⁶ cells. 6 Expi293F cells and 50 U / mL Pen-Strep were transfected. Cells were incubated at 37°C, 8% CO2, and shaken at 200 rpm. To enhance expression, 15 µL of enhancement mixture 1 and 150 µL of enhancement mixture 2 were added 21 hours post-transfection. Cells were incubated for 4 days, followed by harvesting the supernatant. The supernatant was centrifuged at 3,000 x g and filtered through a 0.2 µm filter for sterilization. IgG expression levels were measured using an anti-human IgG sensor (ForteBio, USA) on OctetRED (ForteBio, US).
[0596] IgG concentration analysis The IgG1-huCD3-H1L1 antibody was expressed at 72 µg / mL. A 4-fold increase in IgG expression (295 µg / mL) was observed in the IgG1-huCD3-H1L1-LT41K mutant. A similar expression level (311 µg / mL) was observed in the IgG1-huCD3-H1L1-LLKNH mutant, specifically including the T41K mutation. When tested individually (IgG1-huCD3-H1L1-LF10L, IgG1-huCD3-H1L1-LK55N, IgG1-huCD3-H1L1-LL97H), other mutations in these constructs did not show increased expression compared to IgG1-huCD3-H1L1.
[0597] A second group of mutations showing increased expression was observed for the combination of R23A and A35P. While the IgG1-huCD3-H1L1-LLTGPEAEY variant lacking both R23A and A35P did not show increased expression (83 µg / mL), the IgG1-huCD3-H1L1-LLAPTGPEAEY variant containing additional R23A and A35P mutations did show a 3-fold increase in expression (237 µg / mL). Individually, neither R23A nor A35P showed increased expression levels (56 and 81 µg / mL, respectively).
[0598] Example 4 - Bispecific CD3xCD20 antibody binding to Daudi and Jurkat cells Flow cytometry analysis was performed on bsIgG1-huCD3-H1L1-FEALxCD20-7D8-FEAR, human CD3-negative CD20-positive Daudi (American Type Culture Collection, ATCC® CCL-213™, derived from human Burkitt lymphoma), and human CD3-positive CD20-negative Jurkat (Deutsche Sammlung von Mikroorgansimenund Zellkulturen, DSMZ® ACC 282). TM This antibody is derived from an acute T-cell leukemia (ITL) cell line. In addition to the inactive mutations L234F, L235E, and D265A on both arms, the bispecific antibody contains the F405L mutation on one arm and the K409R mutation on the other arm.
[0599] Cells (1x10) 5 Cells / well were incubated in 96-well polystyrene round-bottom plates (Greiner bio-one, cat. no. 650101) with serially diluted antibodies (range 0.041–30 µg / mL, 3-fold dilution step [AE] and 0.00061–10 µg / mL, 4-fold dilution step [FI]) in 100 µL PBS / 0.1% BSA / 0.02% azide (here referred to as staining buffer) at 4°C for 30 min.
[0600] After washing twice in staining buffer, cells were incubated in 50 µL of a secondary antibody at 4°C for 30 min. R-phycoerythrin (PE)-conjugated goat-anti-human IgG F(ab')2 (cat. no. 109-116-098, Jackson ImmunoResearch Laboratories, Inc., WestGrove, PA), diluted 1:200 in staining buffer, was used for all experiments. Cells were then washed twice in staining buffer, resuspended in 30 μL of staining buffer, and analyzed on an iQue screener (Intelligent Corporation, USA). Figure 1 AE), or resuspend in 100 µL staining buffer and analyze on FACSCANTO II (BD Biosciences). Figure 1 FI). The combined curves were analyzed using nonlinear regression (S-shaped dose-response with variable slope) and GraphPad Prism V75.04 software (GraphPad Software, San Diego, CA, USA).
[0601] Figure 1AF results showed that bsIgG1-huCD3-H1L1-FEALxCD20-7D8-FEAR and bsIgG1-huCD3-H1L1-FEALxCD20-2F2-FEAR exhibited dose-dependent binding to Daudi cells, with higher maximal binding than the monospecific bivalent CD20 antibodies IgG1-7D8 and IgG1-2F2. For bsIgG1-huCD3-H1L1-FEALxCD20-11B8-FEAR, bsIgG1-huCD3-H1L1-FEALxCD20-RTX-FEAR, and bsIgG1-huCD3-H1L1-FEALxCD20-GA101-FEAR, the maximal binding was similar to that of the bivalent monospecific CD20 antibodies IgG1-11B8, IgG1-RTX, and IgG1-GA101. The maximum binding of bsIgG1-huCD3-H1L1-FEALxCD20-11B8-FEAR, bsIgG1-huCD3-H1L1-FEALxCD20-RTX-FEAR, bsIgG1-huCD3-H1L1-FEALxCD20-GA101-FEAR, and the bivalent monospecific CD20 antibodies IgG1-11B8, IgG1-RTX, and IgG1-GA101 is lower than that of bsIgG1-huCD3-H1L1-FEALxCD20-7D8-FEAR, bsIgG1-huCD3-H1L1-FEALxCD20-2F2-FEAR, and the bivalent monospecific CD20 antibodies IgG1-7D8 and IgG1-2F2. The maximum binding of huCD3-H1L1-FEALxCD20-2C6-FEAR is comparable to that of the monospecific CD20 antibody IgG1-7D8.
[0602] Figure 1G indicates that the CD3xCD20 bispecific antibody containing the CD3-specific huCLB-T3 / 4 Fab-arm binds to Daudi cells. bsIgG1-huCLB-T3 / 4-FEALxCD20-7D8-FEAR and bsIgG1-huCLB-T3 / 4-FEALxCD20-2F2-FEAR show binding comparable to the monospecific CD20 antibody IgG1-7D8. For the CD3xCD20 bispecific antibody containing the CD3-specific huCD3-H1L1 Fab-arm, bsIgG1-huCLB-T3 / 4-FEALxCD20-11B8-FEAR and bsIgG1-huCLB-T3 / 4-FEALxCD20-GA101-FEAR, binding is lower than that of the monospecific CD20 antibody IgG1-7D8 and the CD3xCD20 bispecific antibody containing the CD20-specific 7D8- or 2F2-Fab-arm.
[0603] Figure 1H I and II showed that CD3xCD20 bispecific antibodies containing either the CD3-specific huCD3-H1L1- or huCLB-T3 / 4-Fab-arm bound to JurkaT cells. All CD3xCD20 bispecific antibodies with a CD3-specific Fab-arm derived from IgG1-huCD3-H1L1-FEAL showed comparable binding to JurkaT cells, regardless of the source of the CD20-specific Fab-arm. Figure 1H Similarly, all CD3xCD20 bispecific antibodies with CD3 Fab-arm derived from IgG1-huCLB-T3 / 4-FEAL showed comparable binding ( Figure 1 G). Monospecific bivalent parental CD3-specific antibodies IgG1-huCD3-H1L1 and IgG1-huCLB-T3 / 4 bind to JurkaT cells in ECMO cells. 50 The value is lower than that of the CD3xCD20 bispecific antibody.
[0604] Example 5 – bsIgG1-huCD3-H1L1-FEALxCD20-7D8-FEAR and concentration-dependent simultaneous binding of T cells and B cells Human B cells express the surface antigen CD20 but lack CD3 expression. In contrast, human T cells express the surface antigen CD3 but lack CD20 expression. The bispecific antibody bsIgG1-huCD3-H1L1-FEALxCD20-7D8-FEAR recognizes both CD3 and CD20, thus enabling it to bind to both human B and T cells. The simultaneous binding of the bispecific antibody bsIgG1-huCD3-H1L1-FEALxCD20-7D8-FEAR to both B and T cells was demonstrated by incubating 100 µL of heparinized whole blood from healthy donors at 37°C for 2 hours in the presence of antibody at concentrations ranging from 0.001 to 100 µg / mL in 10-fold dilution steps, obtained by adding different volumes of undiluted antibody to blood samples. CD20 antibody 2F2 and bsIgG1-huCD3-H1L1-FEALxb12-FEAR, which specifically recognize CD20 or CD3 respectively and therefore cannot bind to B and T cells simultaneously, were used as negative control antibodies. Cells were washed twice in staining buffer (1200 RPM, 3 min) and incubated at 4°C for 30 min with antibodies specific to CD4 (CD4-PE; Becton Dickinson, cat. no. 555347) or CD8 (CD8-PE; Miltenyi, cat. no. BW135 / 80) (identifying different subsets of T cells) and CD19 (CD19-APC; DAKO, cat. no. C7224) (identifying B cells). Prior to analysis, red blood cells were lysed by adding 100 µL of erythrocyte lysis buffer (10 mM KHCO3 / 0.01 mM EDTA / 155 mM NH4Cl, dissolved in dH2O) (KHCO3: Sigma, cat. no. P9144; EDTA: FLUKA, cat. no. 036; NH4Cl: Sigma, cat. no. A-5666). Samples were analyzed by flow cytometry using a FACSCANTO II equipped with an automated plate carrier (Becton Dickinson). CD4 + CD19 + or CD8 + CD19 + The number of double-positive events, indicating the simultaneous binding of bsIgG1-huCD3-H1L1-FEALxCD20-7D8-FEAR to human T and B cells, was quantified by CD4 / CD19 and CD8 / CD19 quadrant analysis.
[0605] Figure 2 A and 2B show that a cluster of CD4 was observed only in the presence of CD3xCD20 bispecific antibodies.+ CD19 + and CD8 + CD19 + A double-positive event, representing a T-cell-B-cell bimodal distribution, indicates that these bispecific antibodies can bind to both cell types simultaneously. The bimodal distribution is antibody concentration-dependent and correlates with CD4+. + (A) and CD8 + Both T cells (B) and B cells occur.
[0606] Example 6 - In vitro induction of cytotoxicity via CD3xCD20 bispecific antibody Different CD3xCD20 bispecific antibodies were tested in an in vitro cytotoxicity assay using tumor cell lines as target cells and peripheral blood mononuclear cells (PBMCs) or purified T cells as effector cells.
[0607] target cells The following tumor cell lines were used: Daudi and Raji (above), OCI-Ly7 (DSMZ; cat. no. ACC 688; derived from DLBCL), SU-DHL-4 (DSMZ; cat. no. ACC 495; derived from DLBCL), RI-1 (DSMZ; cat. no. ACC 585; derived from DLBCL), NALM-16 (DSMZ; cat. no. ACC 680; derived from B-ALL), and WSU-NHL (DSMZ, cat. no. ACC 58; derived from NHL). The tumor cells were supplemented with 10% bovine serum [Gibco; cat. no. 10371-029] and 25,000 units of penicillin / 25,000 µg streptomycin [Lonza; cat. no. 17-603E] in RPMI. ++ Cells were collected from RPMI-1640 [containing 25 mM HEPES and L-glutamine; Lonza, cat. no. BE12-115F] at a concentration of 5 x 10⁻⁶ cells per ... 6 Cells were centrifuged (1,200 RPM, 5 min) and resuspended in 1 mL RPMI. ++ Add 100 µCi 51 Cr (Chromium-51; Perkin Elmer, cat. no. NEZ030002MC) and incubation (37°C water bath, shaking; 1 hour). After washing the cells twice in PBS (1,200 RPM, 5 min.), the cells were resuspended in RPMI. ++ And count by exclusion using trypan blue. Prepare 1 x 10 5Cell suspension per mL.
[0608] effector cells Fresh PBMCs were separated from 40 mL of erythrocyte sedimentation rate (ESR) amber layer (Sanquin) using a Ficoll gradient (Lonza; lymphocyte separation medium, cat. no. 17-829E) according to the manufacturer's instructions. In RPMI... ++ After resuspending the cells in medium-rebound solution, the cells were counted using Türk solution, red blood cells were excluded, and the solution was adjusted to 10 x 10⁻⁶. 6 Cells / mL concentration.
[0609] Purified T cells were extracted from the erythrocyte sedimentation rate (ESR) and analyzed using RosetteSep. TM Human T-cell enrichment reagent (Stemcell Technologies, cat. no. 15061) or Dynabeads® Untouched™ Human T-cell Isolation Kit (Invitrogen; cat. no. 11344D) from PBMC, obtained according to the manufacturer's instructions. Wash cells twice in PBS and count and adjust to 1 x 10⁻⁶ cells using Türk solution. 6 Cells / mL concentration.
[0610] Cytotoxicity assay: 50 µL 51 Cr-labeled target cells were added to 96-well round-bottom plates. 50 µL of antibody (final concentration range 10 pg / mL-10 µg / mL) / RPMI was added. ++ Then, incubate the cells at room temperature for 10 min.
[0611] Add 50 µL of effector cells (at the effector:target ratio shown), Triton-X-100 (1.7% final concentration; determine maximum solubility) or RPMI. ++ (Assessing background lysis). Incubate cells at 37°C, 5% CO2 for 24–48 hours. After centrifuging cells (1,200 RPM, 3 min.), harvest 75 µL of supernatant into a 1.4-mL tube (Micronic; cat. no. MP226RN) and count the cells using a gamma counter (Perkin Elmer). The percentage of specific lysis is calculated as follows: %Specific lysis = (cpm sample – cpm target cells only) / (cpm maximum lysis – cpm target cells only) x 100. Cpm = counts / minute.
[0612] Figure 3 Showing when using PBMC ( Figure 3A, 3M) and purified T cells ( Figure 3 When B-3L, 3N) are used as effector cells, all bispecific antibodies containing CD3-specific Fab arms (half-molecules) (derived from IgG1-huCD3-H1L1-FEAL or IgG1-huCLB-T3 / 4-FEAL) and CD20-specific Fab arms (i.e., half-molecules) (derived from IgG1-CD20-7D8-FEAR, IgG1-CD20-11B8-FEAR, IgG1-CD20-2F2-FEAR, IgG1-CD20-RTX-FEAR, IgG1-CD20-2C6-FEAR or IgG1-CD20-GA101-FEAR) are able to induce cytotoxicity in the tested B cell lines. Monospecific bivalent antibodies with inert Fc domains (IgG1-7D8-FEAR, IgG1-11B8-FEAR, IgG1-huCD3-H1L1-FEAL, IgG1-huCLB-T3 / 4-FEAL) failed to induce T cell- or PBMC-mediated cytotoxicity in B cell lines. This suggests that for CD3xCD20 bispecific antibodies, cytotoxicity depends on the binding of the bispecific antibody to both CD3 and CD20. As previously disclosed, monospecific bivalent CD20 antibodies with active Fc domains (IgG1-7D8 and IgG1-11B8-F405L) were able to induce antibody-dependent cell-mediated cytotoxicity via PBMCs in Daudi cells. Figure 3 (A, 3M). In this case, the primary effector cells are natural killer (NK) cells. CD3xC20 bispecific antibodies are active at concentrations lower than those of monospecific bivalent CD20 antibodies. Figure 3 C-3F analysis showed that both IgG1-huCLB-T3 / 4- and IgG1-huCD3-H1L1- derived CD3 arms induce cytotoxicity and have similar efficacy. Furthermore... Figure 3 G-3M showed that similar results were obtained using tumor cell lines derived from various B cell lines. These cell lines originated from different B cell tumors, as shown in Table 4. The table also shows the CD20 expression levels on these cell lines.
[0613] Example 7 - Using purified human peripheral blood CD4 via bsIgG1-huCD3-H1L1-FEALxCD20-7D8-FEAR + and CD8 + T cells, as effector cells, induce cytotoxicity in vitro. To determine whether bsIgG1-huCD3-H1L1-FEALxCD20-7D8-FEAR could induce cytotoxic activity in both CD4 and CD8 T cells, a cytotoxicity assay was performed using different subsets of T cells as effector cells. Daudi cells were prepared as target cells as described above.
[0614] PBMCs were isolated from the erythrocyte sedimentation rate (ESR) layer of healthy donors using lymphocyte separation medium as described above.
[0615] T cells (total T cell population, CD4) + or CD8 + T cell populations were isolated from PBMCs using Dynabeads® Untouched™ Human T Cells, Dynabeads® Untouched™ Human CD4 T Cells, or Dynabeads® Untouched™ Human CD8 T Cells Isolation Kits (Invitrogen, catalog numbers 11344D, 11352D, and 11348D, respectively). After isolation, the purity of each fraction was determined by flow cytometry. Cells were incubated with CD3 (CD3-PER-CP; Becton Dickinson, cat. no. 345766) and CD8 (CD8-APC; Becton Dickinson, cat. no. 555369) antibodies at 4°C for 30 min to identify different T cell subsets. Samples were analyzed by flow cytometry using FACSCANTOII equipped with an automated plate carrier (Becton Dickinson). CD3 / CD8 quadrant analysis was performed to quantify CD3+ events (total T cell population) and CD3+ events (total T cell population). + CD8 + Double-positive events (CD8) + T cell population and CD3 + CD8 - Event (CD4) + The frequency of T cell populations.
[0616] Total T cells were added to Daudi cells at an effector-to-target ratio of 10:1, CD4 + T cells exhibit an 8:1 effector ratio: target ratio plus CD8 + T cells are added at an effector-to-target (E / T) ratio of 4:1 or 8:1 (as shown). Figure 4 A), and perform cytotoxicity assays as described above. To test the effect of CD4+ on the cell type when added as an effector cell... + Does T cell inhibit CD8? + T cell activity, using only CD8 +T cells (E / T ratio 4:1) or CD8 + T cells (E / T ratio 4:1) and CD4 + T cells (E / T ratio 8:1) act as effector cells ( Figure 4 B) Perform cytotoxicity assays.
[0617] Figure 4 A study showed that bsIgG1-huCD3-H1L1-FEALxCD20-7D8-FEAR induced T-cell-dependent cytotoxicity in Daudi cells, using total T cells and CD4+. + T cells or CD8 + T cells were used as effector cells. Antibodies bsIgG1-huCD3-H1L1-FEALxb12-FEAR and IgG1-7D8-FEAR, used here as negative controls, did not induce cytotoxicity in Daudi cells (data not shown), indicating that cytotoxicity depends on the recognition of both CD3 and CD20 by bispecific molecules. Figure 4 B shows that CD4 has been added. + T cells to CD8 + T cells, as effector cells, do not reduce the efficacy of bsIgG1-huCD3-H1L1-FEALxCD20-7D8-FEAR.
[0618] Table 6 shows that the purity of the isolated cell fractions is ~90% or higher.
[0619] Table 6: Purity of T-cell subsets, determined by flow cytometry. Example 8 - Kinetics induced by in vitro cytotoxicity of purified T cells as effector cells via bsIgG1-huCLB-T3 / 4-FEALxCD20-7D8-FEAR To determine the kinetics of bsIgG1-huCLB-T3 / 4-FEALxCD20-7D8-FEAR-induced in vitro cytotoxicity, Daudi cells were incubated with bsIgG1-huCLB-T3 / 4-FEALxCD20-7D8-FEAR in the presence of purified T cells, and cytotoxicity was evaluated at different time points. The cytotoxicity assay was performed as described above, except that the supernatant was harvested not only after 24 hours but also at different time points ranging from 3 to 24 hours after incubation.
[0620] Figure 5The results of two independent experiments are shown, using purified T cells derived from two different donors. Using purified T cells from the first donor, dose-dependent cytotoxicity was observed after 12 hours, and even more potent cytotoxicity after 48–72 hours. Figure 5 A). In the presence of purified T cells from a second donor, bsIgG1-huCLB-T3 / 4-FEALxCD20-7D8-FEAR was able to induce cytotoxicity as early as 3 hours after incubation, and its efficacy increased after 16–24 hours of incubation. Figure 5 B).
[0621] Example 9 - Efficacy of in vitro cytotoxicity induced by different effects: CD3xCD20 bispecific antibodies with different target ratios. To determine the cytotoxicity-induced efficacy of CD3xCD20 bispecific antibodies containing CD20 Fab-arms derived from different CD20 antibodies, different effector-to-target ratios were used, and cytotoxicity assays were performed as described above. PBMCs were used as effector cells and Daudi cells were used as target cells.
[0622] like Figure 6 As shown, even at E / T ratios between 10:1 and 25:1, cell killing was observed with the CD3xCD20 bispecific antibody.
[0623] Example 10 - Cytotoxicity of CD3xCD20 bispecific antibody in a Raji-luc co-transplantation model in NOD-SCID mice The in vivo antitumor efficacy of bsIgG1-huCD3-H1L1-FEALxCD20-7D8-FEAR, bsIgG1-huCD3-H1L1-FEALxCD20-11B8-FEAR, and bsIgG1-huCLB-T3 / 4-FEALxCD20-7D8-FEAR was evaluated in a subcutaneous Raji-luc co-transplantation model. In this model, unstimulated human PBMCs, as a source of human T cells, were co-seeded with tumor cells, similar to the model described by Brischwein et al. (Mol. Immunol. 43 (2006), 1129–1143). On day 0, 5 x 10⁵ cells were added to 200 µL PBS / 0.1% BSA. 6 PBMC and 5x10 6A mixture of Raji-luc cells was subcutaneously (sc) injected into the right side of each mouse (female NOD-SCID mice; NOD.CB-17-Prkdcscid / J, Charles-River, 6-11 weeks old). Within one hour of injection, the mice were divided into treatment groups (4-5 mice / treatment group [experimental details omitted]). Figure 7 AF] or 10 mice / treatment group [experimental results shown in] Figure 7 GI]), and each group received a single intravenous (iv) injection of 100-150 µL (bispecific) antibody / PBS. Treatment groups are shown in Ta...
Claims
1. A bispecific antibody comprising a first binding arm having a first antigen-binding region for binding human CD3ε (epsilon), wherein the first antigen-binding region comprises heavy chain variable (VH) regions CDR1, CDR2, and CDR3 having sequences shown in SEQ ID NO:55, 56, and 57, respectively, and light chain variable (VL) regions CDR1, CDR2, and CDR3 having sequences shown in SEQ ID NO:58, DTS, and SEQ ID NO:59, respectively, and a second binding arm having a second antigen-binding region for binding human CD20, wherein the second antigen-binding region comprises: (i) VH CDR1 region of SEQ ID NO:32, VH CDR2 region of SEQ ID NO:33, VH CDR3 region of SEQ ID NO:34, VL CDR1 region of SEQ ID NO:35, VL CDR2 region of DAS, and VL CDR3 region of SEQ ID NO:
36. (ii) VH CDR1 region of SEQ ID NO:38, VH CDR2 region of SEQ ID NO:39, VHCDR3 region of SEQ ID NO:34, VL CDR1 region of SEQ ID NO:35, VL CDR2 region of DAS, and VL CDR3 region of SEQ ID NO:
36. (iii) VH CDR1 region of SEQ ID NO:42, VH CDR2 region of SEQ ID NO:43, VHCDR3 region of SEQ ID NO:44, VL CDR1 region of SEQ ID NO:45, VL CDR2 region of DAS and VL CDR3 region of SEQ ID NO:
46.
2. The bispecific antibody of claim 1, wherein the first antigen-binding region comprises a first heavy chain variable sequence (VH) and a first light chain variable sequence (VL), and the second antigen-binding region comprises a second heavy chain variable sequence (VH) and a second light chain variable sequence (VL), and wherein each of the variable sequences comprises three CDR sequences, namely CDR1, CDR2 and CDR3, and four frame sequences, namely FR1, FR2, FR3 and FR4.
3. The bispecific antibody of claim 1 or 2, wherein (i) the first binding arm comprises a first heavy chain and a first light chain, the first heavy chain comprising a first heavy chain variable sequence (VH) and a first heavy chain constant sequence (CH), and the first light chain comprising a first light chain variable sequence (VL) and a first light chain constant sequence (CL); and (ii) the second binding arm comprises a second heavy chain and a second light chain, the second heavy chain comprising a second heavy chain variable sequence (VH) and a second heavy chain constant sequence (CH), and the second light chain comprising a second light chain variable sequence (VL) and a second light chain constant sequence (CL).
4. The bispecific antibody of claim 1 or 2, wherein the VH sequence of the first antigen-binding region is a) the VH sequence shown in SEQ ID NO:
17.
5. The bispecific antibody of claim 1 or 2, wherein the VL sequence of the first antigen-binding region is the VL sequence shown in SEQ ID NO:
18.
6. The bispecific antibody of claim 1 or 2, wherein the first antigen-binding region comprises the VH sequence shown in SEQ ID NO:17 and the VL sequence shown in SEQ ID NO:
18.
7. The bispecific antibody of claim 1 or 2, wherein the first binding arm is derived from a mouse antibody.
8. The bispecific antibody of claim 1 or 2, wherein the first binding arm is derived from a humanized antibody.
9. The bispecific antibody of claim 1 or 2, wherein the first binding arm is derived from the full-length antibody.
10. The bispecific antibody of claim 1 or 2, wherein the first binding arm is derived from a full-length IgG1,λ (lambda) or IgG1,κ (kappa) antibody.
11. The bispecific antibody of claim 1 or 2, wherein the second antigen-binding region is derived from an antibody that binds to an epitope on human CD20, said epitope not containing the amino acid residue alanine at position 170 or the amino acid residue proline at position 172.
12. The bispecific antibody of claim 11, wherein the second antigen-binding region is derived from an antibody that binds to an epitope on human CD20, said epitope further comprising or requiring asparagine amino acid residues at position 163 and 166.
13. The bispecific antibody of claim 1 or 2, wherein the second antigen-binding region binding to human CD20 comprises the VH CDR1 region of SEQ ID NO:32, the VH CDR2 region of SEQ ID NO:33, the VH CDR3 region of SEQ ID NO:34, the VL CDR1 region of SEQ ID NO:35, the VL CDR2 region of DAS, and the VL CDR3 region of SEQ ID NO:
36.
14. The bispecific antibody of claim 1 or 2, wherein the second antigen-binding region binding to human CD20 comprises: (i) The VH sequence of SEQ ID NO:27 and the VL sequence of SEQ ID NO:28, (ii) The VH sequence of SEQ ID NO:40 and the VL sequence of SEQ ID NO:41, (iii) The VH sequence of SEQ ID NO:37 and the VL sequence of SEQ ID NO:
28.
15. The bispecific antibody of claim 1 or 2, wherein the second antigen-binding region binding to human CD20 comprises the VH sequence of SEQ ID NO:27 and the VL sequence of SEQ ID NO:
28.
16. The bispecific antibody of claim 1 or 2, wherein the second binding arm is derived from a human antibody.
17. The bispecific antibody of claim 1 or 2, wherein the second binding arm is derived from the full-length antibody.
18. The bispecific antibody of claim 1 or 2, wherein the second binding arm is derived from a full-length IgG1,κ (kappa) antibody.
19. The bispecific antibody of claim 1 or 2, wherein each of the first and second heavy chains comprises at least a hinge region, a CH2 region, and a CH3 region, wherein at least one amino acid in the first heavy chain corresponding to the positions T366, L368, K370, D399, F405, Y407, and K409 of the human IgG1 heavy chain has been substituted, and at least one amino acid in the second heavy chain corresponding to the positions T366, L368, K370, D399, F405, Y407, and K409 of the human IgG1 heavy chain has been substituted, and wherein the first heavy chain and the second heavy chain are not substituted at the same positions.
20. The bispecific antibody of claim 19, wherein (i) the amino acid at position F405 of the human IgG1 heavy chain in the first heavy chain is L, and the amino acid at position K409 of the human IgG1 heavy chain in the second heavy chain is R, or (ii) the amino acid at position K409 of the human IgG1 heavy chain in the first heavy chain is R, and the amino acid at position F405 of the human IgG1 heavy chain in the second heavy chain is L.
21. The bispecific antibody of claim 1 or 2, wherein the bispecific antibody comprises a first constant heavy chain (HC) and a first constant light chain (LC), wherein the positions L234, L235 and D265 of the first heavy chain and the second heavy chain corresponding to the human IgG1 heavy chain in SEQ ID NO:15 are F, E and A, respectively.
22. The bispecific antibody of claim 1 or 2, wherein the bispecific antibody comprises first and second constant heavy chains (HC) and first and second constant light chains (LC), wherein the positions L234 and L235 of the first heavy chain and the second heavy chain corresponding to the human IgG1 heavy chain in SEQ ID NO:15 are F and E, respectively.
23. The bispecific antibody of claim 1 or 2, wherein the bispecific antibody comprises first and second constant heavy chains (HC) and first and second constant light chains (LC), wherein the positions L234, L235 and D265 of the first and second constant heavy chains corresponding to the human IgG1 heavy chain in SEQ ID NO:15 are F, E and A, respectively, and wherein the position F405 of the first constant heavy chain corresponding to the human IgG1 heavy chain in SEQ ID NO:15 is L, and the position K409 of the second constant heavy chain corresponding to the human IgG1 heavy chain in SEQ ID NO:15 is R.
24. The bispecific antibody of claim 1 or 2, wherein the bispecific antibody comprises a constant heavy chain (HC) and a constant light chain (LC), wherein the positions L234 and L235 of the first heavy chain and the second heavy chain corresponding to the human IgG1 heavy chain in SEQ ID NO:15 are F and E, respectively, and wherein the position F405 of the first heavy chain corresponding to the human IgG1 heavy chain in SEQ ID NO:15 is L, and the position K409 of the second heavy chain corresponding to the human IgG1 heavy chain in SEQ ID NO:15 is R.
25. The bispecific antibody of claim 1 or 2, wherein the antibody comprises an Fc region that has been modified such that the binding of C1q to the antibody is reduced by at least 70%, at least 80%, at least 90%, at least 95%, at least 97%, or 100% compared to the wild-type antibody, wherein the C1q binding is determined by ELISA.
26. A nucleic acid construct encoding a bispecific antibody as defined in claim 1 or 2.
27. A vehicle for expression, which includes: (i) The nucleic acid sequence encoding both the heavy chain sequence of the first binding arm as defined in claim 1 or 4 and the light chain sequence of the first binding arm as defined in claim 1 or 5; (ii) Encoding the nucleic acid sequences of both the heavy chain sequence of the second binding arm as defined in claim 14 and the light chain sequence of the second binding arm as defined in claim 14.
28. A host cell comprising the expression vector of claim 27.
29. The host cell of claim 28, wherein the host cell is a recombinant eukaryotic host cell or a recombinant prokaryotic host cell.
30. The host cell of claim 28, wherein the host cell is a recombinant microbial host cell.
31. A composition comprising the bispecific antibody of claim 1 or 2.
32. A pharmaceutical composition comprising the bispecific antibody of claim 1 or 2 and a pharmaceutically acceptable carrier.
33. The bispecific antibody of claim 1 or 2, the composition of claim 31, or the pharmaceutical composition of claim 32, used as a pharmaceutical.
34. Use of the bispecific antibody of claim 1 or 2, the composition of claim 31, or the pharmaceutical composition of claim 32 in the preparation of a medicament for treating a disease, wherein the disease is non-Hodgkin's lymphoma (NHL), B-cell leukemia, or diffuse large B-cell lymphoma (DLBCL).
35. A method for generating the bispecific antibody of claim 1 or 2, comprising the following steps: a) Culturing host cells containing the expression vector of claim 27(i), and purifying the antibody from the culture medium; b) Culturing host cells containing the expression vector of claim 27(ii) and purifying the antibody from the culture medium; c) Incubate the first antibody and the second antibody under reducing conditions sufficient to allow cysteine in the hinge region to undergo disulfide isomerization, and d) Obtain the bispecific antibody.
36. A diagnostic composition comprising the bispecific antibody of claim 1 or 2.
37. Use of the bispecific antibody of claim 1 or 2 in a kit for detecting whether cross-linking occurs between cells expressing CD3 and CD20 in a patient-derived sample after administration of the bispecific antibody of claim 1 or 2, wherein the method comprises the following steps: (i) Contacting the sample with the bispecific antibody of claim 1 or 2 under conditions that allow for the formation of a complex between the bispecific antibody and cells expressing CD3 and CD20; and (ii) Analyze whether a complex has been formed.
38. The use of claim 37, wherein the sample is a blood sample, a lymph node sample, or a bone marrow sample.
39. A kit for detecting crosslinks between cells expressing CD3 and CD20 in patient-derived samples, comprising: (i) the bispecific antibody of claim 1 or 2; and (ii) Instructions for use of the kit.
40. The kit of claim 39, wherein the sample is a blood sample, a lymph node sample, or a bone marrow sample.
Citation Information
Patent Citations
Altered antibodies, products and processes relating thereto
EP0629240A1
Methods for producing polypeptides by regulating polypeptide association
EP1870459A1
Downward facing receptacle assembly for cable raceway
US20100155133A1
Single polypeptide chain binding molecules
US4946778A
Induction of a protective immune response in a mammal by injecting a DNA sequence
US5589466A
